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Abstract
HPV-16 is a causative agent of cervical cancer. Gene expression from the virus Is 
tightly controlled depending on the differentiation status of the epithelial cells it 
infects. Whilst early proteins are produced in undifferentiated cells and are 
thought to be continuously expressed throughout differentiation, late proteins are 
expressed only in differentiated cells. In particular, expression of the highly 
immunogenic capsid proteins, L1 and L2, is confined to the most differentiated 
cells, where immune surveillance is low. However, L1 and L2 transcripts have 
been detected in less differentiated cells, suggesting mechanisms exist to prevent 
their expression in these cells. A number of c/s-acting RNA regulatory elements 
have been identified within the HPV-16 late region, which may be involved in 
regulating late gene expression during differentiation. Of particular relevance is 
the 79 nucleotide late regulatory element (LRE), which spans the final LI exon and 
ends in the late 3’UTR. This element has been shown to confer negative 
regulatory activity upon reporter genes in undifferentiated epithelial cells. In 
addition, several cellular proteins with roles during RNA metabolism are known to 
associate with the element. One such protein, splicing related SR protein, 
SF2/ASF, associates with the LRE indirectly In both undifferentiated and 
differentiated HPV-16 infected epithelial cells, potentially via a splicing-like 
complex. This protein is also upregulated during differentiation of HPV-16 infected 
epithelial cells, and for these reasons, it is the main focus of this project.
The aim of this project was to investigate the role of SF2/ASF in the life cycle of 
HPV-16, and to determine how the virus regulates this protein, as well as other SR 
proteins. As SF2/ASF is upregulated in cells expressing HPV-16 E2, experiments 
were undertaken to determine if SF2/ASF expression is transactivated by E2. 
Promoter transactivation studies were performed using the CAT reporter gene 
fused to the SF2/ASF promoter. Results demonstrate that the promoter is 
transactivated in cells expressing E2. Furthermore, to determine a direct role for 
E2 in transactivation, chromatin Immunoprécipitation assays were used to show 
presence of E2 at the endogenous SF2/ASF promoter. However, a direct 
interaction could not be observed in vitro, using electrophoretic mobility shift 
assays. Whilst direct interaction is possible in vivo, it is likely that one or more 
cellular proteins aid the interaction. As the SF2/ASF promoter is as yet undefined, 
nothing is known about its cellular regulation. Therefore, further EMSAs were
performed to determine if cellular partners of E2 could be found to associate with 
this promoter. In the case of Sp1, potential association of the protein with the 
SF2/ASF promoter was observed in vitro, using supershift assays. However, 
association of this protein with the promoter was not determined in vivo. This 
suggests Sp1 may be involved in E2-mediated regulation of SF2/ASF; however, 
further experiments are required to confirm this role.
The next aim was to discover if HPV-16 regulates SR proteins, other than 
SF2/ASF, during the life cycle. This was achieved using western blot and 
immunofluorescence techniques, comparing undifferentiated and differentiated 
HPV-16 infected epithelial cells and cell extracts. Whilst elevated levels of a sub­
set of SR proteins, including SF2/ASF, SRp20, SRp55, SRp40 and SC35 were 
observed upon differentiation, this was not the case for all SR proteins analysed. 
This suggests the SR proteins which are regulated during HPV-16 infection may 
be Important for processing of late transcripts in differentiated cells. Furthermore, 
SF2/ASF and SRp20 were observed to redistribute from nuclear speckles to 
diffuse cytoplasmic localisation upon differentiation. However, redistribution was 
observed inconsistently, the reason for which is unclear. To determine if viral 
proteins E2 and E1^E4 were involved in regulating potential SR protein shuttling, 
they were expressed in undifferentiated and differentiated epithelial cells. 
However, this had no effect on SR protein distribution, and little or no co­
localisation was observed. This suggests that either SF2/ASF and SRp20 do not 
shuttle during differentiation of HPV-16 infected epithelial cells, or that shuttling is 
reliant on other viral proteins or processes. Furthermore, levels of a major protein 
kinase for SR proteins, SRPK1, was also shown to increase upon differentiation of 
HPV-16 infected epithelial cells, and cellular distribution of this protein was 
changed upon differentiation.
The final aim of this PhD was to determine a role for SF2/ASF in LRE mediated 
regulation of late gene expression. SF2/ASF is shown to interact indirectly with 
the LRE in both undifferentiated and differentiated cells. However, protein levels 
are elevated and hyperphosphorylated within differentiated cells. This change in 
abundancy and/or phosphorylation may be involved in activation of the LRE in 
differentiated cells. To study this, undifferentiated epithelial cells were transfected 
with reporter constructs containing the late 3’UTR from HPV-16, either including or 
lacking the LRE. Undifferentiated epithelial cells were co-transfected with these 
constructs and vectors expressing SF2/ASF. Potential changes in reporter gene
iv
expression were then assayed. Results showed no observable change in reporter 
protein activity upon overexpression of SF2/ASF. In contrast, changes were 
observed at the RNA level. Polyadenylated RNAs seemed to increase upon 
expression of SF2/ASF in the presence of the LRE. The data also suggests the 
LRE may act as an instability element, and may regulate transport and/or 
translation independently of SF2/ASF.
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1 Introduction
1.1 Papillomaviruses
Papillomaviruses (PVs) are small, circular, double-stranded (ds) DNA viruses with 
genomes of -8.0kb. They infect epithelial tissue and are the causative agent in 
many benign skin lesions, such as warts and papillomas. Furthermore, 
papillomavirus are associated with cervical carcinoma and other tumours in 
infected individuals (Walboomers et al. 1999). The PV family is divided into 
different types based on host specificity and genome homology (reviewed by zur 
Hausen and de Villiers 1994). Many types have been found infecting a wide 
variety of species, including humans, cattle, dogs and rabbits. In humans, over 
100 types have been identified which infect a variety of epithelial tissues 
throughout the body (reviewed by Bernard 2005). Each type is specific for the 
epithelial tissue and in most cases, the anatomical site it infects. For example, 
human papillomavirus type 16 (HPV-16) is known to infect the mucosal epithelium 
of the anogenital tract, whilst HPV-2 infects cutaneous tissue of the hands. 
Furthermore, host specificity is absolute, although homology is greater between 
mucosal types compared with cutaneous types, irrespective of species (reviewed 
by zur Hausen 1996).
1.1.1 Classification
PVs were classified as members of the Papovaviridae family, which also includes 
polyomaviruses, in the mid-1950s to 1960s. These are non-enveloped DNA 
viruses, with circular genomes, which have icosohedral capsids of 45-55nm in 
diameter. However, similarities between the two virus types are superficial, with 
little genetic homology being observed (Danes et al. 1982). Therefore, PVs were 
recently characterised as a separate family (reviewed by de Villiers et al. 2004). 
PV classification is based on either serotype or genotype identification. Although 
serotype is useful for some HPV types, most phylogenetic research is based on 
genetic analysis of PV genomes. Initially, typing was done using Southern blot 
hybridisation and restriction patterns, however, more recent methods utilise PCR. 
Most commonly a region of the LI gene is analysed as it is thought to be the most 
conserved region of the PV genome. A new HPV type is established where LI 
sequences differ by at least 10% compared with that of any other HPV type.
Sarah Mole, 2007 Chapter 1, 2
Furthermore, differences of 2-10% define sub-types and less than 2%, a variant. 
The designation, e.g. HPV-(number), is given following isolation and complete 
genome characterisation.
Following the classification of PVs as a family of viruses, alterations were made in 
terminology relating to the phylogenetic tree. This led to the introduction of the 
term genus to replace supergroups, and species to replace groups. Whilst virus 
types within a genus are not always associated with similar lesions, each species 
is composed of highly related viruses with similar pathogenicity. A phylogenetic 
tree based on L1 ORF sequences and showing 118 PV types is depicted in figure
1.1 (reviewed by de Villiers et al. 2004). Here, viruses are classified into 16 
genera, alpha-PV being the largest containing 15 species and 61 types. Alpha- 
PVs, previously termed supergroup A, are clinically most important, as HPV types 
associated with mucosal and genital lesions are found within this genus. Species 
7 and 9 contain the majority of the ‘high-risk’ HPV types, so named due to their 
association with cervical carcinogenesis. For example, species 7 contains HPV- 
18 and species 9 contains HPV-16 and -31. The second largest genera are the 
beta-PVs, which contains epidermodysplasia verruciformis (EV) associated HPVs. 
EV is a rare cutaneous disorder characterised by persistent HPV infection. Beta- 
PVs are composed of 25 HPV types, divided into 5 species. They mainly cause 
flat-to-papillomatous, wartlike benign lesions of cutaneous tissue, however viral 
DNA has previously been detected in mucosal epithelial tissue. Species 1 is the 
largest group containing 10 virus types including HPV-5 and -8, which are 
commonly detected in EV-associated squamous cell carcinoma. Furthermore, 
virus types from other species within the genus are also associated with malignant 
cutaneous lesions. There are a further three genera which contain HPV types, all 
of which are less well defined than types from alpha and beta genera. The 
remaining genera contain types found in various mammals and birds.
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Figure 1.1: A phylogenetic tree of papillomavirus types
The tree shows 118 PV types based on LI ORF sequences. Genera are 
given by the outermost semicircles, whilst numbers show species in the 
inner semicircles. There are 16 genera, and high-risk mucosal types are 
found with the alpha genus.
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1.1.2 Pathogenicity
HPVs infect epithelial cells at three target sites: the skin, the respiratory tract and 
the anogenital tract. Each type has a particular tissue tropism, either cutaneous or 
mucosal, often for a particular site. Infection occurs through micro-lesion in the 
epithelium and the viral genome enters the basal layer cells (see section 1.1.5: 
The life cycle). Following infection, the viral genome can be maintained as an 
extrachromosomal episome, and replication is linked with the host chromosome, 
within basal layer cells. Furthermore, the genome can be amplified during the 
productive phase, allowing for completion of the virus life cycle. In these instances 
the virus causes benign lesions, such as warts and papillomas. Warts from a 
number of HPV types, such as 1, 2 and 7 generally regress spontaneously. 
However, the viral genome can also integrate into the host chromosome, which in 
some cases results in progression of a lesion towards malignancy (Figure 1.2). 
The tumourigenic property of papillomaviruses was first elucidated from studies of 
cottontail rabbit papillomavirus (CRPV) (reviewed by Howley 1996). This was the 
first example of a mammalian tumour virus. It was found to cause papillomas in 
cottontail rabbits, extracts from which resulted in disease transmission if inoculated 
onto scarified cottontail or domestic rabbit skin (Shope 1933). Malignant 
transformation was observed within 6 months in 25% of animals, with the majority 
of these progressing to metastatic tumours (reviewed by Breitburd et al. 1997). 
Many properties of virus-induced cancer biology were elucidated from CRPV 
studies. For example, it was found that productive infection no longer occurs with 
malignant progression (Kidd and Rous 1940) and that application of certain 
chemicals accelerates the progression rate (Rous and Kidd 1936).
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Figure 1.2: Progression towards malignancy
A Schematic diagram of epithelium, from normal tissue to invasive 
carcinoma. Note the increase in thickness from normal tissue to very 
mild dysplasia (episomal papillomavirus infection), with increasing 
basahsuprabasal cells ratio upon progression of CIN severity (Grade I 
to III) and in situ carcinoma, indicative of integrated genomes and 
mutagenesis of cellular genes. Eventual result is invasion of cells 
through the basal membrane.
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HPV types can be divided Into ‘high’ and ‘low’ risk categories depending on their 
capacity to cause HPV-related tumours. For example, cervical cancer is the 
second most common cancer of women in the developed world and the major 
causative agent is HPV-16 (Walboomers et al. 1999). Other HPV types are known 
to infect the anogenital tract. However, only the ‘high-risk’ types, such as HPV-16, 
-18, -31, -33 and -45 are frequently found in anogenital malignancies (reviewed by 
Shah and Howley 1996). HPV-16 is associated with 50-60% of cervical cancers 
(Walboomers et al. 1999), whilst the next most common, HPV-18, is detected in 
10-20% of cases (Koutsky 1997; Sasieni and Adams 2001). Cancer develops 
from precursor lesions, known as cervical intraepithélial neoplasias (CIN) (Figure 
1.2). These are graded l-ll, depending on severity, with CIN I resembling 
production infection and CIN II and III showing progressive increase in the 
proliferative phase of the life cycle and increased expression of viral oncoproteins 
(reviewed by Doorbar 2005). Time taken to clear infection is thought to be 
involved in progression to malignancy, and indeed HPV-16 tends to persist for 
longer periods than other high-risk types (Giuliano et al. 2002). High-risk HPVs 
are also associated with carcinoma at a number of lower genital sites; however, 
cervical cancer is the most common (reviewed by Canavan and Doshi 2000). This 
is suggested to be due to the high susceptibility of the transformation zone, where 
cells are rapidly turned over, to carcinogens (reviewed by Shah and Howley 1996). 
The ‘low-risk’ types, HPV-6 and -11, cause genital warts (Condylomata 
acuminate), which generally regress spontaneously or with treatment and are very 
rarely associated with tumours. Studies have shown that whilst HPV-11 is 
detected most often in immunosuppressed individuals, control patients are more 
often infected with HPV-6 (Brown et al. 1999). Furthermore, these low-risk HPVs 
are commonly found in Recurrent Respiratory Papillomatosis (RRP), where 
infection of the upper respiratory tract results in growth of papillomas, which may 
cause airway obstruction. HPV-6 and -11 cause the vast majority of RRP cases, 
with HPV-11 causing more severe disease (Maloney et al. 2006). Virus 
transmission is believed to be vertical during birth; however, cases have been 
identified in individuals born by caesarean section (reviewed by Shah and Howley
1996). Therefore, in utero transmission is also suggested to be the route of 
transmission in rare cases. There is a similar relationship between HPV types and 
other malignancies such as EV-associated squamous cell carcinoma (SCC) 
(Harwood et al. 2004; reviewed by Sterling 2005). EV is rare condition in which 
sufferers develop warty and scaly areas of skin, especially on sun-exposed sites.
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Generally lesions progress to SCC before the age of 40. In this case, HPV-5 and - 
8, are highly correlated with tumour formation, and are found in about 90% of 
cases. However, integration of the viral genome into the host chromosome is not 
required for progression to malignancy (Harwood et al. 2004).
1.1.3 Risk factors
HPV infection is associated with a number of risk factors. For example, 
immunosupression is known to result in development of HPV-associated lesions 
more frequently than in normal patients (Brown et al. 1999) and sexual activity 
(Kjaer et al. 2001), as well as age of first intercourse (Parazzini et al. 1992), are 
also known to play a role in acquisition of HPV. Furthermore, certain types of 
sexual behaviour, such as multiple partners results in increased HPV incidence 
(Clavel et al. 1998; Clavel et al. 1999). In general, HPV infection is cleared by the 
immune system, with only a relative few high-risk HPV infected women developing 
high-grade cervical lesions (Frisch and Goodman 2000; reviewed by Goodman 
2000). In addition, incidence of high-grade lesions increases in women using oral 
contraceptives, suggesting this affects disease progression, rather than HPV 
infection (Negrini et al. 1990). Although, there are general risks factor, such as 
smoking, infection with other STI’s, diet, multiple pregancies and family history, 
studies have shown that social class, religion and economic opportunities also 
play a role, with incidence of cervical cancer showing regional and cultural 
differences (Drain et al. 2002). Furthermore, infection with more than one HPV 
type is also associated with higher-grade lesions (Fife et al. 2001).
1.1.4 Detection and treatment
Detection of genital HPV infection is currently not performed on a population basis. 
Instead techniques using clinical diagnosis of potential pre-cancerous cells are 
employed. Techniques, each with different strengths, are Papanicolaou (Pap) 
smears and colposcopic morphology. During a Pap smear exfoliated genital cells 
are examined for increased nuclear/cytoplasmic ratio with darker and more 
Irregular nuclei (dyskaryosis). Dyskaryosis can be used as a marker for severity of 
the CIN lesion, with very severe dyskaryosis indicating invasive cancer (reviewed 
by Hudson 1990). Whilst this technique is very specific (-90%), it has poor 
sensitivity for HPV infection (reviewed by Trofatter 1997). Upon persistence of 
abnormal pap smears, a patient is referred for colposcopy (Gamzu et al. 2002). In
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this case cells of the cervix are swabbed with acetic acid and a colposcope is used 
to view the cells, with dysplasia showing as white areas. A biopsy is taken, 
followed by removal of abnormal cells. Colposcopy is very sensitive but, like pap 
smears can only detect clinically apparent infection (reviewed by Trofatter 1997).
Whilst population based Pap smear testing has reduced the incidence of cervical 
cancer, It is costly, time consuming and prone to human error. Furthermore, this 
type of screening is not performed in developing countries. Consequently, 
research is ongoing to produce reliable methods to detect infection with high-risk 
HPVs. Two such methods are PCR-ELISA and Hybrid Capture II (HC-II). PCR- 
ELISA involves labelled probe detection of a PCR product, generally amplified 
from the E7 or LI ORFs (Venturoli et al. 1998; Zerbini et al. 2001), whilst direct 
interaction of an RNA probe with viral DNA, followed by antibody recognition and 
chemiluminescent detection is the basis of HC-II (Ferris et al. 1998; Poljak et al.
1999). Both techniques show high correlation for HPV detection, and can be used 
to determine viral types, however HC-II is less complex (Venturoli et al. 2002). 
One problem with HC-II is its inability to detect integrated genomes (Clavel et al. 
1998), suggesting a combination of approaches may increase sensitivity and 
specificity of HPV detection.
Treatment against HPV infection generally involves physical removal of lesions. 
For example, periodic laser ablation of RRP lesions is currently the most effective 
treatment for the disease. However, this is costly and can be distressing for 
patients. Therefore, research is ongoing into production of vaccines targeting 
primarily cervical cancer associated HPV types, but also those associated with 
RRP. In June 2006 the American Food and Drug Administration (FDA) licensed a 
vaccine for prevention of cervical cancer and associated diseases (Gardasil, 
produced by Merck). This vaccine composes prophylactic quadrivalent virus like 
particles, comprising LI protein from HPV-16, -18, -6 and -11. Furthermore, 
GlaxoSmithKline (GSK), have developed a bivalent vaccine containing VLPs for 
HPV-16 and -18. Phase III trails for Gardasil and phase II for the GSK vaccine 
show no side effects and 99.7% of those vaccinated develop an antibody 
response (Koutsky et al. 2002; Harper et al. 2004; Villa et al. 2005). There is 
some debate as to when HPV vaccines should be administered. Studies suggest 
immunisation of pre-adolescent girls is most effective, however this is somewhat 
controversial, as these HPVs are sexually transmitted.
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1,1.5 The life cycle
Epithelial cells become more differentiated and less metabolically active the closer 
they move towards the surface of the epidermis, and the only layer that is 
mitotically active is the basal layer (Figure 1.3). Upon division, one daughter cell 
becomes committed to differentiation and moves into the spinous layer (reviewed 
by Fuchs and Byrne 1994). Spinous layer cells are metabolically active and are 
mainly involved in production of keratins, K1 and K10 (reviewed by Fuchs 1993). 
Lysine-rich envelope proteins, such as involucrin, begin to be produced in the 
upper spinous and granular layer (reviewed by Fuchs 1990). in the upper granular 
layer cells stop producing keratins and begin to express components of the 
corn if led envelope and keratin filament matrix proteins. Intracellular degradation 
begins as cells reach the cornified layer; cells become flattened and are sloughed 
from the surface. Major morphological changes associated with terminal 
differentiation of normal epithelial tissue are disintegration of the nucleus, 
extensive kératinisation (cross-linking of keratin intermediate filaments), formation 
of cornified envelopes and lipid secretion (reviewed by Madison 2003). These 
changes are required to form a physical barrier against the environment.
■f
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Figure 1.3: Uninfected and HPV infected epithelial tissue
A Schematic diagram of epithelial tissue, both uninfected and HPV 
infected. Epithelial tissue is composed of basal layer cells, capable of 
division and a number of suprabasa! layers, cells of which become more 
differentiated and less metabolically active the closer to the surface they 
become. Upon HPV infection, the nucleus is retained to allow viral 
replication and gene expression. Whilst not depicted here, extensive 
kératinisation is required to allow virus exit from the outer layers of the 
epithelium. Expression of capsid proteins, LI and L2 is restricted to only 
the most differentiated cells; however, transcripts are observed in less 
differentiated cells.
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PVs gain entry into basal epithelial cells through micro-lesions, via a receptor on 
the surface of the cell. There is some controversy as to the identity of the receptor 
with both heparan sulphate (Giroglou et al. 2001) and oe integrin (Evander et al.
1997) being implicated. Giroglou et al. have shown that infection using HPV-16 
and 33 pseudovirions can be blocked by heparin, a heparan sulphate ligand 
(Giroglou et al. 2001). Furthermore, HPV-16 VLPs Interact with heparan sulphate, 
and binding can be inhibited by increasing heparin concentration (Shafti-Keramat 
et al. 2003). However, other studies indicate heparan sulphate is not required for 
HPV-31b infection of human kératinocytes, although it is necessary for infection of 
some other cells (Patterson et al. 2005). Furthermore, HPV-6b VLP interaction 
with cells can be blocked by anti-Oe integrin antibodies (Evander et al. 1997), and 
expression of Oe integrin in negative cells lines results In VLP binding (McMillan et 
al. 1999). HPV-16 LI VLP binding to cells also correlates with Oe Integrin 
expression (Yoon et al. 2001). In addition, HPV-11 virions and VLPs interact with 
laminin 5 (LN5), a ligand of Oe integrin (Culp et al. 2006). Expression of Oe integrin 
is shown to be essential for infection of LN5 bound particles. In contrast, BPV-4 
infects og integrin positive and negative cells with similar efficiency (Sibbet et al.
2000). It has been proposed that binding to a secondary receptor is required for 
infection (Kawana et al. 2001; Yang et al. 2003). HPV-16 L2 interacts with an 
unknown cell surface protein and enhances infection, a process which Is thought 
to be partly involved in epithelial tropism (Kawana et al. 2001). In addition, Yang 
et al. showed that regions of HPV-16 and BPV-1 L2 are required for infection but 
are dispensible for binding to the cell surface (Yang et al. 2003), and Embers et al. 
showed neutralisation of HPV-16, -6 and 11 infection using anti-L2 antibodies 
(Embers et al. 2004). it has been suggested more recently that internalization of 
virions is relatively slow and that endocytosis of clathrin coated vesicles is required 
(Day et al. 2003; Culp and Christensen 2004; Embers et al. 2004). BPV-1 virions 
co-localise with AP-2, a clathrin adaptor molecule, and HPV-16 VLPs co-localise 
with BPV-1 virions (Day et al. 2003). HPV-16 LI VLPs endocytosis is also 
inhibited by nystatin, an inhibitor of clathrin mediated endocytosis (Bousarghin et 
al. 2002). However, the same study indicates that infection with HPV-31 LI and 
L1+L2 VLPs is not inhibited by nystatin and instead endocytosis is mediated by 
another pathway. Translocation to the nucleus and nuclear entry are thought to be 
mediated primarily by LI and L2, and are discussed further in section 1.1.6.5: L1 
and L2. Once in the nucleus, the genome is established as an episome at -10- 
200 copies per cell. It is thought that a productive phase follows initial infection.
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resulting in an increase in the number of basal cells containing the viral episome 
(reviewed by Doorbar 2005). PV-infection of basal layer cells allows persistence 
of the viral genome, as it is maintained and segregated equally into daughter cells 
at each cell division. This is achieved via association with the host chromosome 
and the genome replicates via theta structures in a bi-directional fashion.
Upon initiation of differentiation, virus infected cells of the spinous layer are 
induced to divide once more. Blockage of the cell cycle at Gg is then thought to 
create an environment for massive amplification of the virus genome via 
vegetative replication (Davy et ai. 2002). Rolling circle replication of viral DNA is 
thought to occur here as multiple copies of the genome are generated from one 
initiation event (reviewed by Lambert 1991; Flores and Lambert 1997). In 
accordance, the nucleus is retained not only to allow replication but also to enable 
expression and processing of late gene transcripts (Figure 1.3). Following genome 
amplification, capsid proteins are expressed and virions are produced. This is 
thought to occur at PML bodies within the nucleus, as these may be the sites of 
viral DNA replication (Day et ai. 1998; Swindle et ai. 1999). The virus is thought to 
escape desquamated cornified cells (DCCs), which are continuously shed from the 
stratum corneum. DCCs are shown to have fragile envelops and are suggested to 
act as a vehicle for delivery of virions to fresh sites of infection (Bryan and Brown
2001).
1.1.6 Gene expression
Although there are many differences between HPV types, and PVs infecting other 
organisms, the genome structure for all is largely similar (reviewed by Shah and 
Howiey 1996). PV gene expression is divided into early (E) and late (L) phases. 
E and L genes are encoded on one strand of the dsDNA genome and are 
produced depending upon the differentiation state of the cell (Figure 1.4) 
(reviewed by Laimins 1996). Replication and transcription are controlled by cis- 
acting sequences within a region of the PV genome called the Long Control region 
(LCR) (reviewed by zur Hausen 1996). Production of viral proteins as well as 
commencement of genome amplification occurs at differing stages of 
differentiation depending on the PV type. For example, genome amplification is 
observed in the mid or upper layers for alpha-PV types, such as HPV-16, where as 
HPV-1, a Mu-PV type, previously found in supergroup E, begins genome 
amplification as soon as cells leave the basal layer (Middleton et al. 2003). Gene
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expression is highly complex and is controlled at both transcriptional and post- 
transcriptional levels. A number of polycistronic RNAs are expressed using 
various promoters and polyadenylation signals. Furthermore, c/s-acting RNA 
elements are involved in directing the appropriate splice patterns depending on 
cell differentiation. Transcripts produced by HPV-16 in infected undifferentiated 
and differentiated epithelial cells have been mapped using RT-PCR and primer 
extension (Figure 1.5) (Milligan et al., 2006; Wildridge and Graham, unpublished). 
Extensive splicing is observed and a number of splice sites and promoters were 
found to be used. Transcripts with the potential to express novel, as well as the 
well-established proteins described below, were found. There are thought to be 
two major promoters, P97, immediately upstream of the E6 ORF (reviewed by 
Smotkin and Wettstein 1986; Grassmann et al. 1996), and Pezo, the differentiation 
specific promoter in the E7 ORF (Grassmann et al. 1996). Promoters are found at 
similar positions within the genome of other HPV types, such as HPV-18 and -31 
(Schneider-Gadicke and Schwarz 1986; Hummel et al. 1992; Ozbun and Meyers
1998). It is suggested that switching occurs between the two promoters several 
times during the virus life cycle. Further promoters have been proposed for HPV- 
16; P542 and p482, in front of the E7 ORF (Braunstein et al. 1999); P430, P441, P446, 
P483, and P489, within E6 (Rosenstierne et al. 2003); P3392. within E4 and P4062/64, 
within in E5 (Milligan et al., 2006), each of which is thought to contribute to overall 
protein expression.
In terms of polyadenylation signals, HPV-16 seems to be complex. There are 3 
polyadenylation signals: the early signal (pAE) at nt 4213, upstream of the L2 
ORF, and two late signals (pAL), at nts 7286 and 7343 (Kennedy et al. 1990). 
Polyadenylation Is regulated in both undifferentiated and differentiated cells by c/s- 
acting RNA elements, particularly in the early and late 3’UTRs. For example, a 
region of the early HPV-16 3'UTR which is U rich and interacts with components of 
the polyadenylation and cleavage machinery, enhances polyadenylation from the 
pAE in HeLa ceils (Zhao et al. 2005). In addition, the pAL signals differ in 
strength, with the more downstream containing a good consensus GU-rich region, 
which would bind polyadenylation factor CstF with more efficiency (see section 
1.2.3: Cleavage and Polyadenylation); however, both are used in vivo, with the 
major site at nt 7343 being used only in differentiated HPV-16 infected epithelial 
cells (Milligan et al., 2006).
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Figure 1.4: Papillomavirus genome structure
A Schematic diagram of a linearised version of the HPV-16 genome 
(not to scale). The major promoters, Pgy and Pg^ Q, as well as the early 
and late polyadenylation signal are shown. ORFs are depicted as 
coloured rectangles, with a summary of major gene functions given 
below each. The LCR is located after the LI ORF.
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Figure 1.5: Transcripts produced by HPV-16 in differentiated 
W12E ceils
A Schematic diagram of transcripts terminating at poly(A) Late 
produced by HPV-16 in differentiated infected epithelial cells (not to 
scale). A linearised version of the genome is shown at the top with 
transcripts depicted below. ORFs are shown as open rectangles with 
the late genes, LI and L2, in green. Arrowheads represent 
promoters, whilst thick bars indicate polyadenylation signals. Within 
the transcripts, diagonal thin lines represent regions that are removed 
by splicing and coding potential of each transcript is given to the right. 
Arrows indicate inferred but not tested termination at the late 
polyadenylation signal. Red stars indicate the most abundant 
transcripts. Transcripts containing El and E2 ORFs have been 
detected in differentiated cells, but terminate at poly(A) Early, and 
therefore are not shown on this figure.
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1.1.6.1 E6 and E7
Two early HPV proteins are E6 and E7, which are involved in inhibition of 
apoptosis and promotion of the cell cycle in basal layer ceils, and are the major 
transforming proteins of the virus (reviewed by Mantovani and Banks 2001; 
reviewed by Munger et al. 2001). Both proteins are expressed at low levels in 
basal layer ceils (Stanley et al. 1989) and continue to be expressed as the cell 
differentiates. E6 and E7 protein from both high and low-risk HPVs are thought to 
be involved in episomal maintenance, extending their roles within the virus life 
cycle (Thomas et al. 1999; Oh et al. 2004). Mutant E6 or E7 HPV-31 genomes 
were able to replicate In transiently transfected cells; however, only genomes with 
functional E6 and E7 were maintained in high copy number (Thomas et al. 1999). 
Similary, HPV-11 genomes lacking E6 or E7 expression were also unable to 
maintain the episomal genome in transfected cells (Oh et al. 2004). It is 
suggested that E6 and E7, modify the cellular environment to prevent removal of 
the extrachromosomal viral genomes.
E6 is -150 amino acids in length and contains two zinc finger-like motifs (Barbosa 
et ai. 1989). It interacts with a number of cellular proteins involved in tumour 
suppression, apoptosis and transcription, amongst other things. The most 
extensively studied interaction with E6 is that of tumour suppressor p53. p53 is 
activated in response to DNA damage and halts the cell cycle at specific 
checkpoints, at which point damage is repaired or the cell is committed to the 
apoptotic pathway (Lowe et al. 1994; Wu and Levine 1994). It is phosphorylated 
by cellular kinases ATM and ATR, and the phosphorylated form acts to 
transcriptional activate expression of genes involved in growth arrest and 
apoptosis (reviewed by Mercer et al. 2007). HPV-16 and -18 E6 are shown to 
interact with p53 in vitro (Werness et al. 1990). Furthermore, Lechner & Laimins 
showed binding affinities varied between p53 and E6 from different HPV types 
(Lechner and Laimins 1994). HPV-16 E6 bound most strongly, followed by -31, - 
18 and lastly -11, suggesting affinity may contribute to oncogenic potential. The 
HPV-16 E6-p53 interaction is important in vivo to stimulate ubiquitin mediated p53 
proteasome degradation (Scheffner et al. 1990). Furthemore, the half-life of p53 is 
significantly reduced in cells expressing HPV-18 E6 (Lechner et al. 1992). This is 
thought to be involved in inhibition of p53 mediated growth suppression and allows 
the G1/S checkpoint, which normally serves as a control for DNA-damaged cells, 
to be bypassed. For example, expression of HPV-16 E6 leads to reduction in p53.
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which correlates with it's ability to block actinomycin D induced growth arrest 
(Foster et al. 1994). In addition, inhibition of DNA synthesis in the epidermis 
following treatment with ionising radiation is abrogated in transgenic mice 
expression HPV-16 E6 (Song et al. 1998). Degradation of p53 is mediated via 
interaction with ceiluiar protein, E6-associated protein (E6AP). E6AP is an E3 
ubiquintin ligase and via interaction with HPV-16 and -18 E6, it mediates p53 
ubiquitination (Huibregtse et al. 1991; Huibregtse et al. 1993; Scheffner et al. 
1993). The role of E6AP in p53 degradation is aiso observed in HeLa cells, where 
overexpression results in decreased levels of p53 (Tails et al. 1998). Furthermore, 
a catalytically inactive E6AP can act as a dominant negative upon p53 regulation. 
No such effects were observed using an HPV negative cell line, suggesting E6AP 
mediates p53 degradation only in the presence of E6 (Tails et al. 1998). High-risk 
E6 also associates with other pro-apoptotic proteins, such as Bak (Thomas and 
Banks 1998). Bak is a Bcl-2 family member which is involved in reinforcing 
upstream apoptotic signals to push cells through apoptosis and is highly 
expressed in differentiating kératinocytes (Krajewski et al. 1996). HPV-18 E6 is 
shown to induce degradation of Bak, again via association with E6-AP, a process 
that inhibits apoptosis (Thomas and Banks 1998).
E6 Is also implicated in the degradation of PDZ-domain containing proteins, 
human discs large (hDIg), MAGI-1, -2 & -3, MUPP1 and human scribble (hScrib). 
These proteins are thought to act as tumour suppressors, and hDIg, MAGI-1 and 
MUPP1 are strong inhibitors of cellular transformation (Massiml et ai. 2004). 
Furthermore, HPV-18 E6 can overcome the growth suppression effects of hDIg. 
Kiyono et al. showed interaction between hDIg and both HPV-16 and -18 E6 via a 
PDZ-binding domain in the C-terminal region of E6 (Kiyono et al. 1997). This 
interaction was not observed with HPV-11 and -5  E6, suggesting it is a unique 
function of high-risk cervical HPVs. In addition, expression of HPV-16 but not 
HPV-11 E6 results in downregulation of hDIg via proteasome mediated 
degradation (Gardiol et al. 1999). A similar situation has been observed for MAGI- 
1, -2 & -3, MUPP1 and hScrib, where an interaction is necessary for proteasome 
mediated degradation (Glaunsinger et al. 2000; Lee et al. 2000; Nakagawa and 
Huibregtse 2000; Thomas et al. 2002). In addition to degrading hScrib, HPV-16 
E6 expression is shown to result in loss of integrity of tight junctions, as shown by 
the relocalisation of tight junction component ZO-1 (Nakagawa and Huibregtse 
2000). However, there is some debate as to the mechanisms involved in 
degradation. In the case of hScrib, HPV-39 E6 acts via E6AP, in a similar manner
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as described above for p53 (Nakagawa and Huibregtse 2000). HPV-16 E6 
interaction with E6-AP is also implicated in hDIg and hScrib degradation 
(Matsumoto et al. 2006). However, Pim et al. showed that mutant HPV-16 and -  
18 E6 proteins which are unable to bind E6AP and do not degrade p53, are still 
able to target hDIg for degradation (Pim et al. 2000). In addition, immunodepletion 
of E6AP from rabbit reticulocyte lysate inhibits HPV-16 E6 induced p53 but not 
MAGI-1 degradation (Sterlinko Grm et al. 2004). This suggests that mechanisms 
involved in PDZ-domain containing protein degradation may differ for each protein 
and possible HPV types. Regardless of the mode of degradation, the C-terminal 
PDZ-binding domain of HPV-16 and -18 E6 is necessary for cell transformation 
(Kiyono et al. 1997). In addition, transfections using PDZ-binding E6 mutant 
HPV-31 genomes, showed retarded growth and reduced viral copy number when 
compared to wild type (Lee and Laimins 2004), and mutant HPV-16 E6 was 
unable to induce epithelial hyperplasia in transgenic mice, despite retaining the 
ability to Inactivate p53 (Nguyen et al. 2003). This indicates that PDZ-domain 
containing protein binding by high-risk E6 is an important function of E6.
Apart from its function in degradation of a number of cellular proteins, E6 is 
involved in transcriptional regulation. In particular, interaction of HPV-16, -18 and 
BPV-1 E6 with, and subsequent inhibition of transcriptional activity of co-activators 
CBP/p300, is required for optimal transforming activity (Patel et al, 1999; 
Zimmermann et al. 1999; Zimmermann et al. 2000). CBP/p300 play roles in 
activation of a number of genes Involved in cell cycle regulation, differentiation and 
immune responses. HPV-16 E6 is shown to downregulate p53-mediated 
transcriptional regulation via interaction with CBP/p300 (Zimmermann et al. 1999). 
This is achieved in an E6AP independent manner, and E6 can displace the 
CBP/p300-p53 interaction, which is required for p53 to transactivate cellular 
promoters. Therefore, HPV-16 E6 not only causes degradation of p53, but also 
inhibts its activity. Furthermore, expression of HPV-16 E6 decreases the ability of 
CBP/p300 to activate p53 and NF-kappaB responsive promoters (Patel et al.
1999). NF-kappaB can regulate genes such as interleukins (ILs), and IL-8 
expression, which is Involved in the local immune response, requires NF-kappaB, 
CBP/p300 and related co-activator p/CAF for activation (Huang and McCance 
2002). HPV-16 E6 represses IL-8 expression by competing with NF-kappaB for 
CBP/p300 binding. Furthermore, HPV-16 and -18 E6 also interact with other co­
activators, such as hADA3, the yeast homologue of which bridges transcription 
factors with histone acétylation and the basal transcription machinery (Kumar et al.
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2002). E6 is shown to cause hADA3 degradation in vivo and also abrogates Its 
co-activation function with p53.
E7 is a smail protein of ~100 amino acids and contains an LXCXE motif and two 
zinc finger motifs (reviewed by Hebner and Laimins 2006). An important function 
of high-risk E7 oncoproteins is interaction with and degradation of the Rb family of 
proteins. Rb is a downstream target of p53 and is involved in celi-cycie control at 
the Gi/S phase checkpoint, via differential phosphorylation. Hypophosphorylated 
Rb interacts with E2F, preventing it from activating transcription of genes involved 
in S phase. Expression of HPV-16 E7 is shown to cause failure of G1 arrest 
following gamma-irradiation; however, whilst decreased hypophosphorylated Rb is 
detected, p53 levels are elevated (Demers et al. 1994; Slebos et al. 1994). In 
Caski cells, which express HPV-16 E7, both Rb and E7 are regulated by ubiquitin 
mediated proteasome degradation (Wang et al. 2001). E7 is shown to promote Rb 
ubiquitination, and inhibition of proteasomal degradation leads to an increase in 
hypophosphorylated Rb; however, Rb is not observed to complex with E2F, 
suggesting that E7 acts to block this interaction. Furthermore, HPV-18 E7 is 
shown to disrupt the Rb-E2F interaction in HeLa cells, without affecting E2F-cyclin 
A association, a complex that promotes E2F mediated transactivation and 
proliferation (Pagano et al. 1992). Although this is thought to be important to E7 
function, blocking the Rb-E2F interaction is not sufficient for HPV-16 E7 to inhibit 
anti-proliferative signals (Helt and Galloway 2001). Furthermore, a number of 
studies have revealed that inactivation of Rb by E7 is not the only factor involved 
in E7-induced transformation. For example, Balsitis et al. showed that Rb 
inactivation in transgenic mouse models does not account for the entire phenotype 
observed in mice expressing HPV-16 E7 in undifferentiated epithelial cells, and 
expression of E7 in Rb null mice was shown to increase hyperplasia and dysplasia 
(Balsitis et al. 2003; Balsitis et al. 2006). Furthermore, when HPV-16 E7 
transgenic mice were crossed with Rb mutant mice, in which Rb was unable to 
bind E7, a modest delay in terminal differentiation was observed (Balsitis et al.
2005). Indeed, HPV-16 E7 complexed with E2F-cyclin A/cdk2 in S phase (Arroyo 
et al. 1993). HPV-16 E7 interacts directly with E2F and synergism is seen 
between the two proteins upon activation of an E2F responsive promoter for cyciin 
E (Hwang et al. 2002). This is also observed in Rb negative cells, showing that 
this function of E7 is Rb-independent. Interaction of E7 with other Rb family 
members has also been observed. Whilst HPV-16 E7 disrupts association of E2F 
with Rb, and family members p i07 and p130, HPV-6 E7 only affects p i07 and
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p130 interactions with E2F (Armstrong and Roman 1997). This possibly reflects 
the transforming potential of the two E7 proteins.
E7 proteins are also shown to interact with cyclins and cyciin dependent kinases 
(cdk's), as well as cyciin kinase inhibitors (CKIs). HPV-16 E7 is thought to interact 
with cdk2, via cyciin A, an interaction which does not require Rb (Tommasino et ai.
1993). In addition, HPV-18 E7 associates with cyciin E in vitro and in vivo 
(McIntyre et al. 1996). Interaction is shown to be via p i07 and the complex 
phosphorylates pi 07, a function which is dependent upon cyciin E. HPV-16 E7 is 
also able to repress the CKI, p21^'^^ inhibitory activity upon cyciin E/cdk2 (Funk et 
ai. 1997). This is achieved via direct interaction between the two proteins and is 
thought to allow uncoupling of proliferation and differentiation in HPV-16 E7 
expressing kératinocytes (Jones et al. 1997). HPV-16 E7 also interacts with CKI 
P27KIP1 (Zerfass-Thome et al. 1996). This represses p27"^ "^  ^ inhibition of cyciin E 
and also its suppression of transcription of cyciin A. In addition, expression of 
HPV-16 E6 or E7 is suggested to cause genomic instability, which is llkeiy 
involved in malignant progression. For E6 this is thought to be achieved via 
inactivation of p53 (White et al. 1994); whereas, E7 is shown to cause abnormal 
centromere duplication when expressed in human kératinocytes (Duensing et al.
2000). Expression of mutant HPV-16 E7 that cannot inactivate CKI p21^"^\ does 
not induce centromere abnormalities. Furthermore, inhibition of cdk2, which is 
involved in linking centromere duplication with the GI/S transition, also abrogates 
E7s ability to induce centrosomal abnormalities (Duensing et al. 2000). In 
addition, HPV-16 E7 induces mis-segregation and aneuploidy, requiring the region 
spanning the Rb binding domain, but in a pRb independent manner (Duensing and 
Munger 2003). Expression of HPV-16 E6 or E7 in human kératinocytes also 
results in un- or misaligned chromosomes and an increase of genetic material is 
observed at metaphase (Duensing and Munger 2002). The anaphase checkpoint 
is also by-passed and a number of anaphase bridges, which reflect structural 
chromosomal abnormalities, are observed. However, expression of HPV-6 E6 and 
E7 have no effect on centromere or chromosomal stability, suggesting this is a 
function specific to the high-risk oncoproteins (Duensing and Munger 2002). This 
function for HPV-16 E6 and E7 is also evident in basal epithelial cells transfected 
with HPV-16 genomes (Duensing et ai. 2001). In addition to the role in malignant 
progression by mutation of cellular genes, it is suggested that genome instability 
may also stimulate integration of viral genomes (Melsheimer et al. 2004). 
Melsheimer et al. showed that a greater proportion of HPV-16 associated cervical
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lesions with integrated genomes show aneuploidy, when compared with the lower
percentage of aneuploid cell lines without integrated HPV-16 genomes.
1.1.6.2 E5
The E5 protein also has a role in cell transformation in some PV types, such as 
BPV-1 (DiMaio and Mattoon 2001); however, E5 is not detected in HPV 
associated tumour celis (DiMaio and Mattoon 2001). This does not rule out a 
proliferation stimulating activity of E5, which may function in benign lesions or in 
initiation of the carcinogenic process. E5 is predominantly expressed upon 
differentiation, although low levels are thought to be present in undifferentiated 
celis. Although there seems to be functional homology between E5 from different 
papillomavirus types, there is little sequence homology. In agreement, E5 from a 
number of papillomavirus types are known to down-regulate the major 
histocompatablilty complex (MHC) class I (Ashrafi et al. 2002; Ashrafi et al. 2005). 
MHC class I (or HLA I in humans) is involved in antigen presentation, followed by 
lysis by cytotoxic T lymphocytes of infected cells. The molecule is a ternary 
complex composed of heavy chain, p2 microglobulin and peptide (Solheim 1999). 
Down-regulation is achieved by several mechanisms including inhibition of heavy 
chain gene transcription or protein stability, and repression of complex assembly 
and/or transport (Ashrafi et al. 2006). HPV-16 E5 is known to cause retention of 
HLA I in the Golgi apparatus, hence preventing its transport to the cell surface 
(Ashrafi et al. 2005). This is achieved via interaction with the heavy chain 
component of the complex (Ashrafi et al. 2006). HPV-16 E5 also interacts with the 
16kD subunit of the vaculolar H^-ATPase and leads to increased presentation of 
the epidermal growth factor receptor (EGFR) on cells expressing E5 (Straight et al. 
1993; Straight et al. 1995). Furthermore, HPV-16 E5 interacts with ErbB-4, a 
growth factor receptor which is related to EGFR (reviewed by Carpenter 2003). 
This interaction inhibits ErbB-4 induced c-jun expression and phosphorylation, 
resulting in increased cell proliferation (Chen et al. 2007). These data suggest 
HPV-16 E5 may have a proliferative stimulatory function, which may function 
within benign lesions.
1.1.6.3 El and E2
El and E2, the viral replication and maintenance proteins are expressed at early 
stages in differentiated cells to massively increase the number of viral genomes by
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vegetative replication (Mohr et al. 1990; Winokur and McBride 1992). Although El 
and E2 expression is observed throughout the PV life cycle, the highest levels are 
observed upon differentiation when vegetative viral genome replication occurs 
(Maitland et al. 1998). Interaction of E2 with the viral LCR is thought to facilitate 
interaction of El with the proximal AT-rich, El binding site, via direct E1-E2 
interaction, whilst E l ATP-dependent heiicase activity is then involved in DNA 
unwinding and recruitment of cellular replication factors. Kuo et al. showed that 
both El and E2 are essential for HPV-11 DNA replication in a cell-free system 
complemented with cell extracts (Kuo et al. 1994). Furthermore, E2 is shown to 
inhibit El driven origin-independent replication. HPV-11 E1 DNA binding is largely 
non-specific and an E1 binding site is not essential for high affinity E1/E2 complex 
formation on the origin (Dixon et ai. 2000). HPV-16 El is also unable to associate 
with the origin in the absence of E2, and origin interaction is shown to require 
direct binding between E1 and E2 (Masterson et al. 1998). Similarly HPV-31 b E1- 
origin association requires E2 binding sites and is enhanced by E2 (Frattini and 
Laimins 1994). In contrast, BPV-1 replication using a cell-free system 
complemented with mouse or HeLa cell extracts, show that E2 is not an absolute 
requirement for replication (Muller et al. 1994). However, at low levels of E1, E2 
stimulates El origin binding and origin-specific unwinding, without affecting 
heiicase activity (Seo et al. 1993). In addition, like HPV-11 E2, BPV-1 E2 
suppresses non-origin dependent replication by E1 (Bonne-Andrea et al. 1997). 
HPV-1 a El is also sufficient for replication of HPV-1 a and BPV-1 origin containing 
plasmids in vivo] however, both HPV-1 a El and E2 are required for replication 
from HPV-6b and HPV-18 origins (Gopaiakrishnan and Khan 1994). This 
suggests the intrinsic strength of the El binding site, rather than the El protein 
itself, may determine whether E2 is required or not. However, in either case, E2 
seems to ensure replication from the viral origin and not any other site.
In addition to E1 and E2, papillomavirus replication is shown to require a number 
of cellular proteins. For example, HPV-11 cell-free DNA replication requires the 
HPV-11 origin sequence, DNA polymerase a and 5, replication protein A and 
topoisomerase I and II (Kuo et al. 1994). DNA polymerase a/primase is the key 
enzyme involved in initiation of DNA synthesis and is composed of four subunits: 
p i 80, the polymerase, p58 and p49, with primase activity and p70, a cell cycle 
dependent phospho-protein. HPV-16 and HPV-11 El interact with the p70 subunit 
(Masterson et al. 1998; Conger et al. 1999). In addition, HPV-11 and BPV-1 El 
associate with the pi 80 subunit (Park et al. 1994; Conger et al. 1999). Interaction
_ __
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of HPV-11 E2 with both p70 and pi 80 subunits was shown to be essential for viral 
DNA replication (Conger et al. 1999). In addition, antibody’s recognising pi 80 
inhibited BPV-1 viral replication in cell-free systems (Park et al. 1994). This 
suggests that recruitment of DNA polymerase a/primase to the viral origin is 
essential to replication. Furthermore, BPV-1 El interacts with the replication 
protein A (RPA) complex (Han et al. 1999). The RPA complex, which is 
composed of three subunits, associates with single stranded DNA (ssDNA) and 
has roles during DNA replication, repair and recombination. Loo and Melendy 
showed that BPV-1 El-RPA interaction can be inhibited by increasing 
concentrations of ssDNA (Loo and Melendy 2004). It is suggested that disruption 
of the El-RPA complex results in continuous recruitment of RPA to the replication 
fork, due to the proximity of ssDNA from the lagging strand throughout replication. 
More recently, HPV-11 and BPV-1 El have been found to interact with 
topoisomerase I (topo I), a protein involved in decreasing torsional stress of 
supercoiled DNA (Glower et al. 2006). Interaction was shown to stimulate topo I 
relaxation activity upon the PV origin (Glower et al. 2006) and viral DNA unwinding 
mediated by HPV-11 E1 requires topo I, as well as RPA, to proceed (Lin et al.
2002). In addition, recruitment of BPV-1 El to the viral origin was stimulated by 
topo I, but not RPA or DNA polymerase a/primase, in vitro. HPV-11 E2 aiso 
interacts with topo I (Glower et al. 2006). This interaction stimulates DNA 
relaxation activity in an origin independent manner, but does not affect E2 DNA 
binding.
Other cellular proteins involved in PV replication include chaperones. HPV-11 El 
associates with molecular chaperons hsp70 and hsp40 (Liu et al. 1998). These 
interactions independently enhance El-origin binding and replication in a cell-free 
system, however no synergism was shown between the two proteins. Whilst El 
predominantly binds DNA as a hexamer in the absence of chaperons, hsp 40 
promotes di-hexamer formation (Liu et al. 1998). As El functions as a hexamer in 
DNA unwinding, formation of di-hexamers would provide enough El for bi­
directional unwinding of DNA. Phosphorylation of El is also important, and BPV-1 
and HPV-11 El interact with cyciin E/cdk complexes, via cyciin E, a regulator of S 
phase during the cell cycle (Gueille et al. 1998; Ma et al. 1999). Phosphorylation 
of HPV-11 El is important for replication (Ma et al. 1999) and is shown to be 
achieved using one or more cyclin/cdk complexes in vivo (Gueille et al. 1998). 
Deng et al. showed that non-phosphorylated El has cytoplasmic localisation due 
to a nuclear export signal (NES) (Deng et al. 2004). This was inactivated by cdk
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phosphorylation, resulting in E1 nuclear retention, where it is available to regulate 
viral DNA replication. In contrast, cyciin A/cdk2 phosphorylation of BPV-1 El on 
Serine 283 is not required for viral replication (Hsu et al. 2006). Instead this 
promotes nucleo-cytoplasmic shuttling in S phase, when cyciin A/cdk2 is active, a 
process thought to prevent viral replication.
E2 is a well-studied protein of approximately 42 kDa, and has many roles in both 
undifferentiated and differentiated cells. The E2 protein has been functionally 
divided into three regions: (1) the N-terminal, transactivation domain, (2) the C- 
terminal, DNA binding and dimerization domain and (3) the hinge region joining 
the two (Hegde and Androphy 1998; Antson et al. 2000). In BPV-1, splice 
variation results in expression of three forms of the protein: E2-TA 
(transactivation), containing ail three domains, and two truncated versions, E2-TR 
and E8/E2-TR (trans-repression) (Choe et al. 1989). E2-TR contains the hinge 
and C-terminal domain, whilst the E8 ORF, which is located in the El ORF spliced 
to the E2 mRNA, also containing the C-terminal region, encodes E8/E2-TR. It is 
thought that E2-TR and E8/E2-TR act as dominant negatives of E2-TA, as they 
retain DNA binding and dimerization activity but lack the ability to control 
transcriptional regulation (Lambert et al. 1987). The transactivation and DNA 
binding domains are largely conserved among different PV types; however, the 
hinge is variable in both length and sequence (McBride et al. 1989; Gauthier et ai. 
1991).
in basal layer cells E2 is known to tether virus genomes to the ceiluiar 
chromosome to ensure equal partitioning to daughter cells during cell division. For 
example, BPV-1 genomes, as well BPV-1 E2 are shown to associate with mitotic 
chromosomes, in a DNA binding independent manner, via the N terminal region, 
throughout mitosis (Skiadopoulos and McBride 1998; Bastien and McBride 2000). 
In contrast, HPV-11, -16 and -18 E2 co-localise with mitotic chromosome during 
prophase and metaphase and migrate to the central spindle microtubules at 
anaphase, requiring the C-terminal region (Dao et al. 2006). This is again 
achieved via interactions with cellular proteins and recently interaction with mitotic 
chromosome binding protein, Brd4 was observed between the E2 protein of some 
PV types (You et ai. 2004; Baxter et al. 2005). You et al. have shown that BPV-1 
E2 interacts with Brd4 via the Brd4 C-terminal domain (Brd4-CTD) and that 
expression of Brd4-CTD inhibited viral episome association with mitotic 
chromosomes and BPV-1 mediated cell transformation, in a dominant negative
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fashion (You et al. 2004). Brd4 was seen to relocate from diffuse coating of 
condensed chromatin, to random punctuate dots in BPV-1 E2 expressing cells 
(McPhillips et al. 2005). Furthermore, studies using yeast plasmids containing an 
autonomous replication site (ARS) and E2 binding sites to replace the centromeric 
(CEN) maintenance element, have shown that Brd4 is required for BPV-1 E2 
induced maintenance of the plasmid (Brannon et al. 2005). Stable expression of 
Brd4-CTD in BPV-1 transformed cell lines also results in morphoiogical reversion 
and complete elimination of viral DNA (You et al. 2005). HPV-16 E2 was also 
shown to interacts with Brd4 and abolishment of binding eliminates chromosome 
association (Baxter et al. 2005). However, further analysis has revealed that this 
interaction is not required for viral replication and instead Brd4 acts to regulate 
HPV-16 E2-mediated transcription (Schweiger et al. 2006). In support of this, co­
localisation of HPV-16, as well as -11, -31 and -57 E2 with mitotic chromosome 
does not require Brd4 interaction (McPhillips et al. 2006) and no interaction is 
observed between HPV-11, -16 and -18 E2 with Brd4 during mitosis (Dao et al. 
2006). Therefore, Brd4 interaction with a-PV E2 proteins is suggested to regulate 
transcription rather than replication or maintenance of viral genomes. It is also 
thought that binding of HPV-11 E2 to E1BS proximal sites within the LCR may play 
a role in preventing binding of negative regulators, such as CCAAT displacement 
protein (GDP) to the origin of replication (Narahari et al. 2006). GDP association 
with the origin is decreased in E2 expressing cells. Furthermore, E2 is shown to 
alleviate GDP mediated inhibition of replication (Narahari et al. 2006).
Another cellular process E2 is known to be involved in is apoptosis. HPV-18 and 
BPV-1 E2 have been shown to repress endogenous E6/E7 expression in HeLa 
cells (Desaintes et al. 1997). An increase in p53 transcription activity is observed, 
which Is required for E2-induced G1 arrest but not apoptosis. Furthermore, HPV- 
18 and BPV-1 E2 do not activate the main p53 responsive gene involved in 
promotion of apoptosis, Bax, even though p53 levels are increased (Desaintes et 
al. 1999). p53 accumulates after E2-induced apoptosis has begun, suggesting it is 
not involved in this process. In contrast a downstream target of p53
is transcriptionally activated by E2 expression, leading to G1 arrest (Desaintes et 
ai. 1999). HPV-16 E2 has also been shown to interact directly with p53 via the G- 
terminal domain (Massimi et al. 1999). This interaction correlates with the ability 
of p53 to inhibit HPV DNA replication. Furthermore, HPV-16 E2 expression in 
HPV transformed cells results in decreased growth and cell death (Sanchez-Perez 
et al. 1997; Webster et al. 2000). HPV-16 E2 also promotes apoptosis in non-HPV
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transformed cells, which correlates strongly with p53 binding (Parish et al. 2006). 
However, HPV-18 E2 can induce apoptosis in p53 negative cells (Demeret et al.
2003). This is found to be achieved via activation of Caspase 8 by autocleavage 
(Demeret et ai. 2003; Biachon et al. 2005). In addition, p53 binding is dispensable 
for E2-induced apoptosis in HPV-transformed cells, in agreement with previous 
data (Parish et al. 2006). in the same study, HPV-6 and -11 E2 failed to induce 
apoptosis and did not interact with p53. Blanchon et al. show that induction of 
apoptosis by E2 proteins from different PV types may be a consequence of cellular 
localisation (Biachon et al. 2005). HPV-16 and -18 E2 are found to shuttle 
between the nucleus and the cytoplasm, whereas HPV-6 and -11 E2 are 
predominantly nuclear. Cytoplasmic location is shown to correlate with apoptosis 
(Biachon et al. 2005).
E2 proteins are known to transcriptionally activate/repress the viral LCR, via a 
number of E2 binding sites (E2BSs). In the case of HPV-16 and other mucosal PV 
types, such as HPV-18 and BPV-4, 4 E2BSs are present within the LCR, each 
differing in E2 binding affinity (Figure 1.6) (reviewed by Kalantari and Bernard
2006). Differential binding of E2 to these sites, which is at least partly due to E2 
levels, is known to affect the repression/activation of E6 and E7 (or E5 and E7 in 
the case of BPV-4), as well as viral genome replication, via the early promoter 
(Steger and Corbach 1997; Morgan et al. 1998). For example, at low to 
intermediate concentrations BPV-4 E2 activates E5/E7 transcription (Morgan et al. 
1998). Conversely, as E2 levels rise, E5/E7 expression is inhibited and mutation 
of E2BS1, which is 3bp upstream of the TATA-box, results in abrogation of trans­
repression by E2. A similar situation is observed for HPV-18, where low E2 
expression allows transactivation at the early promoter, whereas high E2 causes 
repression (Steger and Corbach 1997). HPV-18 E2 has high affinity for BS4, 
binding of which is thought to be involved In transactivation of the early promoter. 
Furthermore, affinity for E2BS1 is low; suggesting binding of this site at high 
concentrations of E2 is involved in repression. In agreement, BPV-1 E2 binds 
E2BS1 from the HPV-18 LCR with high affinity and is able to repress the promoter 
more efficiently than HPV-18 E2 (Steger and Corbach 1997). The proximity of 
E2BS1 with the TATA-box is suggested to inhibit recruitment of TBP to the 
promoter, and hence to prevent Pre-initiation complex formation, as in the case of 
BPV-1 (Dostatni et al. 1991). Indeed, mutation of E2BS1 in the BPV-4 LCR Inhibits 
repression of the early promoter at high levels of E2 (Morgan et al. 1998). For 
HPV-18, E2BSs 1-3 are required for full repression of the early promoter in
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epithelial cells, and displacement of Sp1 when E2 occupies BS2 is thought to 
contribute to this (Demeret et al. 1997). HPV-16 E2 is also shown to displace Spl 
from the overlapping Spl BS when bound to BS2, and E2BS1 & 2 are again 
shown to be necessary for repression (Tan et al. 1994). Sp1 is elevated in 
epithelial cells, such as HaCaT cells, when compared with fibroblasts, and it is 
suggested to be a major cellular factor controlling expression from the HPV-16 
early promoter (Apt et al. 1996). In addition, Spl can transactivate the HPV-18 
LCR via the promoter proximal binding site overlapping E2BS2 (Hoppe-Seyler and 
Butz 1992). This suggests displacement of Sp1 from the E2BS2 proximal Spl 
binding site within mucosal PV LCRs is important to repression of the early 
promoter by E2. However, binding of HPV-16 E2 to BS1 & 2 results in increased 
repression, compared with binding to either site alone, indicating that displacement 
of both Sp1 and TBP are required for efficient repression (Tan et al. 1992; Tan et 
al. 1994). In contrast, Bechtold et al. reported that high expression of HPV-16 E2 
represses E6 and E7 from integrated HPV-16 genomes; however, no such 
repression was observed in cells containing episomal copies of HPV-16 (Bechtold 
et al. 2003). This is suggested to be due to the closed conformation of the HPV- 
16 p97 promoter in episome containing cells. However, it is not clear at what 
stage of differentiation cells were assayed for E6/E7 repression and it is possible 
that the chromatin conformation of the promoter may change throughout 
differentiation to help control E6/E7 expression. Therefore, HPV-16 E2 may be 
able to repress the p97 promoter in episomally infected cells only at certain stages 
of differentiation.
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In addition to E2 responsive regions and Sp1 binding sites, a number of other 
celiular transcription factor (TF) binding sites are found within the LCR, and 
interaction of E2 with cellular proteins is known to affect transcriptional activity. A 
region between E2BS 3 and 4, the tissue specific enhancer, is shown to cause 
transactivation in only keratin expressing cells via synergism of a number of 
cellular TFs (Figure 1.6). For example, expression from the HPV-18 LCR is 
specifically enhanced in epithelial cells (Bernard et al. 1989). Similarly, sequences 
in the HPV-16 LCR respond to celiular factors in kératinocytes and cervical cancer 
celis, but not fibroblasts (Cripe et ai. 1987). The BPV-4 LCR, and specifically a 
region between E2BS3 & 4, is also shown to confer expression of reporter 
constructs in kératinocytes, but not fibroblasts (Morgan et al. 1999). In addition, 
BPV-4 E2 shows similar tissue specificity with respect to BPV-4 early promoter 
regulation (Morgan et al, 1998) This was found to be a promoter specific affect, as 
E2 was able to transactivate the BPV-4 LCR, when it was fused to an SV40 
promoter, in both epithelial ceils and fibroblasts. HPV-16 E2 is also shown to 
activate the BPV-4 early promoter in epithelial cells (Vance et al. 1999). In this 
study, a thymidine kinase (tk) promoter was fused to the 5’ region of the LCR 
containing the early promoter and E2BS1 & 2, with 6 adjacent consensus E2BSs 
upstream. HPV-16 E2 activated this promoter with 10-fold more efficiency in 
epithelial cells, compared with fibroblasts. Therefore, epithelial specificity of E2 is 
not reliant on the enhancer region (Vance et al. 1999). As well as E2, cellular 
proteins are suggested to be involved in tissue specificity via the LCR. As 
discussed, Spl levels are elevated in epithelial cells, suggesting this may be 
involved (Apt et ai. 1996). Furthermore, cellular factors, such as C/EBP and AP-1 
are shown to associate with the HPV-31 LCR enhancer region in vitro (Sen et al.
2004). Similarly, binding sites for several TFs, including C/EBP, AP-1, NF1, and 
Oct-1 are found within the HPV-16 LCR (Sibbet and Campo 1990; Chong et al.
1991). Using DNAse I protection a number of footprints are observed within the 
HPV-16 LCR in the presence of HeLa extracts in the epithelial enhancer region 
between E2BS3 & 4 (Gloss et al. 1989). In addition to E2 responsive elements 
and the epithelial specific enhancer, there are also repressor sequences within the 
LCR. A region of the BPV-4 LCR, upstream of E2BS2 and overlapping the origin 
of replication, confers repression in the context of the LCR, as well as the SV40 
promoter (Vance et al. 2001). This element binds a SOKda cellular protein in 
epithelial cells and fibroblast, suggesting its repressive activity is ubiquitous. A 
similar element is found within the HPV-16 LCR, which contains two similar
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sequences, found to bind the same complex in vitro (O'Connor et al. 1998). This 
element also represses in the context of the SV40 enhancer and tk promoter, and 
is found to be orientation-independent but position-dependent. A silencer, which is 
acted upon by YY1, is also located within the HPV-16 LCR (O'Connor et al. 1996). 
Repression is achieved by inhibition of AP-1 transactivation via interactions with a 
binding site within the silencer region (O'Connor et al. 1996). In addition, siRNA 
mediated knock-down of Brd4 is shown to reduce repression of the E6 promoter in 
HeLa cells (Wu et ai. 2006). E2 association with the LCR is enhanced in 
increasing Brd4 concentrations, whilst there is a reduction In TFIID and RNA 
polymerase II recruitment. This suggests the LCR of mucosal PV types is 
complex and is acted on by a number of ceiluiar factors to ensure correct 
transcriptional regulation during the viral life cycle.
E2 is known to regulate cellular genes, for which cellular factors are again 
necessary. For example, BPV-1 E2 interacts with Spl, a cellular transcription 
factor, an interaction which can target E2 to promoters lacking E2 binding sites, 
resulting in regulation of transcription (Li et al. 1991). Sp1-E2 interaction also 
facilitates downregulation of telomerase via Spl binding sites within the hTERT 
promoter, a function common to both high and low-risk types, HPV-6, -11,-16 and 
-18 (Lee et al. 2002). In addition, HPV-8 E2 has been shown to interact with Sp1 
and activate p21^^^^^ '^^  ^ expression via a region proximal to the transcription start 
site containing a number of Spl binding sites (Steger et al. 2002). In this case, the 
HPV-8 E2 hinge region is shown to be necessary for synergism with Spl, whereas 
HPV-18 E2 transactivation domain mutants are unable to support 
transactivation. Other cellular proteins HPV-8, -16, -18 and BPV-1 E2 are known 
to interact with include C/EBPa and p, which are involved in regulation of 
keratinocyte differentiation in the epithelium (Hadaschik et al. 2003). The 
interaction is mediated by the C-terminal region of HPV-8 E2 and synergises 
transcriptional activation from both a synthetic promoter containing C/EBPp and 
the proximal involucrin promoter containing C/EBPa sites. Transactivation is 
independent of E2 binding sites within the DNA, but is dependent upon interaction 
of E2 with C/EBP, as mutant forms of E2 that do not interact with C/EBP, do not 
synergise transactivation. This suggests E2 may promote keratinocyte 
differentiation. In addition, HPV-8 and -18 E2 downregulate p4-integrin 
expression, which is involved in detachment of kératinocytes from the basement 
membrane (Oldak et al. 2004). Whilst HPV-18 E2 is also shown to induce
I
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apoptosis, HPV-8 does not and can bind the p4-integrin promoter directly, which 
results in displacement of one or more cellular factor.
Like many viral transcriptional regulating proteins, E2 from several PV types is 
known to interact with a number of components of the basal transcription 
machinery. Interaction with these components can affect formation of the pre­
initiation complex (PIC), composed of a number of TF complexes and RNA 
polymerase II itself, and can therefore affect the frequency of transcription 
initiation. For example, interaction has been observed between BPV-1 E2, and 
TATA-box binding protein (TBP), via the C-terminal region and TFIIB, via the 
transactivation domain (Rank and Lambert 1995; Benson et al. 1997). TBP is a 
component of TFIID that binds DNA directly via the TATA-box, whilst TFIIB is 
recruited to the complex following TFIIA and TFIID, but prior to RNA polymerase II. 
HPV-8 E2 also associates with TBP, requiring its C-terminal region (Enzenauer et 
al. 1998), whilst HPV-16 E2 interacts with TFIIB (Benson et al. 1997). In the case 
of BPV-1, co-operative association of TBP and E2 to a minimal promoter 
containing only E2 binding sites (E2BSs) and a TATA element is involved in E2 
mediated transcriptional control, depending on the distance between the elements 
(Dostatni et al. 1991; Steger et al. 1995). When E2BSs are placed 3nt from the 
TATA-box, TBP binding is inhibited. In the case of HPV-11, repression of 
transcription is not alleviated by pre-formation of TBP-TATA complex, suggesting 
E2 does not simply cause steric hindrance but represses PIC formation at a stage 
later than this (Hou et al. 2000). However, for BPV-1 E2, with 8nts separating 
E2BSs and the TATA-box the two proteins interact with the promoter co­
operatively, requiring the E2 hinge region (Ham et al. 1994; Steger et al. 1995). In 
this case E2 is shown to activate transcription not by increasing recruitment of 
TBP, but by decreasing its dissociation rate with the TATA element, thereby 
stabilising formation of the PIC (Ham et al. 1994). HPV-8, -18 and BPV-1 E2 
proteins are also known to interact with other components of TFIID, known as 
TBP-associated factors (TAFs) (Enzenauer et al. 1998; Carrillo et al. 2004). HPV- 
8 E2 interacts with TAFII55 in vitro via the hinge and C-terminal region (Enzenauer 
et al. 1998), whilst HPV-18 and BPV-1 associate with TAFII80 and TAFII250 
(Carrillo et al. 2004). Interaction with TAFII250, which inhibits binding of TBP to 
the TATA-box (Liu et al. 1998), was found to differ in strength between the two 
BPV-1 and HPV-18 E2 proteins (Carrillo et al. 2004). As TAFII250-E2 interaction 
has the potential to affect TBP-promoter association, this difference may reflect
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the fact that BPV-1 E2 is a stronger viral transactivator than HPV-18 E2. 
However, both E2 proteins interact with TAFII80 with similar strength, suggesting 
this interaction may be important to the transcriptional activity of E2 proteins in 
general.
Further to interactions observed with cellular transcription factors, E2 also interacts 
with co-activators, which affect transcription via indirect association with DNA. For 
example, HPV-18 E2 interacts with cellular co-activator, cAMP response element- 
binding protein-binding protein (CBP) and p300, via the N-terminal transactivation 
domain (Lee et ai. 2000). CBP/p300 has a role in preventing the Gq/Gi transition 
during the cell cycle and its transactivation function is necessary for E2-mediated 
growth arrest in HeLa celis. This interaction was found to be necessary for HPV- 
18 E2 dependent transcription as sequestration of CBP/p300 by Adenovirus El A, 
a protein known to interact with it, resulted in inhibition of E2 activated transcription 
from constructs containing E2 binding sites within the promoter (Lee et al. 2000). 
Furthermore, CBP/p300 contains Histone Acetyl Transferase (HAT) activity, which 
when lacking from the protein synergises with HPV-18 E2 only modestly, 
suggesting this may be necessary for E2 mediated transcription. HPV-8 E2 also 
binds to p300, an interaction which again synergises transcription (Muller et al. 
2002). p300 is shown to be upregulated during epithelial differentiation in this 
report, suggesting it may be involved in differentiation specific transcriptional 
regulation by E2. Furthermore, a similar co-activator, which is known to interact 
with CBP/p300, p300/CREB-binding protein-associated factor (p/CAF), also 
contains HAT activity and can synergise HPV-18 E2 transcription in a similar 
fashion to CBP/p300 (Lee et al. 2002). Interaction was observed between p/CAF 
and HPV-18 E2 in vivo and with HPV-6b, -11 and -16 E2 in vitro, requiring the 
transactivation domain. Indeed, overexpression of both CBP/p300 and p/CAF 
increases HPV-18 E2 mediated transcription to greater extent than either protein 
alone, suggesting possible co-operative recruitment of the two proteins by E2. 
Furthermore, as for CBP/p300, the HAT function of p/CAF is essential as HAT 
mutants are shown to inhibit transcription (Lee et al. 2002). HPV-16 E2 also 
interacts with topoisomerase II p-binding protein 1 (TopBPI) (Boner et al. 2002). 
TopBPI has 8 BRCA1 domains, which are involved in the response to DNA 
damage, transcription and replication, in its C-terminal region. Interaction is 
mediated via the N-terminal domain of E2 and is shown to enhance transcription 
and possibly replication. E2 mutants within the N-terminal domain do not support
"  -i-i
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TopBPI mediate transactivation; however this domain does not act as a dominant 
negative (Boner et al. 2002), suggesting TopBPI may not be an essential cellular 
partner for E2-mediated transcription.
E2 has also been found to interact with other papillomavirus proteins. As 
discussed, E2 binds to E1 to facilitate viral genome replication (Mohr et al. 1990;
Berg and Stenlund 1997). Furthermore, E2 is known to associate with both viral 
oncoproteins E6 and E7 (Grm et ai. 2005; Gammoh et al. 2006). HPV-16 E2 is 
shown to cause redistribution of HPV-18 E6 from diffuse staining throughout the 
celis to predominantly nuclear localisation (Grm et al. 2005). Direct interaction 
with HPV-16 E6 is shown to be mediated by HPV-16 E2 C-terminal sequences.
This interaction results in increased E2 transcriptional activity but inhibits E2 
mediated replication. The ability of HPV-16 and -18 E6 to degrade MAGI-1 and 
MAG I-3 is also disrupted in cells expressing HPV-16 E2 (Grm et al. 2005). 
Furthermore, binding of HPV-16 E2, via the hinge region, to HPV-16 E7 is thought 
to inhibit celiular transformation by E7 (Gammoh et al. 2006). As expression of E2 
results in stabilisation of E7, it is suggested that E2 inhibits transformation by 
sequestering E7 to mitotic chromosomes. For HPV-16, interaction of E2 with the 
minor capsid protein L2 is also known to inhibit E2 mediated transactivation; 
however, replication was unaffected (Okoye et al. 2005). An L2-E2 interaction is 
not essential for inhibition. E2 levels were seen to decrease in HaCaT but not 
C33A ceils, upon co-transfection with L2. This suggests L2 may not act by 
decreasing E2 levels, as a similar degree of transactivation inhibition was 
observed in each cell line. Although it is not known whether E2 can 
simultaneously interact with factors controlling replication and transcription, it is -g 
possible that the choice of interaction may influence the replication and 
transcription states of the virus (Rank and Lambert 1995). Furthermore, the 
choice of interaction, with both viral and cellular proteins, may also regulate which 
genes are up and down-regulated by E2 in a particular cell.
1.1.6.4E1^E4
As the cell differentiates, late proteins begin to be expressed. E4, which is 
expressed as a chimera with five amino acids from the N-terminus of El and is 
known as 2:1*54, was named an early protein due to its position within the 
genome. However, although it is expressed throughout the life cycle, it is most 
abundant at later times during productive infection (Doorbar et al. 1997). E1*E4 is
3
__
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a small protein which accumulates in the cytoplasm and there is little sequence 
homology between different HPV types (Doorbar et al. 1989; Roberts et al. 1997). 
HPV-1 E1*E4 is progressively cleaved from the N-terminus to produce 4 isoforms: 
17K, 16K, 11K and 10K. The protein is also known to oligomerise and little is 
thought to be in monomeric form within infected cells (Doorbar et al. 1996; 
Ashmole et al. 1998). It is a multifunctional protein and there is some debate as to 
the functions of E1*E4 from different viral types. For example, interaction with 
keratin intermediate filaments is observed for both HPV-1 and -16 E1*E4 (Doorbar 
et al. 1991; Roberts et al. 1994). This is achieved via a LLXLL motif in the N- 
terminal region (Roberts et al. 1994). HPV-16 E1*E4 binds keratin 18 directly via 
this motif and can homo-oligomerise via the C-terminus, providing a mechanism 
whereby E1*E4 can cause filament cross-linking (Wang et al. 2004). Whilst the 
cytokeratin network is seen to collapse in cells overexpressing HPV-16 E1*E4, this 
is not the case in HPV-1 E1*E4 expressing cells (Doorbar et al. 1991; Roberts et 
al. 1993). In addition, mutations in the C-terminus of HPV-16 E1*E4 are shown to 
inhibit cytokeratin collapse, indicating that homo-oligomerisation of the protein may 
be important to this function (Roberts et al. 1997). Following network collapse 
HPV-16 E1*E4 associates with mitochondria, causing their detachment from 
microtubules (Raj et al. 2004). This results in a reduction in the membrane 
potential and induction of apoptosis, which is suggested to make cells more fragile 
ready for virion egress.
HPV-16 E1*E4 has been shown to block cells in G2 of the cell cycle possibly 
creating an environment for vegetative replication of the genome to occur (Davy et 
al. 2002). A region within the N terminus containing a putative NLS, cyclin-binding 
site and cdk phosphorylation site is shown to be required. HPV-11 and -18 E1*E4 
can also induce G2/M arrest (Davy et al. 2002; Nakahara et al. 2002). In contrast 
HPV-1 E1*E4 is shown in one study to cause arrest (Knight et ai. 2004); however 
in another no such phenonmenon is observed in E1*E4 expressing cells (Davy et 
al. 2002). The discrepancy is probably due to expression of different E1*E4 
isoforms, as the latter study focused on the full length 17K form, whilst Knight et al. 
used the N terminal truncated 16K isoform. In all Instances studied so far 
however, G2/M arrest is achieved by retaining cdkl/cyciin B1, the cyciin kinase 
complex required for progression into mitosis. In the cytokeratin networks of 
infected cells (Nakahara et ai. 2002; Knight et al. 2004; Davy et al. 2005). For 
HPV-16, E1*E4 mutants which are unable to bind cdkl are unable to induce G2 
arrest (Davy et al. 2005). Furthermore, HPV-16 E1*E4 associates with cyciin A2,
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which is involved in the G2/M transition (Davy et al. 2006). This interaction is 
observed in G2 cells and results in redistribution of cyciin A2 to the cytoplasm. 
The requirement for E1*E4 for vegetative viral genome replication is also 
somewhat controversial. Studies investigating this use kératinocytes transfected 
with E1*E4 null mutant genomes in raft culture. Whilst HPV-11 E1*E4 is shown to 
be dispensable for viral genome amplification (Fang et al. 2006), both HPV-16 and 
-31 E1*E4 seem to be necessary (Nakahara et al. 2005; Wilson et at. 2005). 
Furthermore, HPV-16 E1*E4 is shown to contribute to episome replication in 
undifferentiated cells, and low levels of expression are observed in these cells 
(Nakahara et al. 2005); however, HPV-31 E1*E4 does not affect episome 
maintenance or early gene expression (Wilson et al. 2005). In addition, HPV-16, 
but not HPV-1 or - 6, E1*E4 associates with E4-DEAD box protein (E4-DBP), via 
the C-terminal region (Doorbar et al. 2000). E4-DBP Is a shuttling protein with 
RNA heiicase activity. Interaction between the two proteins results in cytoplasmic 
relocalisation of E4-DBP, and loss of E1*E4 keratin binding activity causes both 
proteins to become localised to the nucleoli. E1*E4 is also shown to partially 
inhibit the RNA heiicase activity of E4-DBP. Furthermore, E4-DBP is known to 
interact with HPV-16 late RNAs, suggesting HPV-16 E1*E4 may have functions 
during post-transcriptional processing of late transcripts (Doorbar et al. 2000).
1.1.6.5 LI and L2
LI and L2 encode the major and minor capsid proteins, respectively, and are 
expressed following genome amplification in the upper layers of the epithelium. 
Each HPV-16 capsid contains 256 copies of LI and 72 copies of L2, forming a 
capsomere icosohedral shell (Modis et al. 2002). Virus-like particles are known to 
form in the absence of L2, however L2 is thought to enhance packaging and 
infectivity. During infection the capsid proteins are involved in cell contact, 
endocytosis (see section 1.1.5: The life cycle), translocation across the cytoplasm 
and nuclear entry. HPV-16 L2 binds p-actin, which is thought to facilitate transport 
across the cytoplasm during infection (Yang et al. 2003). In support of this, BPV-1 
LI co-immunoprecipitates with tubulin, and virions co-localise with micro-tubules in 
the cytoplasm by electron microscopy (Liu et al. 2001). Furthermore, HPV-16 L2 
is suggested to be required for endosome escape as pseudovirions containing LI 
only are retained in the vesicular compartment (Kamper et al. 2006). Nuclear 
entry is facilitated by L2. L2 protein from a number of PV types interacts with 
Karyopherin (Kap) subunits, which are nuclear import adaptor/receptor proteins
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also known as importins (Darshan et al. 2004; Fay et al. 2004; Bordeaux et al. 
2006; Klucevsek et al. 2006). Kap’s form heterodimers of one a and one p 
subunit, and L2 from different PV types is shown to interact with Kap 02, Pi, P2, 
and p3 via nuclear localisation signals in the L2 N and C-terminal regions. L2 is 
also involved in viral DNA binding and it is suggested that it is responsible for 
translocation of the genome to the nucleus (Day et al. 2004; Fay et al. 2004; 
Bordeaux et al. 2006; Klucevsek et al. 2006).
L2 aiso has functions during production of mature virions. HPV-33 L2 contains an 
ND10 localisation domain, which is necessary for L2 induced recruitment of Daxx 
and loss of Sp100 from ND10 domains (Becker et al. 2003). This is thought to be 
important as ND10 domains are suggested to be the sites of viral DNA replication. 
Furthermore, involvement of PML, a major component of ND10 domains, is 
somewhat controversial. Whilst authentic BPV-1 infection is elevated in PML 
positive celis, as compared to PML negative cells (Day et al. 2004), assembly of 
HPV-33 into VLPs requires L2 to be in the nucleus, but neither ND10 localisation 
or PML are necessary (Becker et al. 2004). Formation of LI capsomeres occurs 
in the cytoplasm, followed by translocation to the nucleus via the Kap a2pi 
heterodimer (Merle et al. 1999; Nelson et al. 2002). HPV-16 and -45 L1 interacts 
with Kap a2 to facilitate Import and this requires RanGDP and GTP (Nelson et ai. 
2002). HPV-11 LI also enters the nucleus using the same adapter heterodimer 
via interaction with Kap a2 (Merle et al. 1999). In addition. Interaction of LI with 
Kap P2 in the case of HPV-16 and -45, and Kap p3for HPV-11 is shown to cause 
inhibition of import of cellular proteins containing an M9 NLS, such as hnRNP A1 
(Nelson et al. 2002; Nelson et al. 2003). It is suggested that this import is inhibited 
during the productive phase of the life cycle.
1.1.6.6 Tumour Progression
In tumour ceils, E6 and E7 of high-risk HPVs, are expressed at high levels, which 
drives proliferation (Durst et al. 1991). The high levels of expression are 
commonly caused by integration of the viral genome into cellular DNA resulting in 
loss of expression of other HPV genes. Specifically, E2 is lost and the break 
points of integration are often within the E2 ORF. E2 is thought to transcriptionally 
down-regulate E6 and E7 in episomally infected cells, during differentiation (see 
section 1.1.6.3: El and E2) (Dowanhick et al. 1995; Goodwin et al. 2000). Loss of
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this down-regulation may result in uncontrolled E6 and E7 expression. In addition, 
endogenous expression of Sp1 which is thought to be a major transactivator of the 
HPV-16 E6/E7 promoter, is elevated in transformed cells (Apt et al. 1996). 
Furthermore, steady-state E6/E7 mRNA levels are increased upon integration of 
the HPV-16 genome in HPV-16 infected epithelial cells (Jeon and Lambert 1995). 
However, this is not only due to elevated transcriptional activation but is also a 
product of increased RNA stability (Jeon and Lambert 1995). As the E6/E7 
transcripts that are produced in cells with integrated genomes are not 
polyadenylated using the HPV-16 early 3’UTR, it was suggested this region might 
contain an instability element. Indeed, when fused to the p-giobin gene, the HPV- 
16 early 3’UTR was able to substantially reduce stability of p-globin transcripts in 
fibroblasts (Jeon and Lambert 1995). In addition, deletion of the HPV-16 early 
3'UTR from a truncated version of HPV-16 genome containing only the early 
region, driven by a CMV promoter, increases mRNA steady-state levels in HeLa 
cells (Zhao et al. 2005). This suggests that increased mRNA stability, as well as 
more efficient transactivation of the early promoter, results in the high levels of 
E6/E7 expression observed in transformed cells. However, this has not been 
shown to be sufficient to cause tumour progression and mutagenesis of cellular 
genes plays a role. This is backed up by cell culture observation, in which 
integration of the genome results in a growth advantage over episome-containing 
cells and loss of differentiation but cells are not tumourigenic (Jeon et al. 1995). 
However, expression of BPV-1 E2 in HeLa cells to repress HPV-16 E6 and E7 
expression results in inhibition of cellular DNA synthesis, and p53 and pRb 
induction (Goodwin et al. 2000). Furthermore, expression of HPV-16 E6 and E7 
expression alleviates E2-medlated growth inhibition; suggesting continued E6 and 
E7 expression is necessary for optimal proliferation of transformed cells. In 
transgenic mice expressing HPV-16 E6 or E7 in undifferentiated epithelial cells, 
treatment with carcinogens known to act at different stages of tumour progression, 
reveals differing roles for E6 and E7 at different stages of tumourigenesis (Song et 
al. 2000). E7 primarily affects the promotion stage, whilst E6 acts more strongly in 
malignant conversion. In vivo, the eventual result is loss of differentiation 
capabilities, uncontrolled growth and progression to invasive carcinoma.
Sarah Mole, 2007 Chapter 1, 38
1.1.7 Tissue culture
Due to the tight association of the PV life cycle to epithelial differentiation, tissue 
culture analysis has been problematic. Many cell lines have been derived from 
cervical carcinomas in which the HPV genome is integrated. Although the 
transforming mechanisms of the E6 and E7 proteins can be studied in these 
systems, they are not indicative of the natural life cycle of HPV. W12 is a cell line 
derived from an HPV-16 infected CIN I lesion, in which the genome is episomal 
and is maintaining the natural pattern of HPV infection (Stanley et al. 1989). A 
sub-clone of W12 cells, W12E has been derived which whilst maintaining the 
features of W12 cells, can also be maintained in culture for more passages (up to 
18) before genome integration occurs (Jeon et al. 1995). These cells also exhibit 
typical epithelial cell morphology consistent with CIN I lesions and can be 
differentiated in vitro, allowing for the comparison of gene expression and the 
effects thereof, between undifferentiated and differentiated cells. For example, in 
monolayer culture the density of W12E cells influences the state of differentiation. 
At low density cells are undifferentiated, whereas higher density results in 
differentiation (McPhillips et al. 2004). Cells can be harvested at different time 
points after seeding to obtain undifferentiated and differentiated samples. 
Furthermore, cells can be grown in organotypic-raft cultures to allow the formation 
of epithelial tissue in vitro. This tissue can be used in staining experiments, to 
detect when and where within a three-dimensional structure, certain RNAs and 
proteins are expressed.
1.2 RNA processing
To understand fully the relevance of the protein complexes binding papillomavirus 
c/s-acting RNA elements, it is necessary to outline the mechanisms of RNA 
processing. In eukaryotic cells, there are a number of proteins that direct the 
appropriate processing, transport and stability of pre-mRNAs. These processes, 
as well as transcription itself, are intertwined, creating a complex machine from 
which mature mRNA transcripts are produced (reviewed by Minvielle-Sebastia and 
Keller 1999). RNA processing factors are known to associate with the RNA 
polymerase II C-terminal domain, and are thereby in close proximity to the nascent 
transcript as soon as it is produced. Each process will be discussed in Isolation,
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but links will be drawn where relevant, particularly with respect to interacting 
proteins involved in each process.
1.2.1 Capping
The first process to occur during RNA processing is capping of the 5’ end of the 
pre-mRNA (reviewed by Shatkin and Manley 2000). This occurs in nucleus after 
synthesis of -20-25 nts, when a 7-methyiguanosine triphosphate 5’ cap is added 
(reviewed by Bentley 2002), Méthylation of the cap stabilizes mRNAs against 5' 
exonuclease activity and is involved in inhibiting decapping (reviewed by Furuichi 
and Shatkin 2000). Capping is achieved via three enzymes: RNA triphosphatase, 
guanylyltransferase (GT) and 7-methyltransferase (MT). GT and MT associate 
with the Serine 5 phosphorylated GTD of RNA polymerase II (reviewed by Bentley 
2002). Whilst RNA triphosphatase and GT are released from the mRNA following 
capping, MT can be found associated with the GTD at the 3’ end of the gene. 
Furthermore, MT is shown to associate with importin a, a molecule which along 
with importin (3 is involved in nuclear import of proteins containing nuclear 
localisation signals (reviewed by Nakielny and Dreyfuss 1999). This interaction 
promotes targeting of MT to its substrate and also increases cap méthylation. A 
complex composed of two subunits, 20 and 80KDa, called the cap-binding 
complex (GBG) associates with the mRNA cap (reviewed by Izaurralde and Adam 
1998). Gapping and polyadenylation are linked during mRNA processing. GBG 
may be involved in cleavage at the 3' end of an mRNA as its depletion from HeLa 
nuclear extracts, results in decreased levels of cleavage (Flaherty et al. 1997). It 
is thought that interaction between GBG and 3' end processing complexes, 
stabilises 3’ end complex formation. In addition, translation of uncapped RNA is 
reduced in in vitro translation assays (Both et al. 1975; Muthukrishnan et al. 1975). 
The cap associates with eukaryotic translation initiation factor 4F (elF4) family and 
this promotes ribosome attachment which in turn results in increased initiation of 
translation (Gingras et al. 1999). Gircularisation of the mRNA via cap and poly(A) 
tail complex interactions also increases translation initiation (reviewed by Sachs et 
al. 1997). Therefore, the cap is essential to the stability, processing and 
translation of an mRNA molecule.
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1.2.2 Splicing
In eukaryotic cells splicing occurs via formation of a number of complexes, E, A, B 
and C (Figure 1.7). The E splice complex is formed via RNA-RNA, protein-RNA 
and protein-protein interactions. This involves recognition of the 5’ and 3' splice 
sites. The 5’ splice site is defined by one sequence (GURAGU, where R 
represents a purine), whilst the 3’ splice site composes three parts; a branch point 
site (BPS) (YNYURAY, where Y is a pyrimidine and N is any nt), a poly-pyrimidine 
tract and the splice site itself (YAG/N) (reviewed by G rave ley 2000). Splice sites 
within eukaryotic genomes can be highly degenerate and recognition often 
depends on nearby c/s-acting elements, which either repress or enhance splicing 
from a particular site via the action of a number of RNA-binding proteins (see 
section 1.4: SR proteins). Association occurs between the U1 small nuclear 
riboncieoprotein (U1 snRNP) complex and a 5’ splice site (Wassarman and Steitz
1992), whilst the U2 snRNP auxiliary factor (U2AF) complex, containing U2AF^® 
and U2AF®®, forms by interaction with the 3’ splice site and polypyrimidine tract, 
respectively (Figure 1.7E). One or more SR proteins, so called because of the 
arginine/serine rich (RS) domain contained in the C-terminal region, bridge the gap 
between U1 snRNP and the U2AF complex, via protein-protein interactions, 
creating a splice site recognition complex necessary for the latter stages of 
splicing (reviewed by Smith and Valcarcel 2000). In subsequent stages many 
more components join the complex, such as snRNPs, SR proteins and splicing 
factor-associated proteins (SAPs), resulting in production of two molecules: an 
intronless mRNA and a lariat intron (Figure 1.7A-C) (reviewed by Reed and 
Palandjian 1997). Briefly, in formation of the A complex, U2 snRNP associates 
with the BPS, followed by displacement of U1 snRNP by a U6/U4.U5 trl-snRNP 
particle to form the B complex, in the pre-spliceosome to spliceosome transition. 
Loss of U2AF then results in the C complex and catalysis is completed, producing 
the intronless mRNA and the lariat intron, associated with U2, U5 and U6 snRNPs.
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Figure 1.7: Splicing
E) shows the early (E) complex with U1 snRNP (red) bound at the 5’ 
splice site, U2AF (purple) bound at the 3’ splice site and one or more SR 
proteins (yellow) bridging the gap to adjoin the two. A) Shortly after E 
complex formation, U2 snRNP (green) binds the branch point site (BPS) 
to form the A complex. B) U1 snRNP is displaced by a U6/U4.U5 tri- 
snRNP particle (blue). 0 ) U2AF is lost from the complex and catalysis is 
completed to produce the lariat intron, associated with U2, U5 and U6 
snRNPs and the intronless mRNA.
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1.2.3 Cleavage and Polyadenylation
In processing of the 3’ end of most mRNAs, the transcript is cleaved and 
polyadenylated, two processes which are tightly coupled. There are a number of 
factors involved in these processes, and, as with splicing, RNA sequences are 
required. The core polyadenylation signal is almost invariable, consisting 5'- 
A(A/U)UAAA-3’, located approximately 10 to 30 nucleotide upstream of the 
cleavage and polyadenylation site, and a more variable GU or U rich element is 
often found 10 to 50 nucleotides downstream (Figure 1.8A) (reviewed by 
Proudfoot 1991). The downstream element may be involved in modulating 
efficiency of polyadenylation from a specific site. A third sequence, UGUA, can be 
found in one or more copies at variable distance upstream of the cleavage site (Hu 
et al. 2005). Protein complexes involved in cleavage and polyadenylation include, 
poly (A) polymerase (PAP), cleavage and polyadenylation specificity factor 
(CPSF), cleavage stimulatory factor (CStF), cleavage factors (CFl/GFII) and 
poly(A) binding protein II (PABII) (Figure 1.8). The first event is thought to be 
interaction of the CPSF complex, composed of 4 subunits of 30, 70, 100 and 
160KDa, with the A(A/U)UAAA sequence within the core element (Jenny et al. 
1994; Murthy and Manley 1995). CstF, composed of CstF-77, CstF-64 and CstF- 
50, associates with the GU rich region via CstF-64 and stabilises CPSF-RNA 
interactions by direct protein interaction (Weiss et al. 1991; MacDonald et al.
1994). PAP then binds to the complex, followed by cleavage. It is suggested that 
requirement for PAP within the complex prior to cleavage may ensure tight 
coupling between cleavage and polyadenylation (reviewed by Keller 1995). CFl 
and CFl I are also required for cleavage. Although their exact functions are as yet 
undefined, CFl interacts with the UGUA sequence and can allow polyadenylation 
in the absence of an A(A/U)UAAA motif via recruitment of CPSF and PAP (Brown 
and Giimartin 2003; Venkataraman et al. 2005). Polyadenylation then proceeds 
rapidly requiring PAP, CPSF and PABII. PABII joins the complex shortly after 
polyadenylation starts to regulate efficiency and tail length (Wahle 1991; Bienroth 
et al. 1993). It stimulates the reaction after addition of approximately 10 
nucleotides, and then slows polymerisation when the tail reaches 200-250 
nucleotides (reviewed by Wahle and Keller 1996). As length of the poly(A) tail is 
consistent amongst different transcripts, it is thought that A’s are counted by 
continued binding of PABII (Figure 1.8E) (Wahle 1995).
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Figure 1.8: Cleavage and Polyadenylation
A) CPSF interacts with the A(A/U)UAAA sequences and CstF associates 
with the GU or U rich region cooperatively. CFl interacts with a further 
sequence, UGUA at variable distance upstream of the cleavage site. 
Although the RNA is shown linearised here, it is likely that the complex is 
formed by bending of the molecule. CFII is also required; however it’s 
binding properties are not known. PAP then enters the complex via 
interactions with CPSF. B) Following cleavage, CstF and CFl and II are lost 
from the complex. C) Approximately 10 A’s are added to the cleaved RNA 
before PABII associates with the complex. D) PABII binds the poly(A) tail 
and induces productive polyadenylation. E) Continuous PABII binding is 
thought to regulate tail length.
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1.2.4 Exon definition
In many lower eukaryotes, splicing complexes are formed across the relatively 
small introns. This results in each splice junction contributing to the splicing of 
only one intron (Figure 1.9A). However, in mammalian cells where introns can be 
thousands of base pairs in length and exons small in comparison, the complex 
often forms across the exon in a process called 'exon definition’ (Figure 1.9B) 
(reviewed by Berget 1995). Interaction then occurs between complexes formed at 
adjacent introns to facilitate splicing. Here each splicing complex contributes to 
the splicing of two introns, on each side of the exon in question. For internal 
exons the process of exon definition is adequate; however, problems arise when 
splicing the terminal introns. An E complex cannot form over the 5’ and 3’ most 
exons due to the lack of a 3’ splice site at the start of the first exon and 5’ splice 
site and the end of the last. In this situation it is thought that the splicing 
machinery interacts with end processing machinery to facilitate splicing (Figure 
1.9C). For example, interaction of the CBC associated with the 5’ cap interacts 
with U1 snRNP which enhances splicing of the first intron (reviewed by izaurralde 
and Adam 1998). Similarly, splicing machinery bound at the 3’ splice site of the 3’ 
most exon interacts with cleavage and polyadenylation factors, thus creating a 
complex capable of splicing the final intron. For example, U1A, a component of 
the U1 snRNP complex, interacts with cleavage and polyadenylation specificity 
factor (CPSF) (Lutz et al. 1996). This interaction affects both polyadenylation rate 
and tail length by stabilising A(A/U)UAAA-CPSF interactions. Furthermore, U1A, 
whilst complexed in U1 snRNP, binds the upstream efficiency element (USE) of 
the SV40 late polyadenylation signal (Lutz and Alwine 1994). U1A also is known 
to inhibit polyadenylation of its own mRNA (Gunderson et al. 1994), whilst U1-70K 
is involved in inhibition of BPV-1 late gene transcript polyadenylation (Gunderson 
et al. 1998). Another component of U1 snRNP, U1 snRNA also interacts with the 
SV40 late and adenovirus L3 polyadenylation signals (Wassarman and Steitz
1993). For SV40, addition of a 3’ splice site upstream enhances binding and 
polyadenylation (Niwa et al. 1990). In addition, mutation of the polyadenylation 
signal inhibits splicing of the 3’ most intron in vitro (Niwa and Berget 1991). 
Furthermore, presence of a 5’ splice site within the 3’ most exon has been shown 
to repress polyadenylation in vitro and in vivo (Niwa et al. 1992). Interaction 
between U2AF®® and poly (A) polymerase (PAP) has also been observed, which is 
believed to facilitate splicing (Vagner et al. 2000). Furthermore, mRNAs which
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have been spliced but not polyadenylated have never been observed in vivo. 
Therefore, the relationship between splicing and polyadenylation is of great 
important to correct post-transcriptional processing in mammalian cells.
1.2.5 mRNA transport
All communication between the nucleus and the cytoplasm is mediated via the 
central channel of nuclear pore complexes (NPCs) (reviewed by Taura et al. 
2005). For many molecules and complexes this is using Ran-dependent transport 
via importins. In contrast, export of bulk cellular mRNA is mediated by Ran- 
independent mechanisms. The majority of mRNA is thought to be exported from 
the nucleus via nucleo-cytoplasmic shuttling, export receptor, TAP (reviewed by 
Cullen 2003; Taura et al. 2005). TAP forms a heterodimer with p15/NXT1, which 
then associates with both polyadenylated mRNA and NPCs. Interaction between 
TAP and p15/NXT1 is essential to the shuttling activity of TAP and also stimulates 
NPC association (Katahira et al. 2002; Wiegand et ai. 2002). However, TAP is not 
a good RNA binding protein and is thought to associate with mRNAs via 
components of the mRNP complex. For example, Aly/REF1, which forms a 
complex with a number of other proteins -20-24 nts upstream of the exon-junction, 
termed the exon-junction complex (EJC), interacts with TAP (Le Hir et al. 2000; 
Zhou et al. 2000; Rodrigues et al. 2001). Aly is also a shuttling protein, which is 
shown to enhance mRNA export in vivo (Zhou et al. 2000). In addition, TAP is 
known to associate with splicing associated proteins such as U2AF^^ (Zolotukhin 
et al. 2002) and SR proteins, SF2/ASF, SRp20 and 9G8 (Huang et al. 2003). 
However, although splicing may seem to be important for export of mRNAs, those 
lacking introns are still efficiently exported from the nucleus to the cytoplasm in 
transfected cells. Furthermore, RNA interference mediated knock-down of 
Aly/REFI shows this protein is not essential for bulk mRNA export, suggesting the 
EJC and splicing may not be essential for export of mRNAs (Gatfield and 
Izaurralde 2002). In addition, mRNA export is tightly linked to cleavage and 
polyadenylation. It is thought that this is achieved via protein-protein interaction 
between cleavage and polyadenylation factors and export proteins. In support of 
this, yeast strains defective for certain mRNA 3' end processing proteins, such as 
PAP, also show defective mRNA export (Hammell et al. 2002). However, at 
present little is known about how export is coupled with cleavage and 
polyadenylation.
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Figure 1.9; E complex formation in eukaryotic splicing
A) A U1 snRNP complex forms on the 5' splice site, whilst U2AF65 and 
U2AF35 bind the 3' splice site. The complex is bridged by SR proteins.
B) In mammalian cells where introns are much larger than exons the E 
complex forms over exons. However, this becomes a problem when 
splicing terminal exons, which is overcome by interaction of the splicing 
machinery with end processing factors. 0 ) depicts the possible 
interaction at the 3'end.
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1.2.6 mRNA stability
Another important mechanism for controlling gene expression post- 
transcriptionally is by regulating RNA stability. Half-lives of different mRNA 
molecules can differ markedly from several minutes, in the case of human cytokine 
mRNAs (reviewed by Ross 1995), to many hours, as for globin family members 
(Weiss and Liebhaber 1995). Whilst c/s-acting RNA elements regulating stability 
can be found in coding regions, they are most commonly found within the 3’UTR. 
In particular, AU-rich elements (AREs) are often found to regulate stability of an 
mRNA in a c/s-acting manner. AREs act via interaction with cellular proteins 
known as ARE-binding proteins, which includes the Hu family. The Hu family 
contains 4 members; HuC and HuD, which are expressed only in neurons, HuB, 
which Is expressed in neurons and gonads, and HuR, which is ubiquitously 
expressed in proliferating cells. As HuR is known to associate with c/s-acting RNA 
elements within the late region of HPV-1 and -16, we will focus of this member of 
the family. HuR is shown to interact with AREs within the 3’UTR of some mRNAs, 
and act as a nuclear export adapter. For example, HuR is shown to interact with 
pp32 and APRIL, which associate with nuclear export factor CRM1 (Brennan et al. 
2000). In addition, inhibition of CRM1 mediated export specifically represses 
export of mRNAs containing a c-fos ARE, to which HuR is known to bind, in the 
3’UTR. Once in the cytoplasm, HuR is thought to regulate stability of the bound 
mRNA molecule. Overexpression of HuR in mouse cells, results in increased 
cytoplasmic stability of mRNAs containing a c-fos ARE (Peng et al. 1998). This 
correlates with HuR binding to the ARE, as confinement of HuR in the cytoplasm 
via inhibition of transcription, increases HuR-ARE interaction and also increases 
cytoplasmic mRNA stability.
1.3 Papillomavirus late gene expression
Papillomavirus capsid proteins are highly immunogenic and their expression is 
tightly controlled until productive genome replication is complete. For different PV 
types, expression is observed at different stages of differentiation. HPV-16 has a 
late productive phase compared with other mucosal HPVs, resulting in expression 
of capsid proteins in only the most differentiated cells. However, late unprocessed 
RNAs can be detected in less differentiated infected cells during the HPV-16 life 
cycle (Milligan et al., 2006). Therefore, regulatory mechanism must exist at the
Sarah Mole, 2007 Chapter 1, 48
post-transcriptional level to prevent late gene expression in undifferentiated cells. 
In accordance, many PV late transcripts have been the subject of studies 
investigating this and a number of elements have been found which result in 
down-regulation of late gene expression in undifferentiated epithelial cells, as well 
as conferring repression upon reporter gene constructs (Kennedy et al. 1990; 
Furth and Baker 1991; Kennedy et al. 1991; Yes: Schwartz 1998; Sokolowski et al. 
1998; Gumming et al. 2002). These sequences can be found in both coding and 
non-coding regions of the RNA and seem to be divergent between papillomavirus 
types. However, for some there are similarities with respect to sequence and 
proteins binding, which may indicate a largely similar mechanism of late transcript 
down-regulation by different papillomavirus types (Sokolowski et al. 1999; Koffa et 
al. 2000; Collier et al. 2002; Gumming et al. 2003; McPhillips et al. 2004; 
McPhillips et al. Unpublished).
1.3.1 Late 3’UTR Regulatory Elements
Although down-regulation of late gene expression is observed in the presence of 
c/s-acting elements found within PV coding regions, it has also been shown that 
stronger negative elements are often found partially or fully within non-coding 
regions (Sokolowski et al. 1999; Gumming et al. 2002). For example, a 53nt 
element immediately upstream of the poly (A) signal in the late 3'UTR of the BPV- 
1 genome is known to affect late gene expression (Furth and Baker 1991). The 
element inhibited reporter gene expression ~6-10 fold in undifferentiated cells, 
when cloned upstream, but not downstream of the polyadenylation signal. 
Furthermore, deletion of the 53nt element from LI expression vectors containing 
the BPV-1 late 3’UTR resulted in increased levels of cytoplasmic LI mRNA, but 
did not alter the stability of the molecule (Furth and Baker 1991). Therefore, it has 
been postulated that presence of this regulatory element reduces efficiency of 
RNA processing. In agreement with this, a consensus 5' splice site is contained 
within the 53nt element: a 9nt region which coincides with inhibitory activity (Furth 
et al. 1994). This study suggests that that U1 snRNA (small nuclear RNA), a 
component of U1 snRNP, which associates with 5’ splice sites during splicing (see 
section 1.2.2: Splicing), interacts with the BPV-1 LRE, via the 5’ splice site, and 
interaction is necessary for inhibition of gene expression. In addition, a U1 snRNP 
complex, containing U1 snRNA, U1A and U1-70K, is shown to form on the 5’ 
splice site in vitro (Gunderson et al. 1998). Inhibition of gene expression is shown
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to be caused via by U1-70K, via interaction with and subsequent inhibition of poly 
A polymerase (PAP) (see section 1.2.3: Polyadenylation).
A similar, yet more complex element has been found within the late region of the 
HPV-16 genome (described in more detail in Chapter 5). Termed the late 
regulatory element (LRE), this element resides at the 3' end of the LI coding 
region and spans into the late 3'UTR (Kennedy et al. 1990; Kennedy et al. 1991). 
It is 79nt in length and contains 4 weak 5' splice sites within its 5' region and a 3' 
GU rich region, of which both regions have been shown to confer negative 
regulatory activity to some degree upon reporter gene expression in 
undifferentiated epithelial cells (Gumming et al. 2003). Within the 5’ region, the 4 
5’ splice sites are shown to act in an additive manner, the second of which is the 
closest to 5’ splice site consensus sequence and has the most inhibitory activity. 
Furthermore, many proteins have been shown to interact, either directly or 
indirectly with the LRE, via both the 5’ and 3' regions, and of those identified, ail 
have roles in RNA processing, transport or stability (Table 1.1) (Dietrich-Goetz et 
al. 1997; Koffa et al. 2000; McPhillips et al. 2004; McPhillips et al. Unpublished). 
For example, GstF-64 and HuR interact, requiring the 3’ GU rich element of the 
LRE (Gumming et al. 2002). GstF-64 is sub-unit of the cleavage stimulating factor 
GstF, which is known to stabilise the formation of polyadenylation and cleavage 
complexes (see section 1.2.3: Gleavage and polyadenylation) (Wilusz et al. 1990) 
and HuR is involved in stabilisation of mRNA in the cytoplasm and transport of 
from the nucleus to the cytoplasm (see section 1.2.6: mRNA stability) (reviewed by 
Keene 1999). Heterogenous nuclear riboprotein (hnRNP) A1, a cellular splicing 
regulatory protein known to antagonise the action of SF2/ASF in terms of splice 
site selection, is also shown to associate with the HPV-16 LRE (Veerapraditsin et 
al. unpublished). hnRNP A1 associates with c/s-acting RNA elements, known as 
exonic splicing silencers (ESSs), and directs splicing to more distal splice sites 
(Eperon et al. 2000). This is achieved by interfering with U1 snRNP binding to 
proximal 5' splice sites. In addition, the protein has roles during mRNA export and 
can affect mRNA stability in the cytoplasm (Izaurralde et al. 1997; Mill et al. 2001). 
A further protein complex thought to bind the LRE bears similarity to a splicing 
early (E) complex (see section 1.2.2: Splicing). It has been shown that a U1 
snRNP like complex, containing Sm and U1A, interacts via U1 snRNA with the 5’ 
region of the LRE (Gumming et al. 2003), whilst U2AF®  ^ binds the 3’ GU rich 
region (Koffa et al. 2000). This is in accordance with their binding properties as 
observed in an E complex. Further studies have shown that a splicing related SR
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protein, Splicing Factor 2/Alternative Splicing Factor (SF2/ASF) also interacts with 
the LRE indirectly when complexed with U2AF®® (McPhillips et al. 2004). 
Therefore, there is the potential for a splicing-like complex, similar to that formed 
over an exon during exon definition (see section 1.2.4: Exon definition), to form on 
the LRE (Figure 1.10). This complex may facilitate and/or interfere with 
processing of late transcripts and in particular may exert effects on 
polyadenylation and splicing of the final intron (see Chapter 5).
Element Associated cellular 
proteins
Publication
E4 ESE Not Known
L2 Polyadenylation 
enhancer
hnRNP H 
GstF-64
Oberg et al. 2005
LI ESS hnRNP A1 Zhao et al. 2004
LRE U1 snRNP-like complex
U2AF-65
SF2/ASF
GstF-64
HuR
hnRNP A1
Gumming et al. 2003 
Dietrich-Goetz et al. 1997 
McPhillips et al. 2004 
Koffa et al. 2000 
Koffa et al. 2000 
Veerapraditsin and 
Graham, Unpublished
Table 1.1: Gellular RNA processing factors interacting with HPV-16 late cis-ac mg
RNA elements
C/s-acting RNA elements are also found within the late 3’UTRs of HPV-1 and -31. 
For HPV-31, a lO Int region spanning the LI coding region and late 3'UTR, was 
shown to have significant sequence similarity to the HPV-16 LRE (Gumming et al. 
2002). This region contains 3 weak consensus 5’ splice sites and a 3' GU rich 
region. When the HPV-31 late 3’UTR, encompassing this element was fused to a 
reporter gene, reporter activity was reduced to a similar extent as observed for 
comparable constructs containing the HPV-16 3'UTR. However, precise deletion 
of the 101 nt element increased gene expression only ~2-3 fold (Gumming et al. 
2002). Additional deletions of the 3’UTR, 3’ of the proposed negative element, 
spanning a 130nt region, further increased reporter activity. Moreover, deletion of 
11 Ont region downstream of the late polyadenylation signal also alleviated 
repression of gene expression to some degree. This suggests that the HPV-31 
late 3’UTR contains two c/s-acting RNA regulatory region, termed the major 
inhibitory element (MIE), containing the LRE-like element, and the minor element 
(SIE), downstream of the polyadenylation signal (Gumming et al. 2002). UV cross- 
linking and electrophoretic mobility shift assays (EMSAs) indicated that the MIE 
interacts with a number of proteins also known to associate with the HPV-16 LRE
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(Gumming et al. 2002). For example, GST-tagged GstF-64 was able to cross-link 
with an MIE probe. In addition, HuR and U2AF®® could be affinity purified from 
HeLa nuclear extracts using MIE probes. An Inhibitory element has also been 
found in the HPV-1 late 3’UTR (Tan and Schwartz 1995; Sokolowski et al. 1997). 
A region spanning nt 6939-7184 was able to inhibit reporter gene activity and the 
amount of cytoplasmic polyadenylated mRNA produced from constructs containing 
the entire HPV-1 3'UTR was reduced, compared with those containing a deletion 
in this region (Tan and Schwartz 1995). A near consensus 5’ splice site was found 
in this region; however, this was not found to be required for inhibitory activity and 
instead an AU-rich element, termed the hi ARE, located between nts 6938 and 
7014, is associated with repression (Tan and Schwartz 1995; Sokolowski et al. 
1997). This region contains two AUUUA and three UUUUU sequences, and U to 
G mutation within these sites abolishes inhibitory activity (Sokolowski et al. 1997). 
Go-immunoprecipitation of hi ARE UV cross-linked proteins revealed that hnRNP 
G1 and G2 interact with this element (Sokolowski et al. 1997). In addition, GST- 
HuR Is able to bind the hlARE, via the AUUUA and UUUUU sites, in EMSA and 
UV cross-linking experiments (Sokolowski et al. 1999). HuR binding affinity to the 
element is shown to correlate with its inhibitory activity (Sokolowski et al. 1999), In 
addition, levels of HuR are elevated in the cytoplasm of cells in which the hlARE 
is less inhibitory (Garlsson and Schwartz 2000). It is suggested that HuR may 
regulate the hi ARE by increasing stability and/or promoting translation in the 
cytoplasm.
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Figure 1.10; An early splicing complex forms over the LRE
A schematic diagram of a complex known to form on the LRE in both 
undifferentiated and differentiated H PV -16 infected cells. A U1 snRNP like 
complex interacts with the 5 ’ region, whereas U2AF interacts with the 3’ GU  
rich region. Furthermore, S F2/A S F is found to associate indirectly when 
complexed with U2AF, creating an early splicing like complex.
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1.3.2 Cis-acting RNA elements
As well as elements within non-coding regions, studies of several HPV types have 
revealed regulatory elements within the coding regions. These elements have 
been shown to be involved in either regulation of alternative splicing, 
polyadenylation or RNA stability. With particular focus on HPV-16, a number of 
c/s-acting RNA elements are shown to act via interaction with cellular RNA 
processing factors. For example, an exonic splicing enhancer (ESE), 65 nt in 
length has been observed within the E4 ORF of HPV-16 (Figure 1.11) (Rush et al. 
2005). The ESE is AC-rich and bears similarity to AC-rich enhancers, which are 
known to regulate splicing of cellular and viral genes. This has been shown to 
direct splicing to the 3’ splice site at position 3358, upstream of the ESE, hence 
inhibiting use of the differentiation specific 3’ splice site at position 5639, upstream 
of the L2 ORF, within the late region of the genome (Rush et al. 2005). 
Optimization of the 3’ splice site at 3358, negates the presence of the ESE, 
suggesting this element is necessary to direct splicing to a sub-optimal splice site. 
Presence of this ESE also results in polyadenylation from the early poly (A) site 
(pAE), which produces transcripts lacking LI and L2 (Rush et al. 2005). 
Furthermore, an exonic splicing silencer (ESS) has been found downstream of the 
differentiation specific 3’ splice site at 5639, which also acts to inhibit use of this 
splice site (Figure 1.11) (Zhao et al. 2004). This element is shown to associate 
with hnRNP A1 (Table 1.1) and directs splicing to more distal 3' splice sites. This 
highlights the importance of balance between cellular RNA processing factors in 
the control of late gene expression. Furthermore, deletion of these elements 
results in increased levels of late RNAs, suggesting they may also affect RNA 
stability (Zhao et al. 2004; Rush et al. 2005).
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Figure 1.11: Cis-acting RNA elements within the late region of 
HPV-16
A schematic diagram of the 3 ’ portion of the HPV-16 genome, showing 
the late region (not to scale). O RFs are sown as coloured rectangles, 
splice sites’ and polyadenylation signals as vertical arrows and cis- 
acting RNA elements as open rectangles. Each elem ent acts, via 
interactions with cellular RNA processing factors, to regulate splicing, 
stability, polyadenylation, export and potentially translation of late 
transcripts.
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Further regulatory elements have been observed within the L2 ORF. These are 
generally less well defined but are shown to inhibit translation and result in 
instability of L2 containing mRNAs (Oberg et al. 2003). Proteins interacting with 
the L2 RNA elements include hnRNP K and poly(rC) binding protein 1 and 2 
(PCBP-1 and 2), causing inhibition of translation (Collier et al, 1998). 
Furthermore, an element within the 5' region of L2 enhances polyadenylation from 
pAE (Figure 1.11) (Zhao et al. 2005). The region spanning -170-400bp 
downstream of the pAE encodes multiple GGG motifs and can interact with 
polyadenylation factor, CstF-64 and, more strongly, with hnRNP H (Table 1.1). 
Consistent with a role for hnRNP H in enhancing polyadenylation from pAE, levels 
of the protein are seen to diminish upon differentiation of apparently normal 
cervical epithelium (Zhao et al. 2005). However, levels of certain RNA processing 
proteins are regulated during the HPV-16 life cycle, indicating that hnRNP H 
abundance could also respond to infection. There are also elements within the 
late region of HPV-31, which act to inhibit read-through at the early 
polyadenylation signal in undifferentiated cells (Terhune et al. 2001). In this case 
inhibitory activity is localised to the first 800 nts of the L2 ORF; however, little Is 
known about how the region acts to enhance polyadenylation from the early 
signal.
1.4 SR proteins
As previously discussed, an important family of proteins essential to splicing are 
known as SR proteins. These contain one or two RNA recognition motifs (RRMs) 
which binds RNA within the N-terminal region and an RS domain, important for 
protein-protein interactions, in the C-terminal region (Wu and Maniatis 1993; 
reviewed by Caceres and Krainer 1997; reviewed by Graveley 2000). A glycine- 
rich hinge separates the two domains. RS domains are common to splicing 
factors, however the RRM is a conserved region of SR proteins. The family 
contains more than 12 members and is divided into two groups: those containing 
one RRM and those containing two (reviewed by Caceres and Krainer 1997). Of 
particular interest here is SF2/ASF, containing two RRMs, which is the key SR 
protein and is the only member of the family found to have essential function in 
Caenorhabditis elegans (Longman et al. 2000). As outlined previously, a complex 
is formed upon initiation of splicing which contains at least one SR protein (see 
section 1.2.2: Splicing). RS domains mediate interactions between SR proteins
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and U1 snRNP and U2AF complex proteins (Cao and Garcia-Bianco 1998). 
SF2/ASF and SC35 are shown to associate with both U1-70K and U2AF^® (Wu 
and Maniatis 1993). In addition, the SR protein RS domain and one of the RS 
domains of U1-70K is required for this interaction (Gao and Garcia-Bianco 1998). 
This is important as SR proteins are thought to bring together splicing components 
over splice junctions and therefore are important in defining splice patterns. 
Furthermore, the phosphorylation status of the RS domain has an impact on this. 
SR proteins can be phosphorylated by three types of kinase: SR protein kinases 
(SRPK1 and SRPK2) (Gui et al. 1994; Wang et al. 1998), the Clk/Sty family 
(Coiwill et al. 1996) and DNA topoisomerase I (Rossi et al. 1996). It has been 
shown that phosphorylation mediates the transition between stages of splicing. 
For example, hyperphosphorylated SR proteins promote the pre-spliceosome to 
spliceosome transition (Mermoud et al. 1994; Roscigno and Garcia-Bianco 1995), 
whilst subsequent de-phosphorylation is thought to be required for the first 
transestérification to occur (Gao et al. 1997). In vitro phosphatase treatment of SR 
proteins prevents formation of the spliceosome and inhibits stable binding of U2 
and U4/U6.U5 snRNPs to the pre-mRNA (Mermoud et al. 1994; Roscigno and 
Garcia-Bianco 1995). In contrast, whilst thiophosphorylated SF2/ASF, which is not 
readily de-phosphorylated, facilitates spliceosome formation in HeLa nuclear 
extracts, splicing is still inhibited, suggesting that SF2/ASF de-phosphorylation is 
required for the latter stages of splicing (Gao et al. 1997). In agreement with this, 
it has been shown that phosphorylation of the SF2/ASF RS domain affects protein- 
protein interactions (Xiao and Manley 1997; Xiao and Manley 1998). 
Phosphorylation of the RS domain enhances interaction with U1-70K in vitro (Xiao 
and Manley 1997). In contrast, hyperphosphorylation of SF2/ASF inhibits 
homodimerisation and binding to other SR proteins (Xiao and Manley 1998). 
Furthermore, SF2/ASF-U2AF^^ association is unaffected by phosphorylation. This 
indicates that SR protein phosphorylation, which results in changes in protein- 
protein interactions, mediates splicing.
Alternative splicing is controlled by hyperphosphorylated SR proteins via 
interaction with c/s-acting elements, such as ESEs and ESSs (Kanopka et al. 
1996). Some evidence suggests that ESEs promote 3' splice site usage via 
recruitment of U2AF®® to adjacent 3' splice sites (Zuo and Maniatis 1996). 
However, this is somewhat controversial, and other studies have failed to detect a 
difference in U2AF binding in the presence or absence of an ESE (LI and 
Blencowe 1999). More recently the RS domain from SR proteins has been shown
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to support splicing when tethered to an ESE and subsequent interaction with the 
BPS is thought to promote pre-splicesome assembly (see section 1.3.1: Splicing) 
(Shen et al. 2004). Furthermore, RS domains from other splicing factors, such as 
U2AF®® are able to associate with the BPS. It has been shown that the RS domain 
of U2AF®® contacts the BPS first, in the E complex, whilst the ESE bound RS 
domain associates during pre-splicesome assembly (Shen and Green 2004). 
However, a further SR protein is required to complete spliceosome assembly and 
the RS domain of this is shown to interact with the 5’ splice site (Shen and Green 
2004). There is also evidence suggesting that ESE bound SR proteins may 
function not only during splice site selection but may also regulated the latter steps 
of the splicing reaction (Chew et al. 1999). Furthermore, ESEs have been 
implicated in 5’ splice site selection, perhaps via SR protein interaction with U1- 
70K, a component of U1 snRNP (Caceres et al. 1994; Ryner et al. 1996). In 
contrast, interaction of hnRNP proteins with ESSs antagonises the action of ESE- 
bound SR proteins. For instance, expression of hnRNP A1 reduces occupancy of 
U1 snRNP with 5’ splice sites, whereas SF2/ASF Increases U1 snRNP-5' splice 
site interactions (Eperon et al. 2000). Furthermore, hnRNP AI was shown to 
reduce interaction of U1 snRNP with 5’ splice sites by direct competition for 
binding. However, this is thought to be achieved by indiscriminate binding of 
hnRNP A1 to the RNA molecule, which is displaced by SF2/ASF binding to ESEs. 
In contrast, hnRNP A1 association with an ESS is thought to inhibit splice site 
usage by mechanisms other than inhibition of U1 snRNP binding (Eperon et al. 
2000).
A sub-set of SR proteins have roles in RNA metabolism other than splicing. For 
example, SF2/ASF, SRp20 and 9G8 are known to shuttle between the nucleus 
and the cytoplasm (Caceres et al. 1998). This was shown using HeLa cells in 
which transcription was inhibited, where shuttling proteins are restricted to the 
cytoplasm. In addition, SF2/ASF, SRp20 and 9G8 can be found in the mouse 
nucleus in interspecies heterokaryons. Whilst shuttling is dependent upon 
transcription in the case of SF2/ASF and SRp20, 9G8 is able to shuttle even when 
transcription is inhibited. Furthermore, SRp20 and 9G8 are able to facilitate 
export of intronless histone H2a mRNA by binding to a 22nt RNA element (Huang 
and Steitz 2001). Both proteins were shown to associate with polyadenylated 
RNA in the nucleus and the cytoplasm, and antibodies that Inhibited this 
interaction, decreased the rate of mRNA export. For SF2/ASF, localisation and 
nucleo-cytoplasmic shuttling is regulated by the RS domain (Cazalla et al. 2002).
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Shuttling is thought to be an intrinsic property of SR proteins; however, presence 
of a dominant nuclear retention signal in SC35, inhibits nuclear export. In addition, 
shuttling SR proteins also interact with export adaptor TAP (Huang et al. 2003). 
Truncated versions of 9G8, containing only the N-terminal region, were able to 
inhibit mRNA export in a dominant negative manner, and could also inhibit binding 
of TAP with SF2/ASF and REF family members. This suggests that all three 
associate with TAP via the same region, shown to be within the N-terminus of the 
protein (Huang et al. 2003). In addition, the RS domain of SF2/ASF and 9G8 is 
not required for TAP interaction in vitro. SF2/ASF is also known to regulate 
translation, as expression is seen to increase from transcripts to which SF2/ASF Is 
tethered in the absence of SF2/ASF binding sites (Sanford et al. 2004). The 
shuttling activity of SF2/ASF is vital for this function, as mutant proteins that are 
unable to shuttle between the nucleus and the cytoplasm are unable to enhance 
translation. In addition, the phosphorylation status of the protein is important to 
each function. Whilst hyperphosphorylated forms are vital for alternative splicing, 
hypophosphorylation is necessary for shuttling and translational activity (Sanford 
et al. 2005). Hypophosphorylated SF2/ASF associates with cytoplasmic RNA with 
greater affinity than hyperphosphorylated forms, and hence is more active in 
regulating translation. In addition, phosphorylation of specific serine residues of 
the RS domain during certain cellular processes has not been determined. This 
suggests SF2/ASF has an integral role during post-transcriptional regulation of 
gene expression, and that phosphorylation of the protein, potentially at different 
serine residues, regulates protein function.
1.4,1 Regulation by SF2/ASF
SF2/ASF has been implicated in regulation of many targets in mammalian cells. 
Of most interest here is its influence on virus gene expression. Expression from 
integrated HIV genomes is as a single RNA which is alternately spliced into over 
40 mRNAs. This is highly complex and relies on several alternate 5’ and 3' splice 
sites. Furthermore, efficient replication is dependent upon the tightly controlled 
regulation of alternative splicing. Regulation is thought to be achieved using 
numerous c/s-acting RNA elements and SR proteins are implicated in the process. 
Depletion of SF2/ASF has been shown to increase the level of HIV-1 tat pre- 
mRNA splicing (Wang et al. 1998), suggesting that SF2/ASF represses tat pre- 
mRNA splicing. SF2/ASF also interacts with the Rev response element (RRE), a
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region of the HIV-1 genome involved In post-transcriptional regulation, in the 
presence but not absence of Rev (Powell et al. 1997). When bound to the RRE, 
Rev regulates the expression of structural, enzymatic and ancillary viral proteins. 
This is achieved partly via activation of Rev mediated splicing, a function which 
can be overcome by SF2/ASF overexpression (Powell et al. 1997). Furthermore, 
an ESE within exon 3 in shown to act in a bi-directional manner upon a 
downstream 3’ splice site and an upstream 5’ splice site (Caputi et al. 2004). This 
is achieved via interactions with SF2/ASF and SRp40, and involves stabilisation of 
U1 snRNP binding to the upstream 5’ splice site.
Adenovirus temporal regulation of the LI late unit is controlled via alternate 3' 
splice site usage. During early infection, use of the Ilia 3' splice site is minimal, 
whilst Ilia pre-mRNA splicing is activated to more than 200-fold in nuclear extracts 
prepared from late adenovirus-infected cells (Muhlemann et al. 2000). SR 
proteins are involved in repression of the Ilia splice pattern by Interacting with an 
intronic repressor element and preventing recruitment of U2 snRNP to the BPS at 
this 3' splice site (Kanopka et al. 1996). SF2/ASF has been implicated in this 
regulation, as its overexpression prevents the early to late shift in mRNA 
expression (Molin and Akusjarvi 2000). This is vital to the viral life cycle as viral 
DNA replication is also blocked, resulting in lower virus yields. Furthermore, the 
virus-encoded protein E4-ORF4 has been shown to activate de-phosphorylation of 
SR proteins, via interaction with cellular protein phosphatase 2A (PP2A), 
inactivating them as alternative splicing regulators in late adenovirus-infected cells 
(Kanopka et al. 1998). Furthermore, E4-ORF4 can interact with 
hyperphosphorylated forms of SF2/ASF directly (Estmer Nilsson et al. 2001). E4- 
0RF4 mutants unable to interact with PP2A or SF2/ASF are unable to alleviate SR 
mediated repression of Ilia splicing. An additional protein found to inhibit the 
splicing enhancer and repressor activities of SF2/ASF is splicing factor-associated 
protein, p32 (Petersen-Mahrt et al. 1999). This function of p32 is established via 
inhibition of SF2/ASF RNA binding and phosphorylation, again highlighting the 
importance of SF2/ASF phosphorylation status to alternative splicing.
1.4.2 SF2/ASF and the HPV-16 life cycle
As mentioned previously SF2/ASF is found to interact, although not directly, with 
the HPV-16 LRE (McPhillips et al. 2004). Direct binding of a U1 snRNP-like 
complex and U2AF®  ^ to the 5’ and 3' LRE regions respectively suggests that a
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splicing like complex forms over the LRE. This complex has been implicated in 
regulation of late gene expression and it has the potential to affect splicing, 
polyadenylation, export and translation of LRE containing transcripts. Although a 
similar complex is thought to form in both undifferentiated and differentiated cells, 
SF2/ASF is found to be hyperphosphorylated and up regulated in differentiated 
cells (McPhillips et al. 2004). It has been suggested that this change in 
abundance and phosphorylation status affects the mode of regulation by the 
complex upon late viral transcripts (see Chapter 5 for more detail). Furthermore, 
there are a number of transcripts produced by the virus in differentiating cells, and 
as discussed c/s-acting regulatory elements have been found within late RNAs. In 
addition, SF2/ASF is upregulated in cells stably expressing HPV-16 E2. 
Therefore, SF2/ASF may be regulated by HPV-16 to enhance late gene 
expression and hence ensure completion of the viral life cycle.
1.5 Aims
The aim of this PhD was to investigate the role of SF2/ASF in regulation of HPV- 
16 late gene expression by the LRE, and to determine how the virus regulates this 
protein, as well as other SR proteins. As reported previously, SF2/ASF is 
regulated in response to HPV-16 infection (McPhillips et al. 2004). As SF2/ASF is 
also upregulated in cells expressing HPV-16 E2, experiments were undertaken to 
determine if SF2/ASF expression is transactivated by E2. Promoter 
transactivation studies were performed using reporter constructs fused to the 
SF2/ASF promoter. To determine a direct role for E2 in transactivation, chromatin 
immunoprécipitation (ChIP) assays and electrophoretic mobility shift assays 
(EMSAs) were performed to show presence of E2 at the SF2/ASF promoter. As 
the SF2/ASF promoter is as yet undefined, nothing is known about its cellular 
regulation. Therefore, further EMSAs were performed to determine if cellular 
partners of E2 could be found to associate with this promoter. To establish if 
SF2/ASF levels were more likely to be regulated by transcription, rather than 
protein stability for example, levels of steady-state SF2/ASF mRNA were 
compared between undifferentiated and differentiated W12E cells. In addition, 
regulation of at least a sub-set of SR proteins may be expected due to the number 
of potential c/s-acting RNA elements, which may act as ESEs, within the HPV-16 
late region, and the extensive alternative splicing observed from the genome in 
HPV-16 infected differentiated cells (Milligan et al., 2006). To investigate the
Sarah Mole, 2007 Chapter 1,61
possibility that SR proteins, other than SF2/ASF, were regulated during the HPV- 
16 life cycle, western blot and immunofluorescence techniques were used, 
comparing undifferentiated and differentiated W12E cells and cell extracts. 
Antibodies recognising a number of SR proteins and SRPK1, an SR protein 
kinase, were used to determine any changes in abundance or localisation upon 
differentiation. In addition, the role of HPV-16 protein E2 and E1^E4 in SR protein 
regulation was also determined. This was achieved using cells lines that stable 
express HPV-16 E2, or epithelial cells transiently transfected with HPV-16 E2 or 
E1^E4 expressing constructs. The final aim of this PhD was to determine a role 
for SF2/ASF in LRE mediated regulation of late gene expression. To study this, 
undifferentiated epithelial cells were transfected with reporter constructs containing 
the late 3’UTR from HPV-16, either including or lacking the LRE. Both HeLa and 
undifferentiated HaCaT cells (a non-tumourigenic spontaneously immortalised 
epithelial cell line) were co-transfected with these constructs and vectors 
expressing SF2/ASF. Undifferentiated W12E cells were not used in these 
experiments due to problems with transfections. Potential changes in reporter 
gene expression were then assayed. CAT assays were performed to determine 
any changes in protein abundance in the presence and absence of elevated 
SF2/ASF, whilst quantitative RT-PCR was used to analyse total and 
polyadenylated CAT RNA levels.
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2 Materials and Methods 
2.1 Materials 
2.1.1 Enzymes
All enzymes were purchased from Roche Applied Science unless otherwise 
stated.
2.1.2 Primers
All primers used in PCR for cloning of inserts, Chromatin Immunoprécipitation, RT- 
PGR and sequencing were purchased from Sigma-Genosys. The name, 
sequence and application of these primers are given in table 2.1.
2.1.3 PiasmidsA/ectors
pGEIVl®-T Easy (Promega): Used to clone PGR products generated by 
amplification using Taq DNA polymerase. The vector is supplied pre-cut with 
EcoRV, with 3’ terminal thymidine residues added to both ends. This provides 
sticky ends which complement the 3' terminal adenosine residues added by Taq 
DNA polymerase to amplified products. Insertion of the PGR product into the B- 
galactosidase enzyme gene causes inactivation of the enzyme, allowing detection 
of recombinant clones via blue/white selection on Xgal/IPTG plates.
pBluescript (BS) KS (Stratagene): Used to clone PGR products generated by 
amplification using Pfu DNA polymerase, and as an intermediate cloning vector. 
pBS contains T3 and T7 bacteriophage promoters at either end of the MGS. The 
MGS is contained with the fi-galactosidase enzyme gene, causing Inactivation of 
the enzyme upon cloning of an insert.
pCI-neo (Promega): A mammalian expression vector containing a
Gytomegalovirus (GMV) immediate-early enhancer/promoter and an SV40 late 
polyadenylation signal. A chimaeric intron, composed of the 5’ splice site from the 
first intron of the human fl-globin gene and the branch and 3' splice site from the 
intron of an immunoglobulin gene heavy chain region, is found upstream of the
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MCS. The plasmid also contains a neomycin phosphotransferase selectable 
marker for selection of stably transfected mammalian cells lines with G418.
pCI-E2; Nucleotides (nt) 2735-3852 of the HPV-16 genome containing the E2 
ORF were cloned Into the Xbal/Sal! sites of pCI-neo, to produce a mammalian 
HPV-16 E2 expression vector.
pET15b:E2(16) (supplied by Julie Burns, University of York): A bacterial
expression vector with a 20 amino acid histidine tag as an in-frame N-terminal 
fusion with HPV-16 E2.
pCG (supplied by Javier Cacares, MRC Human Genetics Unit, Edinburgh): A 
mammalian expression vector containing a CMV promoter and an SV40 late 
polyadenylation signal.
pCG-SF2/T7-SF2 (supplied by Javier Cacares, MRC Human Genetics Unit, 
Edinburgh): A mammalian expression vector for SF2/ASF, either containing or 
lacking a T7 tag. Derived from pCG.
pGCAT3-Basic(B) (adapted from pGL3-Basic, Promega): A Chloramphenicol 
Acetyltransferase (CAT) reporter vector containing a late SV40 polyadenylation 
signal.
pGCAT3-B-SF2 promoter: pGCAT3-Basic with a region spanning Ikb 5' of and 
including the SF2/ASF transcriptional start site, cloned into KpnI/Sall sites (Figure 
3.1).
pLW2: A CAT reporter construct containing an HSV-1 immediate early 5 promoter 
and an SV40 late polyadenylation signal.
pLWI+LRE: A CAT reporter construct containing an HSV-1 immediate early 5 
promoter and the late 3'UTR of HPV-16 from the PstI site at nt 7005 to the EcoRI 
site at nt 7456 (Figure 5.3).
pLWI-LRE: A CAT reporter construct containing an HSV-1 immediate early 5 
promoter and the late 3'UTR of HPV-16 from the SspI site at nt 7226 to the EcoRI 
site at nt 7456 which lacks the LRE (Figure 5.3).
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pLW2(intron)/pLW1(intron)+/-LRE: CAT reporters as described above
containing the chimeric intron from pCI-neo in the BamHI site upstream of the CAT 
gene. pLW1(intron)-LRE differs in that the late 3’UTR of HPV-16 is cloned from
the PstI to the EcoRI site, with the LRE from nt 7127-7206, precisely deleted 
(Figure 5.5).
Primer Sequence (5’ to 3’) Application
SF2pr-1024F GTTACGGTTCTCACATCCATTTTGC Cloning of SF2pr 
EMSA probe 1
SF2pr-829 R TGACACTAGTGTGGGACTAGCGCAGA
ATGC
EMSA probe 1
SF2pr-852F TGACACTAGTCTTCATTAAGTACCGTT
CC
EMSA probe 2
SF2pr-650 R CAGGCATTCTGCGCTAGTC EMSA probe 2
SF2pr~684F TGACACTAGTGTTCTGACGAGAAGGC
GGAAC
EMSA probe 3
SF2pr~482 R GAAACCCGGGTATCTTCGTAG EMSA probe 3
SF2pr-524F TGACACTAGTCAGCTCTGGATTAGAC
GCAC
ChlPs
EMSA probe 4
SF2pr-325R GCAATGAGGATCTTTGAAAGC ChlPs
EMSA probe 4
SF2pr~402 F ATGGTGGGACAACGCTTTAG Endogenous
ChlPs
SF2pr -222 R TTTGCGAACAGAGTGACCAG Endogenous
ChlPs
SF2pr-364F TGACACTAGTCTTTGAAGGCGCCGAG
TTGC
EMSA probe 5
SF2pr-162R GACGTCACCCTCCCCACGAAG EMSA probe 5
SF2pr-199F TGACACTAGTGGGACTTTTTTACCCCC
TTC
EMSA probe 6
SF2pr +5R CTCCCGCGGCCCCTCCAAAATG Cloning of SF2pr 
EMSA probe 6
CAT5' F AATCACTGGATATACCACCGTTGA ChlPs
CATS’ R TGAACGGTCTGGTTATAGGTAC Chips
5S RNA F GGCCATACCACCCTGAACGC ChlPs
5S RNA R CAGCACCCGGTATTCCCAGG ChlPs
SF2 F CTCATCATTCCCCAGAAACC ChlPs
RT-PCR
SF2 F GGCAGGAATCCACTCCTATG ChlPs
RT-PCR
GAPDH F TCCACCACCCTGTTGCTGTA RT-PCR
GAPDH R ACCACAGTCCATGCCATCAC RT-PCR
CAT3’ F CTGGCCTATTTCCCTAAAGG RT-PCR
CAT3’ R CAAACGGCATGATGAACCTG RT-PCR
Table 2.1 : Sequence and application of primers used.
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The antibodies used in western blotting, imuunofluoresence and 
immunoprécipitation experiments are listed in table 2.2 together with their dilution 
and source.
Antibody Western
blotting
Immnuo-
flourescence
ChlP/EMSA
supershift
Source
HPV-16 E2 1/5000 with 
1M NaCI
5p l-C h lP rabbit, Lawrence 
Banks (ICGEB, 
Trieste, Italy)
5pl-ChlP SCT, rabbit, Julie 
Burns, (University of 
York)
neat TVG 261, mouse, 
lain Morgan
TBP 1ml - Chip 4C8/26, mouse, 
Robert White
Involucrin 1/1000 1/1000 5p l-C h lP clone SY5, mouse. 
Sigma
Spl 1 pi
supershift
ab13405, rabbit, 
Abeam
C/EBP p 1 pi
supershift
H-7, mouse, Santa 
Cruz
SF2/ASF 1/500 clone 96, mouse, 
Zymed Laboratories
1/500 clone 103, mouse, 
Zymed Laboratories
SRp20 1/250 1/50 clone 7B4, mouse, 
Zymed Laboratories
9G8 1/10 1/25 clone 98, mouse, 
James Steven in
Phosphorylated 
SR proteins
neat Mb104, mouse, 
(Hanamura et al. 
1998)
SG35 1/250 mouse, Sigma
SRPK1 1/100 1/100 clone G211-637, 
mouse, BD 
Pharmingen
GAPDH 1/2000 6CS, mouse,
Biodesign
International
HPV-16 E1^E4 1/100 B11, FITC 
conjugate, John 
Doorbar
:‘S:
Table 2.2: Dilution and source of all antibodies used.
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2.1.5 Bacterial Culture
The DH5a E. coll strain was used to propagate and maintain all plasmid DNA. L- 
Broth (10g NaCI, 16g Bactopeptone, 5g yeast extract in 1 litre H2O, pH 7.5) and 
agar plates made with 1.5% (w/v) agar in L-Broth were used to grow the bacteria. 
When necessary, L-Broth and agar plates were supplemented with 100pg/ml 
ampicillin.
2.1.6 Radiochemical
Radiochemicals were purchased from the following sources at the stated activity 
level:
a -  [^^P] dCTP 10mCi/ml Amersham (GE Healthcare)
f'^C] Chloramphenicol 50pCi/ml Perkin Elmer
2.1.7 Cell lines
HeLa: An epithelial cell line derived from an aggressive cervical lesion containing 
integrated HPV-18.
J2 3T3: J2 clone of random-bred Swiss mouse 3T3 cells.
W12E: An epithelial cell line containing extrachromosomal copies of HPV-16, 
subcloned from the parental W12 cell line (Stanley et al. 1989; Jeon et al. 1995).
HaCaT: A spontaneously immortalised epithelial cell line (Boukamp et al. 1988).
U20S: An osteosarcoma cell line.
All cell lines were grown at 37'’C in the presence of 5% CO2.
2.1.8 Common Reagents, chemicals and solutions
30% Acrylamide/bisacrylamide 29% (w/v) acrylamide, 1% (w/v) N,N’- 
mix methylene bis-acrylamide
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10 X DNA loading buffer
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15% (v/v) Ficoll Type 400, 0.25% (w/v) 
bromophenol blue, 0.25% (w/v) Xylene 
cyanole
PBS 170mM NaCI, 3.4mM KCI, lOmM 
NazHPO#, 1.8mM KHg PO4, pH 7.2
PBS-Tween (PBS-T) PBS, 0.1% (v/v) Tween 20
5x Protein loading buffer 62.5mM Tris-HCI, 2% (w/v) SDS, 715mM 
(v/v) p-mercaptoethanol, 0.3% (w/v)
bromophenol blue, 20% (v/v) glycerol, pH
6.8
5x Tris-Glycine Buffer 1.25M Glycine, 125mM Tris, 0.5% (w/v) 
SDS
lOx TBE 890mM Tris, lOmM EDTA, 890mM boric 
acid, pH 8.3
TE buffer
Coomassie biue stain
lOmM Tris-HCI, ImM EDTA, pH 8.0
0.02% (w/v) Coomassie Brilliant Blue, 
50% (v/v) methanol, 7% (v/v) acetic acid
Coomassie blue destain 5% (v/v) methanol, 7% (v/v) acetic acid
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2.2 Methods
2.2.1 DNA manipulation and cloning
2.2.1.1 Preparation and transformation of competent bacteria! cells
1ml of a 5ml overnight culture of DH5a cells was inoculated into 100ml L-Broth 
and grown whilst shaking for approximately 2.5-3 hours until the ODeoo was 0.6. 
The culture was then chilled on ice for 10 minutes followed by centrifugation at 
2500rpm for 10 minutes at 4‘'C (Sorvall RT7 bench top centrifuge). After the 
supernatant was discarded, the pellet was resuspended in 20ml ice-cold sterile 
0.1M CaCb and incubated on ice for 30 minutes. Cells were pelleted by 
centrifugation at 2000rpm for 10 minutes at 4°C (Sorvall RT7 bench top centrifuge) 
and the supernatant was again discarded. The pellet was resuspended in 3.6ml 
ice-cold sterile 0.1 M CaCb and 10% glycerol was added. Competent cells were 
stored in aliquots of 200pl at 4°C for use within 48 hours or -70°C for prolonged 
storage.
Competent cells were thawed on ice prior to transformation. 1-50ng of plasmid 
DNA (to a volume of lOpI or less) was mixed with lOOpI competent cells and 
incubated on ice for 30 minutes. Heat shocking at 42°C for 90 seconds was 
performed followed by transfer to ice for 1-2 minutes to allow cooling. 900pl L- 
Broth was added and cells were incubated for 30-90 minutes at 37°C whilst 
shaking. lOOpI cells up to the entire solution following pelleting, were then 
transferred to agar plates containing lOOpg/ml ampicillin and incubated at 37°C 
overnight.
2.2.1.2 Plasmid DNA purification 
Small-scale purification of plasmid DNA
Plasmid DNA was isolated using a Wizard® Plus SV Miniprep kit (Promega) 
according to the manufacturer’s protocol. Alternatively, cells were pelleted from 
1 ml of a 5ml overnight culture by centrifugation for 2 minutes at maximum speed in 
a microcentrifuge (Eppendorf 5415C). The supernatant was discarded and the 
pellet was resuspended in lOOpI Solution I (50mM Glucose, 25mM Tris-HCI, 
iOmM EDTA, pH8.0). After addition of 150pl Solution II (0.2M NaOH, 1% SDS), 
the solution was mixed by inversion. 150pl Solution III (3M Potassium acetate,
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11.5% (v/v) Acetic acid) was then added and the solution was again mixed by 
inversion. Following centrifugation at maximum speed for 2 minutes in a 
microcentrifuge (Eppendorf 5415C), the supernatant was transferred to a fresh 
eppendorf and extraction of nucleic acids using 150pl 
phenol:chloroform:isoamylalcohol (25:24:1) was performed. 720pl isopropanol 
and 40pl 3M NaOAc were added and the solution was mixed by inversion. 
Microcentrifugation was performed at maximum speed for 10 minutes (Eppendorf 
5415C) and the supernatant was removed. 4Q0pl 70% EtOH was added and 
microcentrifugation was repeated at maximum speed for 5 minutes (Eppendorf 
5415C). Following removal of the supernatant and air drying, the pellet was 
resuspended in 20pl TE buffer.
Large scale Caesium Chloride purification of plasmid DNA 
5ml overnight culture was inoculated into 200ml L-Broth plus lOOpg/ml ampicillin 
and incubated at 37°C overnight, with shaking. Cells were pelleted at SOOOrpm for 
10 minutes at 4 '^C in a Beckman J2-21 centrifuge (JA-14 rotor). Following removal 
of the supernatant cells were resuspended in 10ml Solution I (50mM Glucose, 
25mM Tris-HCI, IOmM EDTA, 2mg/ml lysozyme, pH8.0). 20ml freshly prepared 
Solution II (0.2M NaOH, 1% SDS) was added to lyse cells, followed by incubation 
at room temperature for 10 minutes. After addition of 20ml ice-cold Solution III 
(3M Potassium acetate, 11.5% (v/v) acetic acid), the solution was mixed by 
inversion and incubated on ice for 10 minutes. Cell debris was pelleted at 
SOOOrpm for 10 minutes at 4°C in a Beckman J2-21 centrifuge (JA-14 rotor). The 
supernatant was filtered into to a fresh centrifuge bottle through 8ply gauze and 
plasmid DNA was precipitated from the filtrate by addition of 0.6 volumes 
isopropanol. Centrifugation was performed at 8000rpm for 15 minutes at room 
tempreature in a Beckman J2-21 centrifuge (JA-14 rotor). After air drying the DNA 
was resuspended in 5ml TE buffer, to which 5.4g CsCI and 400pl Ethidium 
Bromide (EtBr) (lOmg/ml) was added. Following centrifugation at lOOOOrpm for 10 
minutes at 18°C In a Beckman J2-21 centrifuge (JA-20 rotor), the supernatant was 
transferred to a 6ml ultracentrifuge tube and centrifuged at 48000rpm, overnight at 
18"C in a Beckman L7-65 Ultracentrifuge (TI70 rotor). The plasmid DNA band 
was extracted by puncturing the tube with a needle and syringe, removing the 
plasmid DNA band and transferring it to a 15ml Falcon tube. Repeated extraction 
(x5) with HaO-saturated butan-2-ol was used to remove EtBr from plasmid DNA, 
then 3 volumes TE buffer was added followed by DNA precipitation with 2.5
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volumes 100% ethanol. Following washing with 5ml 70% EtOH, the resulting DNA 
pellet was resuspended in 500pl TE buffer and analysed by restriction digestion.
2.2.1.3 Restriction endonuclease digestion and blunt-ending DNA
Digestion of DNA was performed for 1-3 hr at 37°C in the presence of 
approximately 2U of the restriction enzyme per pg DNA in 1x the appropriate 
buffer (supplied by the manufacturer). Over-hanging 5’ DNA ends were filled-in 
using 2.5U Klenow DNA Polymerase I, Large Fragment, for 10-30 minutes at 
25°C, in the presence of all four dNTPS at a final concentration of 33pM each.
2.2.1.4 PhenoLChloroform extraction and ethanol precipitation
In general, an equal volume of phenohchloroform (1:1) (phenol saturated in TE 
buffer, pH 7.9) was added to the DNA solution, mixed by vortexing and 
microcentrifuged at maximum speed for 5 minutes (Eppendorf 54150). The upper 
aqueous phase was transferred to a fresh tube, an equal volume of chloroform 
was added and the solution was vortexed and microcentrifuged as before. 
Following transfer of the upper aqueous phase to another fresh tube, 1/10 volume 
3M sodium acetate, pH 5.2, and 2.5 volumes 100% EtOH were added. DNA was 
precipitated at -20°C overnight, or on ice for 30 minutes. Pelleting of DNA was 
performed by microcentrifugation at maximum speed for 10 minutes (Eppendorf 
5415C). The pellet was then washed with 70% ethanol, centrifuged for 5 minutes, 
air-dried and resuspended in dHzO or TE buffer.
2.2.1.5 DNA ligation
Inserts were ligated into vectors with compatible ends following restriction 
digestion with the appropriate enzymes and gel extraction (Section 1.2.1.6). 
Reactions were carried out in 20pl volume with 1x ligase buffer and 40U T4 DNA 
llgase per reaction at differing molar ratios, typically 1:3, 1:1 and 3:1. Ligation was 
performed at room temperature for more than 4 hours, or at 4°C overnight. PCR 
products were ligated into pGEM T Easy (Promega) following the manufacturer’s 
instructions.
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2.2.1.6 Gel electrophoresis of DNA and recovery
Agarose gel electrophoresis
DNA was resolved in a horizontal slab gel of 1-2% (w/v) agarose (Roche) in 
IxTBE or IxTAE and electrophoresed in IxTBE/TAE buffer at ~100V. 1x TBE 
was used to product more defined DNA bands, whilst IxTAE was used when DNA 
was to be extracted. 100pg/pl Ikb DNA ladder (Invitrogen) was used as a 
standard size marker. Staining of gels in 0.5pg/ml EtBr for 15 minutes was 
performed following electrophoresis and DNA was visualised under UV light. Gel 
slices containing the appropriate DNA were excised from IxTAE gels and the DNA 
was extracted using a QIAquick® Gel Extraction Kit (50) (Qiagen) following the 
manufacturer’s instructions.
Acrvlamide gel electrophoresis
Resolution of small DNA fragments, less than Ikb in size, was performed on a 6% 
polyacrylamide gel prepared as follows:
30% acrylamide/ 3ml
bisacrylamide mix (BioRad) 
lOxTBE 1.5ml
dHzO 10.5ml
10% APS lOOpI
TEMED 12pl
Electrophoresis was performed at -120V, followed by staining with 0.5pg/ml EtBr 
for 15 minutes and visualisation under UV. DNA was extracted from gel slices by 
incubation at 4°C overnight in 400pl 0.5M NaCI, ImM EDTA and precipitation with
2.5 volumes 100% ethanol. Following pelleting and washing with 70% EtOH, the 
DNA was resuspended in dHgO or TE buffer.
2.2.1.7 Quantification of nucleic acids
The concentration of nucleic acid solutions was calculated using a 
spectrophotometer (Eppendorf BioPhotometer). The A260/A280 ratio was also used 
to determine the purity of the solution, a reading of -1.8 indicating the sample was 
relatively pure.
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2.2,2 Tissue Culture
2.2.2.1 Growth and maintenance of cell lines
HeLa, HaCal and U20S cells were passaged In Dulbecco’s Modified Eagles 
Medium (DMEM), supplemented with 10% foetal calf serum, 2mM L-glutamine 
with or without 50U/ml Penicillin/ 50pg/ml streptomycin (all supplied by Life 
Technologies). 500pg/ml G418 was added if necessary.
J2 3T3 cells were passaged in DMEM, supplemented with 10% donor calf serum 
(Life Technologies) and 2mM L-glutamine.
W12E cells were grown on a feeder layer of J2 3T3 cells in DMEM, supplemented 
with 10% foetal calf serum, 2mM L-glutamine, 0.1 nM Cholera Toxin and 0.4pg/ml 
Hydrocortisone. In preparation for W12E cell plating, J2 3T3 cells were treated 
with Mitomycin C at 4pg/ml for 2-5 hours. Cells were then washed twice with PBS, 
trypsinised and pelleted at lOOOrpm at 4*^0 for 5 minutes (Sorvall RT7). Following 
resuspension, cells were counted using trypan blue exclusion, to identify live cells, 
and plated at 1.10® per 100mm dish. W12E cells were then plated at 2.10® cells 
per 100mm dish from liquid nitrogen stocks. After 24 hours, 0.5ng/ml epidermal 
growth factor was added. During growth, medium was changed every 2 days until 
harvesting, at 5 days for undifferentiated cells and 10 days for differentiated cells. 
To harvest W12E cells, J2 3T3 cells were first trypsinised and washed from plates. 
W12E cells remained adhered to the plate and were harvested either by 
trypsinisation or using one of the methods described in section 2.2.2.4.
2.2.2.2 Preparation of cell stocks
Cells were trypsinised then counted via trypan blue exclusion and resuspended in 
medium to 1.10® cells/ml. 10% (v/v) dimethylsulphoxide (DMSO) was added and 
aliquots of 1.10® cells were transferred to screw cap tubes, left at -70°C 
overnighted, followed by storage in liquid nitrogen.
2.2.2.3 Transfection with lipofectamine reagent
One day prior to transfection 2-8.10'^ cells were plated In 10mm diameter wells in 
culture medium lacking Penicillin/Streptomycin. The following day the transfection
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solution, of the appropriate amount of plasmid DNA, 1pl 2mg/ml Lipofectamine™ 
2000 (Invitrogen) in 100pl DMEM per well, was incubated at room temperature for 
15 minutes. The solution was then transferred to cells, which were incubated for 
24-48 hours.
2.2.2.4 Preparation of cell extracts 
Preparation of total cellular protein extracts
Following removal of media, cells were washed twice in PBS. Protein loading 
buffer was added and plates were incubated at 4'’C for 15 minutes whilst shaking. 
To shear DNA, lysates were passed through a 22-guage needle 10 times and 
transferred to screw cap tubes. Storage was at -20°C. Prior to electrophoresis, 
lysates were incubated at 100°C for 5 minutes, before centrifugation at 12,000rpm 
for 2 minutes (Eppendorf 5415C). Alternatively, a freeze/thaw method was used. 
Cells were trypsinised and pelleted at 13,000rpm at 4°C for 5 minutes (Hettich 
zentrifugen EBA 12 R). Following washing with PBS, pellets were resuspended in 
0.25M Tris-HCI, pH 7.5. Lysates were then frozen on 100% EtOH with dry ice and 
thawed at 37°C, three times. Following centrifugation at 13,000rpm at 4°C for 10 
minutes (Hettich zentrifugen EBA 12 R), the supernatant was transferred to a fresh 
eppendorf and stored at -20®C.
Preparation of Nuclear Extract
Following removal of media and a single PBS wash, cells were scraped into 5ml 
PBS and pelleted at 4°C for 5 minutes at 4000rpm (Sorvall RT7). The pellet was 
then resuspended in 4ml Buffer A (IOmM Tris-HCI, pH 7.9, 1.5mM MgCb, IOmM 
KCI, 0.5mM DTT, 0.5mM PMSF) and incubated on ice for 10 minutes. Following 
homogenisation (x10-15), nuclei were pelleted at 4'"C for 5 minutes at 4000rpm 
(Sorvall RT7) and resuspended in 200pl Buffer C (20mM Tris-HCI, pH 7.9, 25% 
(v/v) Glycerol, 1.5mM MgClg, 0.2mM EDTA, pH 8.0, 0.3M NaCI, 0.5mM DTT, 
0.5mM PMSF). Samples were incubated at 4°C for 30 minutes with rotation, then 
centrifuged at 4°C for 15 minutes at lOOOOrpm (Hettich zentrifugen EBA 12 R). 
The supernatant was transferred to fresh ice-cooled tubes and stored at -70°C.
Preparation of Total RNA
Cells were washed with PBS before addition of 1ml TRIzol® Reagent (Invitrogen) 
per 1.10® cells. Following transfer to 12ml snap-capped tubes (Greiner), samples 
were incubated at room temperature for 5 minutes. 1/5 volume of chloroform was
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added and the sample was shaken vigorously for 15 seconds. After 2-3 minutes 
incubation at room temperature, centrifugation was performed at 10,000rpm for 15 
minutes at 4°C in a Beckman J2-21 centrifuge (JA-20 rotor). The aqueous phase 
was transferred to a fresh tube and % volume isopropanol was added. Following 
incubation at room temperature for 10 minutes, samples were centrifuged at 
10,000 rpm for 10 minutes at 4°C. The pellet was washed with 75% EtOH and 
allowed to air dry, followed by resuspension in DEPC-H2O to -Ipg/p l. To remove 
DNA contaminants, samples were DNase treated using RQ1 RNase-Free DNase 
(Promega) as per the manufacturer's instructions.
2.2.3 Protein Analysis
2.2.3.1 Quantification of proteins
1-1 Opi neat or diluted sample was added to 200pl 1x Bradford Assay reagent 
(BioRad) in a 24-well plate. Standards were also set up in the same way using 
lOpI serial dilutions of BSA (0.1 mg/ml, 0.2mg/ml, 0.4mg/ml, 0.6mg/ml, O.Smg.ml 
and 1 mg/ml), as well as a blank control. Concentrations were then determined 
against standards using an Anthos HT II labtech platereader.
2.2.3.2 SDS-PAGE
Fractionation of proteins, from lysates made in protein loading buffer, was 
performed on a 12% SDS-Polyacrylamide gel, with stacking gel, prepared as 
follows using a mini protein gel electrophoresis system:
12% Separating gel Stacking gel
30% acrylamide/ 
bisacrylamide mix
4ml 650pl
1.5M Tris-HCI, pH8.8 2.5ml N/A
1M Tris-HCI, pH6.8 N/A 2.5ml
10% SDS lOOpI 50pl
dH20 3.3ml 3.05ml
10% APS lOOpI 50pl
TEMED lOpI lOpI
Electrophoresis was performed at 120V in 1x Tris-Glycine buffer, until the 
bromophenol blue reached the bottom of the gel. Proteins were visualised by
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coomassie blue staining of the gel for 30 minutes at room temperature, followed by 
destaining overnight.
2.2.3.3 Western blotting
Foilowing resolution by SDS-PAGE, proteins were transferred to nitrocellulose 
membrane (Amersham) using a Bio-Rad transblot system. Electroblotting was 
performed at 250mA for 2 hours or 100mA, overnight at 4°C. Blocking of the 
membrane was carried out in PBS-T with 5% dried skimmed milk (PBS-T, 5% 
milk) at room temperature for 1 hour, or 4°C overnight. The membrane was then 
incubated in the appropriate dilution of primary antibody in PBS-T, 5% milk for 1 
hour at room temperature, or 4”C overnight. Following washing with PBS-T (1x30 
seconds, 1x15 minutes and 2x5 minutes), the membrane was incubated in 
secondary antibody, either horseradish peroxidase conjugated anti-mouse IgG or 
protein A to detect monoclonal or polyclonal primary antibodies respectively, at a 
dilution of 1:1,000 in PBS-T, 5% milk, for 1 hour at room temperature. The 
membrane was then washed in PBS-T (1x30 seconds, 1x15 minutes and 2x5 
minutes) and subjected to enhanced chemiluminescence (ECL) using the 
Amersham ECL system. Luminescence was visualised to Kodak X-OMAT S film 
and developed using a Konica SRX-101 A film processor. Stripping of 
membranes was performed as required in 50ml Stripping buffer (lOOmM p- 
mercaptoethanol, 2% SDS, 62.5mM Tris, pH 6.8) at 50°C for 30 minutes, followed 
by washing with large volumes of PBS-T (1x30 seconds, 1x15 minutes and 2x5 
minutes).
2.2.3.4 Immunofluorescence
Cells were grown as described previously. Following trypsinisation, cells were 
transferred to 10mm coverslips and grown to -70% confluence. The media was 
then removed and cells were washed three times in PBS. Fixing cells to 
coverslips was performed in SOOpI Fix solution (58mM Sucrose, 5% formaldehyde, 
in PBS) for 10 minutes at room temperature. Following washing three times with 
PBS, coverslips were either stored at 4°C in PBS with 1% (v/v) Foetal calf Serum 
(PBS/FCS), or permeabilised in 500pl -20°C permea mix (70% acetone, 30% 
methanol) for 5 minutes at -20°C. Permea mix was then removed and coverslips 
were again washed three time with PBS. After this cells were incubated at room 
temperature for 1 hour with primary antibody at the desired dilution in PBS/FCS,
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followed by washing six times with PBS. Secondary antibody, FITC or Texas Red- 
conjugated anti-mouse antibody was diluted 1:100 in PBS/FCS and incubated with 
cells for 30 minutes at room temperature. Following washing six times with PBS, 
coverslips were air dried and mounted with mounting fluid (Vector Laboratories) 
onto slides. Slides were stored at 4*’C until required for confocal microscopy 
examination using a LSM 510 meta confocal microscope (Zeiss).
2.2.3.5 His Tagged protein purification
His tagged E2 protein was purified from BL21 bacterial cells. 5ml overnight culture 
was inoculated Into 100ml L-Broth with 100pg/ml Ampicillin and incubated at 37°C 
for 3 hours, whilst shaking. Following addition of ImM IPTG, the culture was 
incubated at 2 5 X  for 4 hours, whilst shaking. Bacterial cells were recovered from 
culture via centrifugation at GOOOrpm for 10 minutes at 4"’C in a Beckman J2-21 
centrifuge (JA-14 rotor) and the supernatant was discarded. Cells were then 
washed with 50mM NaCI, 2mM EDTA, 50mM Tris-HCI, pH 8.0 and centrifuged at 
6000rpm for 10 minutes at 4°C in a Beckman J2-21 centrifuge (JA-14 rotor). The 
supernatant was again discarded and cells were resuspended in 10ml Binding 
buffer (5mM imidazole, 0.5M NaCI, 20mM Tris-HCI, pH 8.0). DNA was sheared by 
sonication (6x30seconds, with 1 minute intervals) and cell debris was pelleted at 
13000rpm at 4°C for 10 minutes (Hettich zentrifugen EBA 12 R). The supernatant 
was then transferred to a fresh universal and applied to a Nickel resin column. 
The column was prepared with 1ml HiseBind® resin (Novagen), a 1:1 slurry in 20% 
EthOH, to a bed volume of 500pl, and allowed to drain. The column was then 
washed with 3 bed volumes dH20 before application of 5 bed volumes 50mM 
NIS04. 3 bed volumes of binding buffer was then added, followed by addition of 
the lysate. At each stage fluid was allowed to drain through the column before 
addition of the next, to ensure maximum purity. To further remove impurities the 
column was subjected to 10x1 bed volume washes with binding buffer and 6x1 
bed volume washes with wash buffer (60mM imidazole, 0.5M NaCI, 20mM Tris- 
HCI, pH 8.0). E2 protein was then eluted from the column via 6x1 bed volume 
washes with elution buffer (1.5M imidazole, 0.5M NaCI, 20mM Tris-HCI, pH 8.0). 
All washes and elutions were stored at -70°C and analysed by SDS-PAGE.
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2.2.4 Analysis of reporter gene expression
2.2.4.1 Chloramphenicol Acetyltransferase (CAT) assays
Transfections were performed as described previously and protein lysates were 
made using the freeze/thaw method. 1-20p! lysate was added to a reaction mix of 
625pM Acetyl Coenzyme A (Sigma), O.OSpCi f'^C] Chloramphenicol and 0.25M 
Tris-HCI, pH 7.5 to 40pl, and incubated at 37°C for 1 hour. 200pl ethyl acetate 
was added and the solution was vortexed for 10 seconds, before centrifugation at 
13000rpm for 5 minutes at room temperature (Hettich zentrifugen EBA 12 R). The 
upper organic layer was then transferred to a fresh tube and lyophilised in an 
Eppendorf Concentrator 5301. Following resuspension in 25pl ethyl acetate, the 
solution was applied to a TLC plate (Merck) and samples were separated in 95% 
chloroform, 5% methanol. Plates were visualised to a phosphoimaging screen 
(Bio-Rad) and analysed using QuantityOne software.
2.2.5 DNA-Protein interaction assays
2.2.5.1 End-labelling of a dsDNA probe
DNA was digested with restriction enzymes leaving a 5' overhang and gel purified 
into 30pl dH20, as described above. a-[®^P] dCTP was then added to the DNA in 
a reaction mix consisting of 1x reaction buffer, 3.3pM dATP, dGTP and dTTP mix 
and 2.5U DNA Polymerase I, Large (Klenow) Fragment. The reaction was 
performed at room temperature for 10-30 minutes, then 3.3pM dCTP was added, 
followed by a further 5 minutes incubation at room temperature. The probe was 
then purified using a mini Quick Spin column (Roche). The column was first 
centrifuged at 6500rpm for 5 minutes at room temperature (MSE Micro 
Centrifuge). The probe was applied to column and centrifuged for a further 3 
minutes at 6500rpm at room temperature (MSE Micro Centrifuge). Free a-[®^P] 
dCTP nucleotides were retained in the column. Specific activity of the probe was 
then determined using a Beckman liquid scintillation counter.
2.2 5.2 Electrophoretic Mobility Shift Assay (EMSA)
Reactions for DNA mobility shifts assays were prepared as follows:
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a- f^P] labelled DNA probe 2,000 cpm
1pg/pl poly dl-dC 2pl
10pg/pl BSA 0.45pl (to 300pg/ml)
3x reaction buffer 5pl
(10mM Hepes, pH 7.9, lOOmM KCI, 5mM MgCIa, 10% glycerol, O.SmM DTT) 
E2 3pl
Nuclear Extract (~5pg/pl) 3.5pl
dHaO to 15pl
The reactions were incubated at room temperature for 15 minutes, and then 
resolved on a 4.5% non-denaturing acrylamide gel (9ml of 30% acrylamide/bis­
acrylamide mix, IxTBE, 44.5ml dHgO, 500pl 10% APS, 50pl TEMED, pre-run for 
45 minutes at 200V) for 2.5 hours at 200V in IxTBE. The gel was then dried and 
potential DNA-protein complexes were visualised to Kodak X-OMAT film at -70°C.
2.2.5.3 Chromatin Immunoprécipitation (ChIP)
Following washing with PBS, cells were scrapped into 1ml PBS and pelleted at 
1500rpm for 5 minutes at 4°C (Sorvall RT7). Cells were then washed in PBS and 
resuspended in 1ml PBS. The solution was added to 10ml pre-warmed PBS, 
0.5% NP40 (PBS/NP40), 1% formaldehyde and incubated at 37°C for 10 minutes. 
Centrifugation was performed at 1500rpm for 5 minutes at 4°C (Sorvall RT7), 
followed by washing with PBS/NP40. Samples were kept on ice from this point. 
Cells were then resuspended in 40ml ice-cold High Salt buffer (PBS/NP40, 1M 
NaCI) and incubated on ice for 30 minutes. Following a second PBS/NP40 wash, 
cells were resuspended in 40ml ice-cold Low salt buffer (0.1% NP40, 0.1 M NaCI, 
IOmM Tris-HCI, pH 8.0, ImM EDTA) and incubated on ice for 30 minutes. 
Centrifugation was performed at 1500rpm for 5 minutes at 4°C (Sorvall RT7) and 
the pellet was resuspended in 1 ml Low Salt buffer, before being passed through a 
needle three times. 1.7ml Low salt buffer and 300pl 20% Sarkosyl were added 
and the solution was applied carefully to the top of 40ml Low salt buffer, lOOmM 
Sucrose with cut blue tips, followed by centrifugation at 7000rpm for 10 minutes at 
4°C in a Beckman J2-21 centrifuge (JA-20 rotor). Following resuspension of the 
pellet in 3ml TE buffer, the solution was again applied to 40ml Low salt buffer, 
lOOmM Sucrose and centrifuged as before. The pellet was then resuspended in 
2ml TE buffer and DNA was sheared by sonication (10x10 second pulses with 10 
second intervals). Once transferred to two eppendorf (1ml each), lOOpI 11x NET
Sarah Mole, 2007 Chapter 2, 79
buffer (5.5% NP40, 1.65M NaCI, 550mM Tris-HCI, pH 7.4, 5.5mM EDTA, 11 mM 
MgCI2) was added, followed by centrifugation at 13000rpm for 5 minutes at 4°C 
(Hettich zentrifugen EBA 12 R). The supernatant was then transferred to fresh 
eppendorf tubes, one per immunoprécipitation, plus a 1/10 input control aliquot. 
Samples were then incubated in the presence of the appropriate concentration of 
antibody at 4°C, overnight with rotation. Following incubation with Protein-A- 
Sepharose beads at 4°C, for 2 hours with rotation, samples were applied to 5ml 
Polypropylene columns (Pierce) and washed with 20ml RIPA buffer (1% NP40, 
150mM NaCi, 50mM Tris-HCI, pH 8.0, 0.1% SDS, 0.5% Deoxycholate), 20ml LiCI 
buffer (250mM LiCI, 0.5% NP40, 0.5% , ImM EDTA, pH 8.0) and 20 ml TE buffer. 
DNA-protein complexes were then eluted from the column in 400pl TE buffer, 1% 
SDS. Proteinase K was added to 125pg/ml and samples were incubated at 42°C 
overnight before two phenol:cholorform:lsoamylalcohol (25:24:1) and one 
chloroform extraction. Following ethanol precipitation, DNA was resuspended in 
40pl TE buffer and analysed using PCR.
2.2.6 RNA
2.2.6.1 RT-PCR
Total RNA was purified as described previously. 1pl 0.5pg/pl Oligo dT or 1pl 
Ipg/pl random primer was incubated with Ipg RNA in 14.5pl DEPC-H2O at 70°C 
for 10 minutes to denature RNA. Following cooling on ice, 2.5pl lOx MgC^free 
PCR buffer, 2.5pl 25mM MgCb, 1pl IOmM dNTPs, 2.5pl 0.1M DTT and 1jii 
rRNasin® RNase inhibitor (Promega) were added and the sample was incubated 
at 42°C for 1 minute. 1pl Superscript II (Invitrogen) was then added followed by 
incubation for a further 50 minutes at 42°C. Reactions were stopped by incubation 
at 70°C for 15 minutes. RNA was then degraded by treatment with 1pl 2U/pl 
RNase H (Invitrogen) for 30 minutes at 37°C and RT-PCR was performed with 
1/10 to 1/100 dilutions of each sample.
2.2.6.2 Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) reactions were set up using total or poly(A)+ 
cDNA, as follows:
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DNA 1pl
SYBR green mastermix (Applied Biosystems) 12.5pl
Forward primer (10pM) 0.75pl
Reverse primer (10pM) 0.75pl
dHaO 10pl
Reaction were carried out on a Applied Biosystems GeneAmp® 5700 Sequence 
Detection System, using the following program:
50°C 2 minutes
95°C 10 minutes
95‘'C 15 seconds
60°C 1 minutes
40 cycles
Each sample was compared to an arbitrary standard curve, calculated from 
reactions using dilutions of unknown concentration of the CAT PCR product. qRT- 
PCR was carried out in the same way using GAPDH primers. Samples were 
normalised by division by the GAPDH value.
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3 HPV-16 E2 Transactivates Expression of Splicing Associated 
SR Protein, SF2/ASF
3.1 Introduction
W12E cells are a subcloned cell line from W12 cells, which were Initiated from a 
low-grade cervical lesion, diagnosed as CIN I (Stanley et al. 1989). They contain 
-100 episomal copies of the HPV-16 genome, which can be maintained through 
several passages and exhibit typical epithelial cell morphology consistent with 
cells from CIN I lesions. These cells can be induced to differentiate using a 
number of methods, perhaps the simplest being in monolayer culture depending 
on their density and calcium concentration in the growth medium. Cells are plated 
at low density in culture medium supplemented with 1.2mM calcium, with regular 
media changes to limit the onset of differentiation. McPhillips et al. showed that 
differentiation begins to occur at day 6 after plating, when cells start to form 
colonies of more than a few cells (McPhillips et al. 2004). Growth from this point 
results in increasing differentiation and markers for differentiation, such as 
Involucrin, are found in abundance by day 7. Using this method of differentiation 
-10-20% of the cells are positive for involucrin by immunofluorescence at day 5, 
whereas this increases to -75-85% at day 10 (McPhillips et al. 2004). Therefore, 
samples are taken at day 5 and day 10 to compare expression between 
undifferentiated and differentiated cells. In western blotting experiments 
comparing undifferentiated and differentiated W12E protein lysates, abundance of 
splicing associated SR protein, SF2/ASF increased -4-8 fold in differentiated 
samples (McPhillips et al. 2004). In contrast, SF2/ASF upregulation was not 
observed in uninfected differentiated epithelial cells, such as HaCaT cells: a 
spontaneously immortalised epithelial cell line, which can also be induced to 
differentiate in monolayer culture depending on cell density, in a similar manner to 
W12E cells (Boukamp et al. 1988). During HaCaT cell differentiation SF2/ASF 
levels diminish (McPhillips et al. 2004). This suggests that SF2/ASF is specifically 
upregulated in response to HPV-16 infection in infected differentiated epithelial 
cells. Therefore, this chapter was undertaken to determine what viral protein(s) 
were involved in SF2/ASF upregulation.
To look at which viral proteins may be involved in SF2/ASF regulation, a further 
cell line analysed for its expression during differentiation was W12G. W12G are
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also subcloned from W12 cells, however the genome is integrated in these ceils 
(Jeon et al. 1995). As such, expression of viral proteins other than E6 and E7 is 
lost and cells have a growth advantage over W12E cells, containing episomal 
HPV-16. However, they are non-tumourigenenic and can be induced to 
differentiated, albeit to a lesser extent, using the same procedures as described 
for W12E cells (Jeon et al. 1995; McPhillips et al. 2004). Therefore, using these 
cells, involvement of HPV-16 proteins other than E6 and E7, could be ruled out, 
should SF2/ASF expression still be shown to be elevated upon differentiation. 
However, comparing W12G undifferentiated and differentiated protein lysates, 
McPhillips et al. showed that integration of the HPV-16 genome abrogated 
SF2/ASF upregulation (McPhillips et al. 2004). Therefore, these data suggest a 
role for episomal HPV-16 in the regulation of SF2/ASF. The virus may achieve 
this by two possible routes. Firstly, one or more viral protein may act to stabilise 
SF2/ASF in differentiated cells. Candidates for this would include E6 and E7. As 
E6 and E7 are expressed in W12G cells where SF2/ASF is not regulated during 
differentiation, it is unlikely that they act to stabilise the protein. However, they 
may be involved in targeting SF2/ASF for degradation. E6 and E7 are known to 
target several cellular proteins for ubiquitin mediated proteasomal degradation, 
and may act in a similar fashion to reguiate SF2/ASF abundance. However, E6 
and E7 are expressed during W12E differentiation, where SF2/ASF is elevated, 
indicating they are unlikely to be involved in targeting it for degradation. 
Furthermore, SF2/ASF is downregulated during differentiation of uninfected 
kératinocytes, suggesting that HPV-16 specifically upregulates protein levels and 
does not simply lose repressive activity in differentiated cells. A further potential 
candidate for regulation of SF2/ASF stability was E1^E4. E1^E4 is not known to 
have roles during regulation of protein stability, however, it has many functions late 
in infection and expression is shown to increase in differentiated cells (Doorbar et 
al. 1997). In these cells it could have somehow been involved in stabilisation of 
SF2/ASF, resulting in the elevated levels observed during HPV-16 infection.
A second possible mechanism by which HPV-16 may regulate SF2/ASF 
abundance is via regulation of gene expression. SF2/ASF is a constitutively active 
gene in undifferentiated epithelial cells, where it is an essential protein. However, 
during differentiation of uninfected epithelium cells become less metabolically 
active and cellular functions begin to shut down. Expression of SF2/ASF is lost 
during differentiation of uninfected epithelial cells, as the protein is no longer 
required (McPhillips et al. 2004). Therefore, even if SF2/ASF stability was
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increased in HPV-16 infected differentiated cells, it is possible that levels would 
still decrease, due to the lack of transcriptional activation. With this hypothesis in 
mind, it is likely that SF2/ASF is upregulated via transactivation in differentiated 
cells. E6 and E7 have roles during regulation of gene expression. HPV-16 E6 
inhibits p53 expression via interactions with cellular co-activator, CBP/p300 
(Zimmermann et al. 1999). In addition, HPV-16 E6 and E7 repress IL-8 
transcription through associations with CBP/p300 and related co-factor, p/CAF, 
respectively (Huang and McCance 2002). E6 and E7 also target p53 and pRb for 
degradation. p53 is Itself a transcription factor (TF), whilst pRb interacts with the 
TF, E2F. Therefore, these proteins have the potential to transcriptionally repress 
SF2/ASF expression in undifferentiated W12E cells. However, as discussed, both 
E6 and E7 are expressed during differentiation of W12E cells, and upregulation of 
SF2/ASF is unlikely to be caused by loss of repression of expression. Therefore, 
the most likely candidate for SF2/ASF regulation is the viral transcription factor, 
E2. HPV-16 E2 is known to control viral gene expression and can interact with 
cellular proteins, which is thought to be involved in transcriptional regulation. 
Furthermore, SF2/ASF is found to be upregulated in cells which stably express 
HPV-16 E2, suggesting a role for this viral protein in transcriptional regulation of 
SF2/ASF (McPhillips et al. 2004).
HPV-16 E2 is known to both transcriptionally activate and repress the virai Long 
Controi Region (LCR) via four binding sites (ACCNeGGT), which differ in E2 
affinity (Steger and Corbach 1997; Morgan et al. 1998). Level of expression of E2 
is at least partly responsible for activation/repression activity. Differential 
occupation of these sites, as well as interaction with various cellular proteins, also 
plays a role (Bouvard et al. 1994; Morgan et al. 1998). The LCR contains an 
enhancer and TF binding sites, and can be controlled by cellular factors such as 
Spl, AP-1 and Oct-1 (Gripe et al. 1987; Sibbet and Campo 1990; Chong et al. 
1991). Interaction of E2 with various cellular partners throughout epithelial 
differentiation is thought to regulate transactivation/repression activity of the viral 
LCR, at the appropriate stage of differentiation. Furthermore, E2 is known to 
regulate cellular genes, for which cellular factors are again necessary. For 
example, HPV-6, -8, -11, -16, -18 and BPV-1 E2 interact with Spl (Li et al. 1991; 
Lee et al. 2002). For HPV-18 E2 this interaction is involved in transcriptional 
downregulation of hTERT (Lee et al. 2002), whereas HPV-8 and -18 E2 
transactivate p21 expression via Spl interactions (Steger et ai. 2002). In addition.
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HPV-8, -16, “18 and BPV-1 E2 interact with C/EBP a and (3, which is shown to 
result in transactivation of involucrin (Hadaschik et al. 2003). Some PV E2 
proteins also interact with components of the basal transcription machinery. For 
example, BPV-1 E2 interacts with TBP and TFIIB, as well as TBP-associated 
factors, TAF1180 and TAFII250 (Rank and Lambert 1995; Carrillo et al. 2004). In 
addition, HPV-11 E2 interacts with TBP (Hou et al. 2000), HPV-8 binds to TBP and 
TAFII55 (Enzenauer et al. 1998), and HPV-18 associates with TAFII80 and 
TAF11250 (Carrillo et al. 2004). These interactions are thought to be involved in 
regulation of pre-initiation complex formation. HPV-8 E2 has also been reported to 
downregulate p4-integrin expression by causing displacement of one or more 
important cellular factors from its promoter (Oldak et al. 2004). Furthermore, co­
activators, which regulate gene expression via indirect DNA association, 
CBP/p300 and p/CAF, are also known to interact with HPV-6b, -8, -11, -16 and -  
18 E2 and, in the case of HPV-18 and -8, synergise transcription (Lee et ai. 2000; 
Lee et al. 2002; Muller et al. 2002). The interaction with CBP/p300 and p/CAF is 
thought to be essential to E2-mediated transcription. In addition, HPV-16 E2 
interacts with TopBPI, which also results in enhanced transcription (Boner et al. 
2002). This suggests E2 is a multifunctional transcription factor that regulates 
transcription via complex associations with a number of proteins.
E2 from HPV-8 and -18 are known to affect not only viral transcriptional 
regulation, but are also involved in regulation of cellular genes, such as hTERT, 
p21 and p4-integrin (Lee et al. 2002; Steger et al. 2002; Oldak et al. 2004). In 
contrast, HPV-16 E2 has not previously been reported to transactivate expression 
of any cellular genes. To demonstrate a function for E2 in HPV-16 mediated 
SF2/ASF transcriptional regulation, a number of techniques were employed. 
Firstly, reporter assays were performed using SF2/ASF promoter region containing 
constructs. Association of E2 with the promoter was also determined both in vitro 
and in vivo, using electrophoretic mobility shift assays (EMSAs) and chromatin 
immunoprécipitation (ChIP). Furthermore, binding of cellular binding partners for 
E2, Spl and C/EBP, with the SF2/ASF promoter was analysed in vitro, using 
supershift EMSAs. Lastly, RT-PCR was used to establish steady-state SF2/ASF 
mRNA levels in undifferentiated and differentiated W12E cells.
Sarah Mole, 2007 Chapter 3, 85
3.2 HPV-16 E2 transactivates the SF2/ASF promoter 
region
To further investigate the effect of E2 upon SF2/ASF regulation, it was first 
necessary to confirm the transactivation function of E2. To achieve this, pGCAT3- 
B-SF2pr was produced (Figure 3.1). This plasmid contains a region spanning 
- Ik b  upstream of and including the putative transcription start site of SF2/ASF, 
fused to the chloramphenicol acetyl transferase (CAT) gene. Due to the 
uncharacterised nature of the SF2/ASF promoter, this region was chosen as we 
expected it would likely contain most c/s-acting sequences involved in E2 
regulation. Furthermore, the placement of the putative transcription start site was 
chosen as this was where the longest sequenced cDNA clone began. Therefore, 
there is no direct evidence that this is the correct transcription start site and was 
used as the best guess when choosing the promoter region. Foilowing PCR 
amplification from human genomic DNA using primers SF2pr -1024 F and +5 R, 
this region was cloned into pGCAT3-Basic, a CAT construct derived from pGL3- 
Basic (Promega), which contains the CAT gene and an SV40 polyadenylation 
signal, with no promoter. To ensure that results presented here are on a linear 
scale, assays using serial dilutions of CAT enzyme were performed and quantified 
by the same method as for subsequent experiments. Figure 3.2 shows a linear 
calibration curve of percentage chloramphenicol (CAM) convertion, as measured 
by optical density, with increasing CAT activity. pGCAT3-B and pGCAT3-B-SF2pr 
were then co-transfected into HeLa cells along with either an empty expression 
vector (pCI) or an HPV-16 E2 expression vector (pCI-E2) (Figure 3.3). As E2 
causes cell growth arrest and apoptosis of HeLa cells, titration experiments were 
performed to ensure the level of E2 expression was optimal to observe 
transactivation at the SF2/ASF promoter (Figure 3.3A). No CAT activity was 
observed in cells transfected with pGCAT3-B either in the presence or absence of 
E2 (data not shown). However, a two-fold increase in CAT activity was observed 
from pGCAT3-B-SF2pr when co-transfected with 50ng pCI-E2, as compared to 
empty vector (Figure 3.3A). Transactivation decreased with increasing pCI-E2 
concentration, suggesting E2 may not activate the SF2/ASF promoter at higher 
concentrations; however it does not trans-repress either. It is possible that higher 
E2 expression may be having an effect on cell proliferation, making cells less 
healthy, and in turn causing inhibition of normal cellular functions, such as 
SF2/ASF expression. The effects of E2 expression on cell viability were not
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assayed; however cells counts, comparing live versus dead cells may have given 
an indication of whether E2 expression was causing apoptosis. In contrast, 
transcription of CAT constructs driven by the herpes simplex virus immediate early 
5 promoter (HSV-IE5) was unaffected by E2 expression (Figure 3.3A). This 
suggests that low concentrations of E2 specifically transactivate the SF2/ASF 
promoter region as described above.
To verify this result, CAT activity was determined from pGCAT3-B-SF2pr 
transfected U20S cell clones, A4 and B1, which stably express E2 to differing 
levels and have previously been shown to have upregulated SF2/ASF when 
compared to non-transfected U20S cells (McPhillips et al. 2004). Therefore, non­
transfected U20S cells were used as a negative control. Similar to results 
obtained with HeLa cells, CAT activity from pGCAT3-B-SF2pr increased in the 
presence of E2 (Figure 3.4A), but no activity was observed in cells transfected with 
pGCAT3-B, either with or without E2 (data not shown). However the extent to 
which E2 transactivates the SF2/ASF promoter in this assay differs between cell 
clones, which is possibly due to the level of E2 expression (Figure 3.4B). Clone 
A4 expresses lower levels of E2 than clone B1. In agreement with the data 
obtained using HeLa cells, it is possible that higher E2 expression does not 
transactivate the promoter due to its affects on cell growth. However, as the effect 
of E2 expression on cell viability was not assayed, no firm conclusion can be 
drawn to account for the differences in SF2/ASF promoter transactivation between 
A4 and B1 clones. Furthermore, E2 failed to transactivate a p-galactosidase 
expression vector driven by the CMV promoter (Figure 3.4A). However, variation 
was observed in the level of reporter activity between cell clones, suggesting there 
are potentially differences between the cells clones with respect to general 
transcriptional activity, and/or transfection efficiency.
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Figure 3.1: pGCAT3-B-SF2pr
Schematic diagram of the SF2/ASF promoter construct used in CAT 
assays. The SF2/ASF promoter (turquoise rectangle) was PGR 
amplified from nt -1024 to +5 with respect to the SF2/ASF transcription 
start site (arrow) and cloned into pGCAT3-B, a CAT vector with no 
promoter, to produce pGCAT3-B-SF2pr, and the insert was sequenced 
using vector specific primers. Probes used in EMSA experiments with 
positions within the promoter are depicted below. Horizontal lines above 
the SF2/ASF promoter region and CAT gene represent primers used in 
Chip assay. IF  & R are SF2pr -524F & -325R; 2F & R are SF2pr -  
402F & -222R; 3F & R are CAT5 F & R.
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Figure 3.2: CAT activity is linear in CAT assays using the TLC 
method
Increasing units of CAT enzyme were added to CAT assays and 
percentage chloramphenicol (CAM) convertion was determined by 
comparing total and converted CAM. Phosphoimaging of TLC run 
samples, followed by measurement by optical density were used to 
measure total and converted CAM. (A) shows almost total convertion 
and (B) shows convertion of a lower range as this is where 
experimental values fall.
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Figure 3.3: Increased CAT activity from pGCAT3-B-SF2pr in the 
presence of E2
A) Protein lysates were produced from HeLa cells co-transfected 
with pGCAT3-B-SF2pr and pCI or 50ng, 100ng or 150ng pCI-E2 and 
CAT assays were performed. Transfections were performed in 
triplicate and the graph represents mean and standard deviation 
about the mean from three separate experiments. B) Western blots 
using equal quantities of protein lysates from HeLa cells transfected 
with pCI or pCI-E2 probed using anti-E2 and anti-GAPDH 
antibodies. GAPDH acts as a loading control.
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Figure 3.4: Increased CAT activity from pGCAT3-B-SF2pr in 
cells stably expressing E2
A) Protein lysates were produced from U20S cells, A4 and B1, 
which stably express E2, as well as non-transfected U20S cells 
(negative) transfected with pGCAT3-B-SF2pr and CAT assays were 
performed. Transfections were performed in triplicate and the graph 
represents mean and standard deviation about the mean from three 
separate experiments. B) Western blots using equal quantities of 
protein lysates from U20S negative, A4 and B1 cells probed using 
anti-E2 and anti-GAPDH antibodies. GAPDH acts as a loading 
control.
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3.3 E2 interacts with the SF2/ASF promoter in HeLa 
ceils
As the SF2/ASF promoter is transactivated in cells expressing E2, it was 
necessary to confirm that this is achieved by E2 directly and not via regulation of 
other cellular proteins. To determine this, presence of E2 at the SF2/ASF 
promoter was assayed. E2 Interacts with many cellular proteins, making it 
possible that it may not interact directly with the promoter, but may be tethered to it 
via involvement in a transcription complex. Therefore, chromatin 
immunoprécipitation (ChIP) experiments, which can detect indirect interaction of a 
protein with DMA, were performed. In these assays protein-DNA complexes are 
immunoprecipitated from cross-linked cellular extracts, purified, the protein is 
degraded and DMA Is subjected to analysis by PCR. For this study, HeLa cells 
were co-transfected with pGCAT3-B-SF2pr and either empty vector (pCI) or an E2 
expressing vector (pGI-E2). As both the anti-E2 antibodies used in these 
experiments were polyclonal and had the potential to recognise epitopes from 
other cellular proteins, it was important to make sure that they were not 
immunoprecipitating any other component involved in SF2/ASF transcriptional 
regulation. Two anti-E2 antibodies were used, both of which were polyclonal, one 
detecting only C-terminal epitopes (E2 CTD), and one raised against the entire 
protein (E2 poly). Not only would this ensure that it was E2 being detected, but it 
was also thought that it might give further information regarding the E2 domain 
involved in SF2/ASF promoter association. Should E2 poly but not E2 CTD detect 
E2 in promoter complexes, it may suggest that E2 associates with the promoter 
via its C-terminal region. If this were the case, it is possible that the C-terminal 
domain of E2 would not be accessible due to Its association with a transcription 
complex on the SF2/ASF promoter. Furthermore, as positive controls, 1/10 
volume of cell extract was removed prior to immunoprécipitation and an anti-TBP 
antibody was used during immunoprécipitation, as this is known to be necessary 
for transcription at all promoters. Antibodies against involucrin, an epithelial cell 
differentiation-specific protein with no reported functions during transcription, and 
beads alone with no antibody were used as negative controls. Following 
purification, immunoprecipitated DMA was assayed using CATS’ F & R primers, 
which amplify a ~200bp region within the S' region of CAT gene, ~200bp 
downstream of the initiation site, SF2pr -S24 F & -32S R, amplify a ~200bp region 
within the middle of the promoter, and SS RNA F & R, which amplify a region
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~200bp of the 5S RNA gene. The 5S RNA promoter is controlled by RNA 
polymerase III, which also requires TBP for its action. However, E2 is not reported 
to regulate RNA polymerase III transcription and should therefore not be detected 
at this promoter.
Figure 3.5 shows pGCAT3-B-SF2pr can be detected in the input control, using the 
primers within CATS’ and SF2 promoter regions, indicating successful transfection. 
Furthermore, TBP can be immunoprecipitated with the SF2/ASF promoter in cells 
transfected with both pCI-E2 and pCI, as observed using CATS’ F & R and SF2pr 
-S24 F & -32S R primers. E2 interaction is detected only in cells transfected with 
pCI-E2 but not pCI, using CATS’ and SF2pr primers. This indicates that E2 is 
interacting, either directly or indirectly, with the SF2/ASF promoter in HeLa cells 
and that the E2 antibodies used are not cross reacting with any other proteins 
involved in SF2/ASF promoter complexes. In addition, whilst TBP is interacting 
with the SS promoter region in cells transfected with pCI-E2, E2 cannot be 
detected. This indicates that E2 is interacting specifically with the SF2/ASF 
promoter. Finally, ChIP experiments were performed using cells transfected with 
pCI-E2 and pGCAT3-B, to ensure E2 is not associated with the CAT construct at a 
region other than the SF2/ASF promoter. Whilst CAT DNA can be detected from 
input samples, TBP and E2 cannot, suggesting E2, like TBP, associates with 
pGCAT3-B-SF2pr via the SF2/ASF promoter region.
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Figure 3.5: E2 associates with the SF2/ASF promoter in HeLa 
cells
HeLa cells were co-transfected with pCI or pCI-E2 and pGCAT3-B- 
SF2pr or pGCAT3-B (lacking the promoter). DNA-protein 
complexes from cell extracts were sonicated into fragments of 
200bp-1kb and subjected to ChIP assays using anti-TBP, two 
polyclonal E2 antibodies (E2-SCT and E2 Poly), anti-involucrin and 
beads only. Primers were used to amplify a region of the CAT gene 
(CATS’ F & R) and SF2/ASF promoter (SF2pr -524F & -325R) to 
determine association with the SF2/ASF promoter (Figure 3.1), and 
SS RNA (SS RNA F & R) as a negative control.
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To build on this, association of E2 with the endogenous SF2/ASF promoter was 
also assayed. This time HeLa cells transfected with either pCI-E2 or pCI, but not 
pGCAT3-B-SF2pr, were subjected to ChIP experiments and primers, SF2pr-402 F 
& -222 R, amplifying a ~200bp region, within the SF2/ASF promoter were used to 
determine association. Furthermore, primers amplifying a ~200bp fragment within 
the 3’ region of the SF2/ASF coding sequence -2.5kb downstream from the 
promoter, SF2 F & R, were used as negative controls. Figure 3.6 indicates that E2 
associates with the endogenous SF2/ASF promoter in the presence but not 
absence of E2. However, this is determined using only the E2 polyclonal antibody, 
as E2 CTD, does not immunoprecipitate with the endogenous promoter. As 
suggested, this may indicate differences in E2 binding to the endogenous and 
plasmid promoters. It is possible that E2 associates with the SF2/ASF promoter 
via its C-terminal region and due to the chromatin conformation of the endogenous 
promoter, E2 CTD is not able to access the complex. In contrast, SF2 F & R 
primers which amplify within the 3' region of SF2/ASF coding sequence, failed to 
detect DNA using anti-TBP or anti-E2 antibodies. This suggests E2 interacts 
specifically with the endogenous SF2/ASF promoter region in HeLa cells.
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Figure 3.6: E2 associates with the endogenous SF2/ASF 
promoter
HeLa ceiis were transfected with pCi or pCI-E2. DNA-protein 
complexes from cell extracts were sonicated into fragments of 
200bp-1kb and subjected to ChIP using anti-TBP, two polyclonal E2 
antibodies (E2-SCT and E2 Poiy), anti-invoiucrin and beads only. 
Primers were used to amplify a region of the SF2/ASF promoter 
(SF2pr -402F & -222R) to determine association with the 
endogenous SF2/ASF promoter (Figure 3.1), and a 3' region of the 
SF2/ASF mRNA (SF2 F & R) as a negative control.
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3.4 E2 does not bind to a potential binding site within 
the distal region of the SF2/ASF promoter
As E2 is a DNA binding protein, analysis of the SF2/ASF promoter was performed 
to determine the presence of any potential E2 binding sites (E2BS). At nt -760 
from the transcription start site, a near consensus E2BS was found with one 
substitution from C to T at nt 9, which may have the potential to bind E2 (Figure 
3.7A). To investigate this possibility, electrophoretic mobility shift assays (EMSAs) 
were performed, in which protein-DNA complexes can be revealed by retardation 
of a DNA probe during electrophoresis. In this case an ~200bp probe spanning 
~10Qnt either side of the potential E2BS was produced by Klenow end labelling of 
Spel cut DNA. Furthermore, ~100bp probes were constructed in the same way 
using a region of the HPV-18 LCR which contains 2 E2BSs and the same region 
with mutated E2BSs to use as positive and negative controls, respectively. E2BSs 
were mutated by C to T substitutions at position 10 in BS1 and positions 2 & 3 in 
BS2, which has previously been shown to abolish E2 binding (Thierry and Howley 
1991). His-tagged HPV-16 E2 was purified from BL21 bacterial cells, however a 
number of contaminates were observed (Figure 3.7B). To counteract this, wash 6 
(lane 3) was used as a negative non-E2 containing lysate, for any non-specific 
binding, whilst elution 1 (lane 4) was used as the E2 containing fraction. EMSAs 
were then performed as described. Figure 3.7C shows that whilst E2 binds the 
positive control probe and occupation of one and two binding sites can be 
observed, E2 fails to interact with either the negative control probe or the SF2/ASF 
promoter region containing the potential E2BS. This indicates that E2 does not 
interact with the potential E2BS within the SF2/ASF promoter in this assay.
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Figure 3.7: E2 does not bind a near consensus-binding site within 
the distal SF2/ASF promoter
A) Sequence of Probe 2 (Figure 3.1) within the distal SF2/ASF promoter. 
The potential E2BS is shown in red with the wobble position highlighted 
in pink. B) Coomassie stained SDS-PAGE gel of wash and elution 
samples from column purification of bacterial expressed His-tagged E2. 
Washes 4-6 (lanes 2-4) and elution's 1-6 (lanes 5-10) are shown, along 
with marker (lane 1). C) EMSAs using a region of the HPV-18 LCR 
containing two binding sites either mutated (mE2BS), or intact (2xE2BS), 
and the SF2/ASF promoter probe (Probe 2). EMSAs were performed 
using probe only, wash 6 (lacking E2) and elution 1 (containing E2).
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3.5 E2 does not interact with the SF2/ASF promoter in 
vitro
Following results that E2 does not bind at a potential E2BS within the SF2/ASF 
promoter in EMSA experiments, it was necessary to determine the possibility of E2 
binding to a non-consensus sequence. Therefore, six overlapping probes of 
~200bp each, covering the entire promoter were synthesised by Klenow end 
labelling of Spel cut DNA (Figure 3.1). To detect whether E2 bound DNA in 
complex with any cellular proteins, assays were also performed in the presence of 
HeLa nuclear extract, with and without E2. This would firstly show any complexes 
which form on the promoter in the absence of E2 and may also elucidate any 
changes brought about by E2. Figure 3.8, panels 1-2 show EMSAs using E2 and 
HeLa nuclear extract with probes 1 and 2 spanning the region nt -1024 to -650 
from the SF2/ASF transcription start site. Probe 2 contains the potential E2BS 
described above. For both regions no complexes are formed either in the 
presence of E2 or nuclear extract. EMSAs using the three most proximal probes 
spanning nt -524 to +5 from the transcription start site are shown in Figure 4.8, 
panels 4-6. Whilst E2 does not interact with these probes, a number of complexes 
are observed upon addition of nuclear extract. This is not surprising as 
transcription is likely to be controlled from this region. However, addition of E2 has 
no effect on complex formation. In contrast, EMSAs using probe 3, nt -684 to - 
482 from the start site, a shift emerged upon addition of E2 and a comparable 
complex was not observed with wash 6 (Figure 3.8, panel 3). A shift was 
observed using wash 6 but it does not correspond to the complex observed using 
E2. Furthermore, addition of nuclear extract strengthens potential E2 binding 
(lane 6). Therefore, E2 may interact with the SF2/ASF promoter via a region nt - 
684 to -482 from the transcription start site.
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Figure 3.8: E2 may bind a non-consensus site within the 
SF2/ASF promoter in vitro
EMSAs using probes 1-6 from the SF2/ASF promoter (Figure 3.1), 
with wash 6 (lacking E2), E2 (elution 1) (Figure 3.7B) and HeLa 
nuclear extract (N.E.). The most distal probes are shown in the top 
panel and the more proximal probes are shown in the bottom panel.
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To investigate whether the protein causing a shift using probe 3 in the above 
experiments is indeed E2, this probe was used in further EMSAs in which non­
radioactive labelled probe 3 was added to reactions in increasing concentrations to 
determine specificity of binding. Non-radiolabelled probe was added to reactions 
15 minutes prior radiolabelled probe. Figure 3.9 shows a slight reduction in E2 
binding upon addition of cold probe; however, binding does not diminish as greater 
concentrations of cold probe are added. This suggests that shifts obtained using 
both wash 6 and E2 may be non-specific, indicating that the shift observed using 
probe 3 might be either unspecific binding of E2 or one of the other proteins within 
the lysate. In contrast, it is possible that E2 associates with the probe in a 
dynamic fashion and that addition of increasing amounts of cold probe has little 
effect on this.
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Figure 3.9: Probe 3 binding by a component of the E2 lysate 
is not specific
EMSA using probe 3 with wash 6 (lanes 2-7) and E2 (lanes 8- 
13), with increasing concentration of non-radiolabelled probe, at 
2, 4, 6, 8 and 9-fold molar excess over radiolabelled probe. Non- 
radiolabelled probe was added prior to radiolabelled probe.
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3.6 Spl may interact with the SF2/ASF promoter in 
vitro
Failure of E2 to interact directly with the SF2/ASF promoter suggests indirect 
association via a co-activator complex. As mentioned previously, E2 interacts and 
co-operates with a number of cellular partners, one or more of which may be 
involved in SF2/ASF transactivation. However, due to the uncharacterised nature 
of the SF2/ASF promoter, it is not known what cellular proteins are found to 
associate with it and regulate expression. Whilst direct E2 interaction with the 
SF2/ASF promoter could not be determined in vitro, there are a number of 
complexes forming in the presence of nuclear extract. Using TFSearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html) a number of potential binding 
sites for cellular proteins were found within the sequence (Figure 3.10). Of 
particular interest, binding sites for Spl and C/EBP (3, are found at -575 and -647, 
respectively, from the transcription start site. Both of these sites fall within probe 
3, which produced 6 complexes when incubated with nuclear extract (Figure 3.11, 
lane 2). Therefore, to determine if any of the complexes formed contain Spl 
and/or C/EBP, supershift experiments were performed. In these assays, 
antibodies are added to the EMSA reaction, and changes in the complexes 
formed, due to antibody binding, are determined. Results indicate that whilst no 
change was observed in the presence of anti-C/EBP antibody, anti-SpI antibody 
was able to shift one of the complexes, when added either before (lane 3) or after 
nuclear extract (lane 4) (Figure 3.11). Shifting seems to result in lower levels of 
complex 4 suggesting this complex may contain Spl. Therefore, this experiment 
indicates that Spl may interact with the SF2/ASF promoter in vitro.
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Figure 3.11: Anti-SpI supershifts complexes form between 
HeLa nuclear extract and probe 3
EMSAs using probe 3 (Figure 3.1) and HeLa nuclear extract (N.E). 
Anti-SpI and anti-C/EBP antibodies were added to binding reactions 
either 15 minutes prior to (lanes 3 and 5), or 15 minutes following 
(lanes 4 and 6) addition of nuclear extract. Horizontal arrows to the 
right indicate complexes formed.
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3.7 SF2/ASF mRNA levels are elevated in HPV-16 
infected differentiated celis
Whilst data presented here suggests a role for HPV-16 E2 in SF2/ASF 
transactivation, this role for the protein has not been demonstrated in the context 
of the HPV-16 life cycle. E2 function is known to be affected by other 
papillomavirus proteins, which may affect the transcription function described here. 
Furthermore, E2 expression levels as observed in cells stably or transiently 
transfected with E2 expression vectors, likely differ from those observed during the 
HPV-16 life cycle. To provide a link between the two, levels of SF2/ASF mRNA 
were determined within undifferentiated and differentiated W12E cells. An 
increase in SF2/ASF mRNA in differentiated cells would suggest that protein 
abundance might be regulated at the level of transcription and not via translation 
or protein stability, for example. Although this would not prove the transactivating 
role of E2 during the virus life cycle, it would indicate that SF2/ASF levels might be 
controlled transcriptionally, most likely by E2. To achieve this, total RNA was 
purified from both undifferentiated and differentiated W12E cells, cDNA was 
produced and RT-PCR was performed using primers within the SF2/ASF coding 
region (SF2 F & R), which produce an ~200bp fragment. As an internal control, 
primers amplifying an ~500bp region of the GAPDH (GAPDH F & R) gene were 
used in the same RT-PCR, as levels of this are shown to decrease during 
differentiation (Steele et al. 2002). Reverse transcription reactions were 
performed in the presence and absence of enzyme to control for possible effects 
of DNA contamination. Figure 3.12 shows upregulation of steady state SF2/ASF 
mRNA in differentiated W12E cells, when compared to undifferentiated cells, 
whereas GAPDH mRNA levels decrease. To control for the effects of 
differentiation, HaCaT cells were used, as they are an HPV-16 negative epithelial 
cell line, which can differentiate in culture. Results here again show no PCR 
products from reactions lacking RT. Although GAPDH mRNA does not decrease 
upon differentiation to the extent observed in W12E cells, SF2/ASF mRNA levels 
also decrease, in accordance with observations at the protein level. Therefore, 
steady state SF2/ASF mRNA levels are specifically upregulated during HPV-16 
infection. This suggests SF2/ASF may be transactivated in HPV-16 infected 
differentiated epithelial cells, most probably by E2.
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Figure 3.12; Increased SF2/ASF mRNA in differentiated W12 
cells
Total RNA was produced from undifferentiated and differentiated 
W12E and HaCaT cells. RT-PCR reaction were performed in the 
absence (lanes 1 and 3) and presence (lanes 2 and 4) of reverse 
transcriptase. Primers amplifying a region of the GAPDH and 
SF2/ASF mRNAs were used in the same PCR reactions to 
determine steady state levels of each mRNA.
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3.8 Discussion
Papillomavirus E2 proteins are known to be involved in regulation of cellular 
proteins, as well as acting upon the viral long control region, from which viral gene 
expression is controlled. Here we show regulation of splicing related SR protein, 
SF2/ASF, by HPV-16 E2. This is the first example of transactivation of a cellular 
promoter by HPV-16 E2. Furthermore, SF2/ASF is the first RNA regulatory protein 
found to be controlled by HPV-16. As discussed previously, epithelial cells 
become less metabolically active, the more differentiated they become. Therefore, 
many cellular proteins are no longer expressed, as they are no longer required for 
the cell to function. One such family are RNA processing proteins, such as 
SF2/ASF, as little gene expression, and hence RNA processing, is observed in 
differentiated epithelial cells. Therefore, in HPV-16 infected differentiated 
epithelial cells, the virus must regulate at least a subset of the factors controlling 
RNA processing to ensure completion of its life cycle. SF2/ASF is known to be 
elevated in HPV-16 infected differentiated epithelial cells, a phenomenon not 
observed in uninfected epithelial cells (McPhillips et al. 2004). Furthermore, 
endogenous SF2/ASF is upregulated in cells expressing HPV-16 E2. This was 
shown using U20S cells, osteosarcoma cell clones, which stably express E2. 
Although E2 is known to induce apoptosis of many cell types, U20S cells are less 
sensitive to this and therefore, higher levels of prolonged E2 expression are 
achievable in these cells. We show here that reporter gene expression driven by 
the SF2/ASF promoter region, is also increased in the presence of E2 and E2 is 
found to associate with the promoter in HeLa cells using ChIP assays. However, 
no direct interaction between E2 and the promoter could be proven in vitro, 
suggesting the association is indirect, possible via a co-activator complex. 
Although cellular partners for E2 have not been identified here, Spl, a cellular 
transcription factor known to interact with E2, may associate with the promoter in 
vitro. We postulate that E2 is tethered to the promoter by one or more cellular 
proteins, such as Spl, and then it is able to regulate SF2/ASF abundance at the 
level of transcription. To add weight to this role of E2 during the HPV-16 life cycle, 
levels of SF2/ASF mRNA were found to be elevated in infected differentiated 
epithelial cells, suggesting control of protein abundance may be at the level of 
transcription, rather than translation or protein stability.
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Levels of reporter gene activity driven by the SF2/ASF promoter region as defined 
above were consistently elevated in cells expressing E2. However, the extent of 
upregulation differed depending on E2 abundance. With increasing E2 expression 
in HeLa cells, transactivation of the SF2/ASF promoter decreased. Furthermore, 
high E2 expression observed in U20S cell clone B1, transactivated the promoter 
to a lesser extent than the lower levels observed in U20S A4. It is therefore 
possible that high levels of E2 have an inhibitory effect on SF2/ASF 
transactivation. High levels of HPV-16 E2 are known to result in inhibition of cell 
growth and promote apoptosis (Sanchez-Perez et al. 1997; Webster et al. 2000; 
Parish et al. 2006). Therefore, with higher E2 levels, cells may be less healthy 
and therefore, expression of SF2/ASF controlled by cellular factors may be 
reduced. In this case, whilst E2 may still transactivate the promoter, it would not 
be observed in reporter assays due to a reduction in normal endogenous 
expression. In addition to variations in SF2/ASF promoter transactivation 
depending on E2 expression levels, there are also differences between HeLa cells 
and the U20S cell clones. The greatest degree of transactivation observed in 
HeLa cells is two-fold, whereas reporter expression increases ~4-fold in U20S 
clone A4, when compared with the control. Therefore, the two cells types may 
differ in levels of cellular proteins involved in E2 mediated transactivation. 
Alternatively, the difference may be due to the susceptibility of the cells to growth 
inhibition and apoptosis. HeLa cells may be more susceptible than U20S cells 
and hence SF2/ASF expression may suffer to some degree at the levels of E2 
expression assayed.
E2 associates with the promoter in HeLa cells, as determined using ChIP assays, 
suggesting it directly transactivates SF2/ASF. However, direct interaction between 
E2 and the promoter, or even changes in complexes formed in the presence of 
nuclear extract and E2 could not be determined in vitro. In particular E2 
interaction with a near consensus binding site could not be determined. The E2BS 
is defined as ACGG(N4)CGGT, with N representing any four bases. The site 
found within the SF2/ASF promoter differs from the consensus at position 9, where 
an T is found instead of a 0. Furthermore, HPV-16 E2 binding to an E2BS is 
found to be susceptible to the spacer region sequence, with preferential binding to 
sites with AT-rich spacers (Hines et al. 1998). It is thought that this provides a pre­
bent DNA molecule, to which E2 binds more easily (Hegde and Androphy 1998). 
However, the SF2/ASF site contains GCCA, within the spacer. In addition, HPV- 
16 E2 has more recently been shown to bind larger sites composed of
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AACCG(N4)CGGTT more efficiently (Dell et al. 2003). Although an A is found 
directly upstream of the near consensus SF2/ASF potential E2BS, the immediate 
downstream nucleotide is G, not T. Therefore, it is possible that whilst one of 
these discrepancies may be tolerated, all three within the same site prevent E2 
from binding. Furthermore, whilst association of E2 with the region-spanning 
probe 3 of the promoter could not be conclusively competed for with increasing 
concentrations of cold probe, it is possible that E2 and/or probe concentration 
have affects on this. The amount of E2 used in EMSA experiments is difficult to 
compare with levels of expression in HeLa or U20S cells. Furthermore, the 
amount of promoter sequence available within transfected cells is unlikely to 
correspond with the levels of probe used in EMSAs. Therefore, it is possible that 
E2 interacts with sequences within the probe 3 region in a dynamic manner, and 
that the concentration of E2 in in vitro experiments is high enough to allow 
transient interaction with both radiolabelled and non-radiolabelled probes, without 
affecting the observed shift obtained with radiolabelled probe. To definitively 
determine that E2 is associating with this probe, similar experiments using non- 
radiolabelled HPV-18 LCR probe, which contains E2BSs proven to associate 
strongly with E2 in vitro, should be performed.
DNA structure and/or cellular proteins may also be important for E2 to associate 
with the SF2/ASF promoter via the near-consensus or a non-consensus site. For 
example, méthylation status and/or looped control regions may be important. 
However, méthylation of E2BSs has been found to inhibit E2 binding (Thain et al. 
1996). Furthermore, méthylation of an E2 responsive promoter has been shown 
to cause inhibition of transactivation (Kim et al. 2003), suggesting the non- 
methylation status of the DNA in the EMSAs presented here, is unlikely to be the 
reason no interaction was observed. Additionally, if specific DNA looped control 
regions were required for E2 binding, observing an in vitro interaction would be 
difficult. Therefore, to further assay the E2 association with the promoter would 
require in vivo analysis. There is some support for a role of the DNA binding 
domain (DBD) in SF2/ASF transactivation in the data obtained from ChIP assays. 
Whilst a polyclonal E2 antibody recognising many regions throughout E2 was able 
to immunoprecipitate the endogenous SF2/ASF promoter from HeLa cells, an 
antibody recognising only the DBD was not. Therefore, it is possible that the DBD 
may be involved in protein-DNA complexes, which the antibody is unable to 
access. Analysing which domain(s) of E2 are involved in SF2/ASF transactivation, 
using transactivation (TA) and DBD mutants in transient transfections, may give
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further indication as to how E2 associates with the promoter. If DBD mutants were 
able to transactivate the promoter, this suggests E2 is not binding DNA directly 
and is probably associating via one or more cellular proteins. Furthermore, the 
DBD of E2 is also involved in association with cellular proteins, such as C/EBP 
and TBP (Rank and Lambert 1995; Enzenauer et al. 1998; Hadaschik et al. 2003). 
Therefore, if these mutants were able to transactivate it would suggest that these 
proteins are not involved in E2-mediated transactivation of the SF2/ASF promoter. 
In addition, inability of E2-TA mutants to regulate SF2/ASF transactivation, would 
suggest that this region of the protein is vital to this function. The TA domain of E2 
associates with CBP/p300 and p/CAF (Lee et al. 2000; Lee et al. 2002), which 
would implicate these proteins in bringing E2 to the SF2/ASF promoter. 
Conversely, should E2-TA mutants transactivate the SF2/ASF promoter, this 
would suggest that E2 functions to recruit cellular factors, which associate with the 
DBD, to enhance transcription. Therefore, these data would give considerably 
more information as to the mechanism by which E2 may associate with the 
SF2/ASF promoter.
The SF2/ASF promoter is likely to be a constitutively active promoter, due to the 
essential nature of SF2/ASF within cells. As such, it would be expected to harbour 
a number of binding sites for cellular transcription factors (TFs) to ensure to high 
level of expression. However, bioinformatic analysis of the promoter to determine 
potential binding sites for cellular TFs indicates that whilst there are sites for a 
number of TFs, no site is found in abundance (Figure 3.10). In addition, no TATA- 
box was observed, indicating that TBP is recruited to the promoter by other cellular 
proteins. A short T-rich stretch is observed at -25 from the start site; however, this 
does not look like any TATA element observed so far. In addition, the conical 
initiation signal (YYANWYY; where Y is C or T, N is any nt and W is A or T) is not 
observed at nt +1. Whilst TATA-less promoters often contain a number of Spl 
binding sites, this promoter region, has very few sites for TF binding within the 
transcription start site proximal region. This suggests that SF2/ASF expression is 
regulated by a number of different TFs, which may act at some distance from the 
transcription start site. In addition, a imperfect TFIIB recognition element (BRE) 
(SSRCGCC; where S is G or C and R is A or G), which is generally found 
immediately upstream of the TATA-box and directly binds TFIIB, is found at -38, 
and an imperfect downstream promoter element (DPE) (RGWCGTG), which 
interacts with TAFs, is located at +35 (Figure 4.10). Therefore, it is possible that 
these elements are involved in regulation of this promoter. The lack of TF binding
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sites may suggest that the promoter is in open chromatin conformation, allowing 
easy recruitment of the TFs that have the potential to bind. Furthermore, in open 
conformation it would be more accessible to viral regulators, such as HPV-16 E2.
A known cellular binding partner of E2, Spl may interact with the promoter in vitro; 
however, this is not proven and association in vivo has not yet been established. 
Therefore, further EMSA and ChIP experiments are required to determine if Spl 
does indeed interact with the promoter. In contrast, TBP is shown in all ChIP 
assays to associate. As mentioned, BPV-1, HPV-8 and -18 E2 proteins are known 
to interact with TBP and/or a number of components of the basal transcription 
machinery (Rank and Lambert 1995; Enzenauer et al. 1998; Carrillo et al. 2004). 
Furthermore, HPV-16 E2 interacts with yeast TFIIB (Benson et al. 1997), providing 
a possible mechanism for E2-mediated transactivation of SF2/ASF. Furthermore, 
there are binding sites within the promoter, such as for Oct-1 and AP-1, which are 
also found within the HPV-16 LCR (Figure 3.10). Mutation of these sites, as well 
as the Spl binding site, may be useful in binding assays and transient 
transfections. Inability of E2 to subsequently associate with and transactivate the 
SF2/ASF promoter would indicate that this cellular protein was involved. A similar 
approach could be employed for other transcription factors known to interact with 
E2, such as C/EBP. C/EBP is not shown to interact with a potential binding site in 
in vitro assays here; however, a further potential C/EBP U> binding site is found 
~1kb from the transcription start site (Figure 3.10). Potential interaction with this 
site has not been assayed. In contrast, mutation of binding sites would not be 
possible for co-activators, CBP/p300 and p/CAF, which do not bind DNA. 
Therefore, overexpression of the protein to induce further activation of reporter 
gene activity driven by the SF2/ASF promoter, or siRNA mediated silencing to 
abolish transactivation, could determine a role for that protein.
Although a role for E2 has been suggested in SF2/ASF transactivation, we must 
prove that this function is performed during virus infection. This is important, as 
E2 is known to associate with many proteins, including other papillomavirus 
proteins. As well as the well-characterised interaction with E l, which facilitates 
replication, the HPV-16 minor capsid protein, L2, inhibits E2 mediated 
transactivation (Okoye et al. 2005). Furthermore, interaction of HPV-16 E2 with 
HPV-16 E6 causes elevated transcriptional activity (Grm et al. 2005) and an HPV- 
16 E2-E7 interaction has been observed which is shown to inhibit E7 induced 
cellular transformation (Gammoh et al. 2006). However, the functional relevance
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of E7 interaction with respect to E2 transcriptional activity, if any, is not yet known. 
Whilst initial experiments suggest that SF2/ASF protein abundance is possibly 
controlled at the level of transcription, further experiments are required to 
definitively determine a role for E2 in SF2/ASF transactivation in HPV-16 infected 
differentiated cells. For example, detection of E2 association with the endogenous 
SF2/ASF promoter in differentiated W12E cells using ChIP assays, would suggest 
a role for it in transactivation. This was not attempted initially due to problems 
amplifying the endogenous SF2/ASF promoter from HeLa cells in ChIP assays. In 
addition, levels of E2 are lower in differentiated W12E cells, when compared with 
transiently transfected HeLa cells, suggesting the antibodies used may be less 
efficient at immunoprecipitating E2-containing complexes. Furthermore, siRNA 
mediated silencing of E2 in infected cells could be employed. Loss of elevated 
SF2/ASF levels in siRNA treated cells would indicate that E2 is responsible for 
transactivation. However, loss of E2 may also impact viral gene expression, as 
well as other aspects of the viral life cycle, possibly making interpretation of this 
experiment difficult. Perhaps siRNA mediated knock-down of cellular factors 
thought to be involved would be useful, not only to determine if E2 is indeed acting 
via these partners, but also to establish whether SF2/ASF is transcriptionally 
activated by E2.
Whilst a role for HPV-16 E2 has been suggested in SF2/ASF transactivation and 
the protein can be found to associate with the promoter in HeLa cells, cellular 
partners have, as yet, not been identified. Spl, a cellular binding partner of E2, 
may associate with the SF2/ASF promoter in vitro. However, further experiments 
are required to prove this association, to determine whether it associates in vivo 
and to discover if it acts to enhance E2-mediated transactivation of this promoter. 
Furthermore, the role of SF2/ASF transactivation by E2 has yet to be 
demonstrated in the context of the natural life cycle of HPV-16.
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4 Regulation of splicing associated, SR proteins by HPV-16
4.1 Introduction
As demonstrated in the previous chapter HPV-16 E2 transcriptionally activates the 
expression of splicing associated SR protein, SF2/ASF. SF2/ASF Is known to 
interact indirectly with the LRE in both HPV-16 infected undifferentiated and 
differentiated cells (McPhillips et al. 2004). However, SF2/ASF is only one 
member of a family of SR proteins involved in splicing regulation during RNA 
processing. To date, no assays have been performed to determine whether other 
SR proteins associate with the LRE. Therefore, it is possible that SR proteins 
other than SF2/ASF may have a role in control of late gene expression. Thirteen 
distinct transcripts are produced by the virus in differentiated cells and five splice 
acceptor and six splice donor sites have been identified (Milligan et al., 2006). 
Furthermore, a number of RNA elements have been found within the virus late 
region (Kennedy et al. 1990; Kennedy et al. 1991; Collier et al. 1998; Gumming et 
al. 2003; Oberg et al. 2003; Zhao et al. 2004; Rush et al. 2005; Zhao et al. 2005). 
Each element is proposed to act via interactions with cellular RNA processing 
factors; however, upon differentiation of uninfected epithelial cells, there is a 
general downregulation of RNA processing proteins (McPhillips 2002). Therefore, 
it is hypothesised that some of these factors are regulated by HPV-16 to ensure 
correct processing of virus transcripts at the appropriate stage of differentiation. 
SR proteins have roles in constitutive and alternative splicing, mRNA export and 
translation (Caceres et al. 1998; Huang et al. 2003; Sanford et al. 2004). As late 
gene expression can potentially be controlled at any or all of these stages, HPV-16 
mediated regulation of SR proteins would be likely. Therefore, the work in this 
chapter was undertaken to determine what effect, if any, episomal infection of 
HPV-16 had upon SR protein levels and localisation, during the viral life cycle.
To fully understand the relevance of this chapter, the roles of a sub-set of SR 
proteins within human cells will be summarised. SR proteins are comprised of two 
regions, the N-terminus containing one or two RNA recognition motifs (RRMs) and 
the C-terminus containing an arginine/serine rich domain (RS domain) of variable 
length. SRp20, SC35 and 9G8 all contain one RRM, whereas SF2/ASF, SRp40, 
SRp55 and SRp75 contain two (Figure 4.1). Whilst the RS domain is involved in 
protein-protein interactions among splicing factors (Wu and Maniatis 1993; Gao
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and Garcia-Bianco 1998), the RRM(s) interact with RNA at specific sequences 
known as exonic splicing enhancers (ESEs) (Kanopka et al. 1996). SR proteins 
contribute to constitutive splicing by bridging U1 snRNP at the 5’ splice site and 
U2AF at the 3’ splice site, to form the spliceosome and contribute to the various 
stages of splicing (reviewed by Reed and Palandjian 1997). During alternative 
splicing however, SR proteins associate with ESEs to facilitate splicing at the most 
proximal splice sites (Caceres et al. 1994; Eperon et al. 2000). In contrast, 
another family of RNA binding proteins, hnRNPs, are known to associate with a 
second type of RNA element, known as exonic splicing silencers (ESSs). This 
interaction directs splicing to more distal splice sites, allowing for regulation of 
splice patterns through the use of competing ESEs and ESSs and varying levels of 
antagonistic SR and hnRNP proteins. Within the late region of the HPV-16 
genome, and particularly within the long exonic sequence encoding the LI capsid 
protein, there are a number of predicted ESEs and ESSs (Figures 4.2). At least 
some of these are likely involved in directing appropriate splicing of late transcripts 
depending on the differentiation status of the cell. Most predicted ESEs for SRp20 
and SRp40, are unlikely to be authentic, due to their high frequency. However, 
potential SF2/ASF, 9G8, SC35 and SRp55 ESEs are less frequent and are more 
likely to be real sites, which may be acted upon by the relevant SR protein. In 
addition, Zhao et al. have revealed an ESS within the 5’ region of LI transcripts, 
which inhibits use of a 3' splice site immediately upstream in undifferentiated cells, 
via interactions with hnRNP A1, confirming the computer modelling, shown in 
figure 4.2 (Zhao et al. 2004). Furthermore, an ESE within the E4 ORF enhances 
splicing from a weak 3’ splice site within the E2 ORF (Rush et al. 2005). However, 
proteins regulating this element have so far not been identified. A sub-set of SR 
proteins also have roles in post-transcriptional regulation of gene expression, other 
than splicing. For instance, SF2/ASF, SRp20 and 9G8 are able to shuttle to 
between the nucleus and the cytoplasm (Caceres et al. 1998). This shuttling 
activity is thought to help link splicing to mRNA export, and all three proteins are 
shown to interact with TAP, the major nuclear export adaptor of cellular mRNA 
(Huang et al. 2003). In addition, SF2/ASF is shown to regulate translation in the 
cytoplasm (Sanford et al. 2004). As discussed, splicing-associated proteins show 
general downregulation during differentiation of uninfected epithelial cells.
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SRp20
SRp40
Figure 4.1: SR protein structure
Schematic diagram of domain structure of a sub-set of SR proteins. 
RNA recognition motifs are shown in red and RS domains of variable 
length are shown in green. The dark blue region depicts a glycine, 
arginine or proline rich region adjoining the domains. In the case of 
9G8 the light blue region indicates a zinc knuckle, unique to this SR 
protein.
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Figure 4.2: A number of potential ESEs and ESSs are found within 
the HPV-16 LI ORF
Potential ESEs and ESSs within the HPV-16 LI ORF were determined 
usirwg FksglRiy/\ fhtto://reqrna.mbc.nctu.ed(.i.tw/index.html). IThe t_1 
ORF is shown in blue at the top, with the LRE shown as an open 
rectangle and stop codon by a vertical arrow. Potential ESEs and 
ESSs are depicted by vertical black tabs, in relation to the LI ORF, 
below. The proteins predicted to bind each element are shown to the 
left along with whether they are potential ESEs or ESSs. The hnRNP 
A1 responsive ESS discovered by Zhao et al. is highlighted by a 
perforated rectangle.
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Therefore, a least a sub-set of RNA processing proteins must be regulated by the 
virus to ensure correct processing, export and translation of viral transcripts in 
differentiated cells. SR proteins would provide a useful target for HPV-16 as they 
have multiple roles during post-transcriptional regulation of gene expression.
The work in this chapter focused on regulation of splicing-related SR proteins 
during the HPV-16 life cycle. Western blots were used to determine changes in 
SR protein expression levels upon differentiation of W12E cells. SR protein levels 
were also assayed in cells stably expressing E2, as E2 is involved in upregulation 
of SF2/ASF protein levels (McPhillips et al. 2004). Furthermore, localisation of SR 
proteins was also determined using immunofluorescence. As SF2/ASF is found to 
be hyperphosphorylated in differentiated W12E cells, HPV-16 mediated regulation 
of SR protein kinase 1 (SRPK1 ), which is a major kinase of SF2/ASF, was also 
determined using western blotting and immunofluorescence. In addition, co- 
localisation of SR proteins and SRPK1, with E1^E4 and E2 was determined, as 
these are the major viral proteins which are likely to regulate SR proteins during 
HPV-16 infection. There are a number of reasons for this. For example, 
expression of both proteins is elevated in differentiated W12E cells (Doorbar et al. 
1997; Maitland et al. 1998). HPV-16 E2 is involved in transcriptional regulation of 
SF2/ASF, as shown in the previous chapter. It is also possible that E2 acts to 
regulate cellular localisation and/or phosphorylation of SR proteins, via regulation 
of SRPK1. SRPK1 may be expected to be regulated by HPV-16 in a similar 
manner to SR proteins, and E2 may regulate SRPK1 abundance, which in turn 
causes hyperphosphorylation of SF2/ASF, and possible other SR proteins. 
Consequently, SR protein phosphorylation status may regulate SR protein 
localisation during HPV-16 infection. Furthermore, HPV-1 E1*E4 has recently 
been shown to interact with SRPK1, which may also be involved in regulating 
phosphorylation status and/or relocalisation of SR proteins during differentiation 
(S. Roberts, personal communication). Although this interaction has not been 
determined for HPV-16 E1^E4, it is possible that it occurs and is involved in HPV- 
16 mediated regulation of SR proteins. Again, E1^E4-SRPK1 interaction may 
cause SR protein hyperphosphorylation, which may regulate cellular localisation. 
In contrast, E1^E4 may interact with both SRPK1 and SR proteins and regulate 
both phosphorylation and localisation directly. Expression of both E2 and E1^E4 
and not simply one or the other, may be necessary to regulate SR protein 
expression, phosphorylation and localisation during the HPV-16 life cycle. 
Therefore, localisation of SR proteins and SRPK1 was determined in
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undifferentiated and differentiated epithelial cells transiently expressing HPV-16 
E2 or E1^E4. Furthermore, differentiated W12E cells were assayed for E1^E4 and 
SR protein or SRPK1 co-localisation by immunofluorescence. Similar experiments 
were not performed for E2 due to the lack of antibodies able to detect the lower 
level of expression of E2 in W12E cells, as compared to stable and transiently 
transfected cells.
4.2 SR proteins, SF2/ASF, SRp20 and SRp75 are 
upregulated by HPV-16 E2
Experiments were performed to determine if SR proteins, other than SF2/ASF, are 
regulated during the virus life cycle. To determine what effect differentiation may 
be having on SR protein abundance, we performed western blots comparing 
protein extracts from undifferentiated and differentiated W12E cells (Figure 4.3). 
As we have previously demonstrated, total SF2/ASF is shown to be upregulated 
~4-8 fold in differentiated W12E cells. Furthermore, total SRp20 is also elevated 
in differentiated W12E cells, although to a lesser extent (-2-4 fold). However, total 
9G8 is not upregulated in response to differentiation, suggesting this protein may 
not be involved in control of late gene expression. To look at a further sub-set of 
SR proteins, Mb104 was used, which recognises a common phospho-epitope of a 
number of SR proteins (Roth et al. 1991). Whilst phosphorylated SRp75 could not 
be detected, levels of phosphorylated SRp30s (SF2/ASF (Zahler et al. 1992), 
SC35 (Fu and Maniatis 1992)) and SRp20 are shown to be elevated in 
differentiated cells. Furthermore, levels of both phosphorylated SRp55 and SRp40 
are upregulated. To ensure elevated phosphorylation of this sub-set of SR 
proteins is due to HPV-16 infection and not differentiation of epithelial cells, 
western blots comparing protein lysates from undifferentiated and differentiated 
HaCaT cells (uninfected epithelial cells) were performed (Figure 4.4). In contrast, 
to the situation in W12E cells, levels of phosphorylated SR proteins, using Mb104, 
and total SF2/ASF and SRp20 remained the same or were depleted upon 
differentiation of HaCaT cells. This suggested a sub-set of SR proteins are 
specifically upregulated during the HPV-16 life cycle.
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Figure 4.3; A sub-set of SR proteins are upregulated in 
response to HPV-16
Western blots using x1, x2 and x4 quantities of protein lysates from 
undifferentiated (W12 U) and differentiated (W12 D) W12E cells. 
Sizes markers in KDa are shown by horizontal lines to the left of 
each blot. Antibodies used in each panel are indicated on the far 
left and SR proteins detected using Mb104 are shown on the right. 
SR proteins which are able to shuttle between the nucleus and the 
cytoplasm are highlighted in red. Involucrin and GAPDH were 
used as a marker for differentiation and loading control, 
respectively.
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Figure 4.4: SR proteins are down regulated during
differentiation of uninfected epithelial cells
Western blots using x1, x2 and x4 quantities of protein lysates from 
undifferentiated (HaCaT U) and differentiated (HaCaT D) HaCaT 
cells. Sizes markers in KDa are shown by horizontal lines to the 
left of each blot. Antibodies used in each panel are indicated on 
the far left and SR proteins detected using Mb 104 are shown on 
the right. SR proteins which are able to shuttle between the 
nucleus and the cytoplasm are highlighted in red. Involucrin and 
GAPDH were used as a marker for differentiation and loading 
control, respectively.
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Having demonstrated that HPV-16 regulates a sub-set of SR proteins, we went on 
to determine whether E2 was involved. This was achieved using two cell clones 
which stably express E2 to different levels (A4 and B1). In addition to SF2/ASF, 
phosphorylated levels of SRp75 and SRp20 are also elevated in cells expressing 
E2, when compared to controls (Figure 4.5). However, phosphorylated SRp55 
and SRp40, which show some elevated levels in differentiated W12E cells, are not 
regulated by E2 alone. Whilst E2 is expressed at all stages of differentiation of an 
HPV-16 infected epithelium, the highest levels are observed in the suprabasal 
layers (Maitland et al. 1998). We hypothesise that E2 expression is elevated in 
these cells to regulate expression of cellular proteins that have functions related to 
the viral late life cycle, such as SR proteins.
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Figure 4.5: A sub-set of SR proteins are upregulated cells 
expressing HPV-16 E2
Western blots comparing equal quantities of protein lysates from 
non-transfected U20S cells (negative), and two U20S cell clones 
stably expressing HPV-16 E2 (A4 and B1). Sizes markers in KDa 
are shown by horizontal lines to the left of each blot. Blots were 
probed using Mb104 and the SR proteins detected are shown on 
the right. SR proteins which are able to shuttle between the 
nucleus and the cytoplasm are highlighted in red. GAPDH was 
used as a loading control.
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4.3 Episomal HPV-16 may cause redistribution of 
shuttiing SR proteins, SF2/ASF and SRp20 but not 
9G8, to the cytopiasm of differentiated ceiis
Having shown that HPV-16 E2 is involved in regulation of SR proteins other than 
SF2/ASF, we wanted to determine the cellular localisation of the shuttling SR 
proteins in both undifferentiated and differentiated HPV-16 infected cells. Cellular 
localisation may be important to the functions of the proteins and may suggest 
roles in export and/or translation of late transcripts. To achieve this, 
immunofluorescence using undifferentiated and differentiated W12E cells was 
performed. As detailed above involucrin was used as a marker for differentiation, 
whilst SC35 was used as a non-shuttling SR protein control. Results here show 
increase levels of involucrin within differentiated cells as expected (Figure 4.6). 
Furthermore, staining for SC35 revealed the protein is localised to speckles within 
the nucleus, the characteristic pattern for SR proteins, in both undifferentiated and 
differentiated cells. This was expected as SC35 does not shuttle between the 
nucleus and the cytoplasm (Caceres et al. 1998). In contrast, in some 
experiments, whilst both SF2/ASF and SRp20 are localised predominantly to 
nuclear speckles within undifferentiated W12E cells, their pattern is more diffuse in 
the nucleus and also in the cytoplasm within differentiated cells (Figure 4.6). 
However, in other experiments, both of these proteins localise to nuclear speckles 
in both undifferentiated and differentiated cells (Figure 4.7). Whilst the reason for 
the difference is unclear, the method of differentiation may impact SR protein 
iocalisation. Cells differentiated in monolayer culture retain nuclear speckling of 
SR proteins, whilst methylcellulose differentiation seemed to result in redistribution 
of SF2/ASF and SRp20. Furthermore, staining for 9G8 revealed this protein to be 
found within nuclear speckles in both undifferentiated and differentiated cells 
(Figure 4.6). Although 9G8 is known to shuttle between the nucleus and the 
cytoplasm, its shuttling activity is not dependent upon transcription, in the way that 
both SF2/ASF and SRp20 are. To ensure possible shuttling of SF2/ASF and 
SRp20 was not a product of epithelial differentiation, immunofluorescence was 
performed using undifferentiated and differentiated HaCaT cell, in this case anti- 
9G8 was used a non-shuttling control, whilst SF2/ASF and SRp20 were monitored 
for redistribution. Figure 4.8 shows all three proteins localised to nuclear speckles 
in both undifferentiated and differentiated cells. This suggests that potential
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redistribution of shuttling SR proteins; SF2/ASF and SRp20 in HPV-16 Infected 
differentiated cells may be due to the presence of virus genomes.
4.4 SR protein kinase 1 (SRPK1) is reguiated during 
differentiation of HPV-16 infected epitheliai ceiis
As discussed, SF2/ASF is hyperphosphorylated in differentiated W12E cells. 
SRPK1 is a potential candidate for this, due to its interaction with HPV-1 E1^E4 
(Roberts, personal communication). Therefore, we wanted to determine whether 
SRPK1 is regulated during the HPV-16 life cycle. Firstly to compare protein levels 
between undifferentiated and differentiated W12E cells, western blots were 
performed. SRPK1 is shown to be elevated ~2 fold upon differentiation of W12E 
ceiis (Figure 4.9). In contrast, in differentiated HaCaT cells, SRPK1 levels are 
shown to diminish. This suggests that SRPK1, like a sub-set of SR proteins, is 
specifically upregulated in response to HPV-16 infection. In addition to analysing 
protein levels, localisation of SRPK1 was assayed In undifferentiated and 
differentiated W12E cells. The protein shows diffuse cytoplasmic location in both 
undifferentiated and differentiated cells (Figure 4.10). However, In undifferentiated 
W12E cells, there is more of the protein In the nucleus, whilst differentiation results 
in redistribution to the cytoplasm. This suggests HPV-16 may regulate cellular 
localisation of SRPK1. To ensure that SRPK1 distribution does not change during 
differentiation of normal epithelial cells, HaCaT cells were used. Figure 4.9 shows 
no change was observed in SRPK1 localisation between undifferentiated and 
differentiated HaCaT cells. However, SRPK1 is found to be predominantly nuclear 
in HaCaT cells, suggesting a fundamental difference between W12E and HaCaT 
cells with respect to SRPK1 localisation. This suggests that SRPK1 protein levels 
are regulated during the HPV-16 life cycle, and the protein redistributes to the 
cytoplasm upon differentiation of HPV-16 infected cells.
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Figure 4.6: Redistribution of SR protein, SF2/ASF and SRp20, 
during differentiation of W12E cells
Immunofluorescence showing localisation of SR proteins, SF2/ASF, 
SRp20, 9G8 and SC35 in undifferentiated (W12 U) and 
methylcellulose differentiated (W12 D) W12E cells. SR proteins are 
shown in green and DAPI stained nuclei are shown in blue. The 
protein stained for is given to the left. Higher magnification of W12 U 
SC35 stained cells shows nuclear speckling pattern. Involucrin was 
used as a marker for differentiation and cells in this panel are shown 
at a lower magnification. Involucrin staining in W12D cells is shown 
at lower exposure due to the intensity of the signal
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Figure 4.7; Redistribution of SF2/ASF and SRp20, during 
differentiation of W12E cells may depend on genome 
integration and/or the extent of differentiation
Immunofluorescence showing localisation of SR proteins, SF2/ASF 
and SRp20 in monolayer differentiated (W12 D) W12E. SR 
proteins are shown in green and DAPI stained nuclei are shown in 
blue. The protein stained for is given to the left. Involucrin was 
used as a marker for differentiation.
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Figure 4.8: Localisation of SR protein during differentiation of 
HaCaT cells
Immunofluorescence showing localisation of SR proteins, 
SF2/ASF, SRp20 and 9G8 in undifferentiated (HaCaT U) and 
differentiated (HaCaT D) HaCaT cells. SR proteins are shown in 
green and DAPI stained nuclei are shown in blue. The protein 
stained for is given to the left. Involucrin was used as a marker for 
differentiation.
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Figure 4.9: SRPK1 is upregulated during differentiation of HPV- 
16 infected epithelial cells
Western blots using x1, x2 and x4 quantities of protein lysates from 
undifferentiated (U) and differentiated (D) W12E and HaCaT cells, 
probed with anti-SRPKI. Sizes markers in KDa are shown by 
horizontal lines to the left of each blot. Involucrin and GAPDH, 
differentiation and loading control western blots are shown in figure 
4.3 for W12E samples and figure 4.4 for HaCaT samples.
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Figure 4.10: Relocalisation of SRPK1 during differentiation of 
W12E cells
immunofluorescence showing localisation of SRPK1 in 
undifferentiated (U) and differentiated (D) W12E or HaCaT cells. 
SRPK1 is shown in green and DAPI stained nuclei are shown in 
blue.
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4.5 SR proteins and SRPK1 do not co-localise with E2 
or E1^E4 in transfected ceiis
To further investigate the localisation of shuttling SR proteins and SRPK1 in W12E 
cells, differentiated W12E and E2 or E1^E4 transfected cells were subjected to co­
localisation immunofluorescence experiments. E2 and E1^E4 were chosen as 
potential candidates for SR protein regulation for reasons discussed in the 
introduction to this chapter. Therefore, stable and transiently HPV-16 E2 or E1^E4 
transfected cells were assayed for SR protein and SRPK1 localisation. Figure 
4.11 shows localisation of SR proteins in U20S cells (B1), which are stably 
expressing HPV-16 E2. Similar results were found using U20S A4, but 
expression of E2 was iower in this cell clone, so detection of E2 was more difficult. 
Neither cell clone was assayed for co-staining between E2 and SR protein or 
SRPK1. No relocalisation of SR proteins was found upon expression of E2, 
suggesting E2 has little effect on SR protein localisation when expressed in U20S 
ceils. However, SRPK1 localises to the nucleus and peri-nuclear region in E2 
expressing cells, whereas the protein shows more diffuse staining throughout the 
cell in the absence of E2. A similar pattern in SRPK1 redistribution is observed 
during differentiation of W12E cell (Figure 4.10), suggesting that E2 may regulate 
SRPK1 localisation. A more definitive experiment to determine whether E2 co- 
localises with SR proteins and/or SRPK1 during HPV-16 infection, would have 
been to co-stain undifferentiated or differentiated W12E cells. However, 
antibodies against E2 did not detect the protein in either undifferentiated or 
differentiated W12E cells, and therefore this experiment was not possibie.
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Figure 4.11: HPV-16 E2 causes redistribution of SRPK1 when 
expressed in U20S cells
Immunofluorescence showing localisation of SF2/ASF, SRp20 and 
SRPK1 in in non-transfected U20S cells (U20S negative) or HPV- 
16 E2 stably expressing U20S cell clone B1 (U20S B1). SR 
proteins and SRPK1 are shown in green, whilst DAPI stained 
nuclei are shown in blue. Expression of E2 is also shown in the top 
panel, where U20S B1 cells are shown at a lower magnification.
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To determine potential co-localisation between HPV-16 E1^E4 and SR proteins or 
SRPK1, similar experiments were performed. Firstly, HeLa cells, as a model for 
undifferentiated epithelial cells, were transiently transfected with an HPV-16 E1^E4 
expression vector. Cells were then co-stained using anti-El ^ E4 and anti-SR 
protein or SRPK1 antibodies. Figure 4.12 shows no change in locaiisation, or any 
co-staining between SF2/ASF, SRp20 or SRPK1 in E1^E4 expressing cells. To 
determine whether epithelial differentiation or tumourigenesis had any effect on 
this, E1^E4 transiently transfected differentiated HaCaT cells, were subjected to 
co-staining experiments. Again E1^E4 did not co-stain with either SR proteins or 
SRPK1 and their ceilular localisation was not affected by E1^E4 expression 
(Figure 4.13). To look at potential co-localisation during the HPV-16 life cycle, 
differentiated W12E ceiis were co-stained with anti-El^E4 and antibodies 
recognising SF2/ASF, SRp20 or SRPK1. Whilst E1^E4 could not be detected in 
undifferentiated W12E cells, it was shown to localise to the cytoplasm in a peri­
nuclear fashion in differentiated cells (Figure 4.14). However, neither SR proteins 
nor SRPK1 were found to obviously co-localise with E1^E4 in differentiated W12E 
ceils. There may be some co-localisation in the cytoplasm for each protein; 
however, it is difficult to confirm this at the magnification shown. Cells used in 
these experiments were differentiated in monolayer culture and retained nuclear 
speckling of SR proteins upon differentiation. Therefore, we cannot discount the 
possibility that should SF2/ASF and SRp20 have been shown to redistribute to the 
cytoplasm in these experiments, they may have co-localised with E1^E4. To 
determine this would require that experiments be repeated using methylcellulose 
differentiated W12E cells.
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Figure 4.12: HPV-16 E1^E4 does not co-localise with or cause 
redistribution of SR proteins when expressed in HeLa cells
Immunofluorescence showing co-staining of HPV-16 E1^E4 
transiently transfected HeLa cells with anti-El^E4 and anti- 
SF2/ASF, anti-SRp20 or anti-SRPKI. SR proteins are shown in 
green, E1^E4 in red and DAPI stained nuclei are shown in blue. 
The SR protein stained for is given to the left. Non-transfected cells 
within each panel act as negative controls.
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Figure 4.13: HPV-16 E1^E4 does not co-localise with or cause 
redistribution of SR proteins when expressed in differentiated 
HaCaT cells
Immunofluorescence showing co-staining of HPV-16 E1^E4 
transiently transfected differentiated HaCaT cells with anti-El^E4 
and anti-SF2/ASF, anti-SRp20 or anti-SRPKI. SR proteins are 
shown in green, E1^E4 in red and DAPI stained nuclei are shown 
in blue. The SR protein stained for is given to the left. Involucrin is 
used as a marker for differentiation and staining is shown at lower 
exposure due to the intensity of the signal. Non-transfected cells 
within each panel act as negative controls.
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Figure 4.14: HPV-16 E1^E4 does not co-localise with SR
proteins or SRPK1 in differentiated W12E cells
Immunofluorescence showing co-staining of HPV-16 E1^E4 and 
SF2/ASF, SRp20 or SRPK1 in differentiated W12E cells. SR 
proteins are shown in green, E1^E4 in red and DAPI stained nuclei 
are shown in blue. The SR protein stained for is given to the left.
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4.6 Discussion
During differentiation of HPV-16 infected epithelial cells, a number of transcripts 
are produced by the virus, which requires extensive alternative splicing (Milligan et 
al., 2006). Furthermore, repression of late gene expression, which is observed in 
undifferentiated cells, needs to be alleviated upon differentiation. A number of cis- 
acting RNA regulatory elements are observed within the HPV-16 late region, and 
these are thought to function via interaction with cellular RNA regulatory proteins 
(Zhao et al. 2004; Rush et al. 2005). Whilst many such factors are abundant in 
undifferentiated epithelial cells, they are depleted upon differentiation (McPhillips 
et al. 2004). Therefore, it was hypothesised that HPV-16 must regulate at least a 
sub-set of RNA regulatory factors during differentiation, to ensure appropriate 
gene expression and completion of the virus life cycle. Two antagonistic factors 
known to be upregulated in HPV-16 Infected differentiated cells are SR protein, 
SF2/ASF and hnRNP A1 (McPhillips et al. 2004; Veerapraditsin 2004). In 
contrast, these proteins are downregulated in response to differentiation of 
uninfected epithelial cells. Therefore, it was suggested that upregulation is a direct 
consequence of HPV-16 infection. Furthermore, as shown in the previous 
chapter, SF2/ASF is transactivated by HPV-16 E2, suggesting that this viral 
protein may be involved in regulating a sub-set of RNA regulatory proteins during 
differentiation. The work in this chapter was undertaken to determine if SR 
proteins other than SF2/ASF are regulated in response to HPV-16 infection, and if 
so, what viral proteins might be involved. As outlined above SR proteins are 
multifunctional proteins, with roles in splicing, mRNA export and translation, 
making them good targets for HPV-16 to regulate late gene expression.
Results here suggest that levels of phosphorylated SR proteins, SF2/ASF, SRp20, 
SRp40, SRp55 and SC35 are upregulated to differing extents in differentiated 
W12E ceils, whereas all SR proteins are shown to maintain their phosphorylated 
levels or phosphorylated forms are downregulated in uninfected differentiated 
epithelial cells. Furthermore, stable expression of E2 in U20S cells results in 
elevated levels of phosphorylated SRp75, SC35, SF2/ASF and SRp20. This 
suggests that HPV-16 E2 is involved in regulation of a sub-set of SR proteins 
during differentiation of W12E cells. To determine if these SR proteins might be 
regulated in a similar manner to SF2/ASF would require promoter analysis. 
Similar to SF2/ASF, little is known about transcriptional regulation of other SR
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proteins. Therefore, a region spanning -1kb upstream of the transcription start 
sites for each of the genes was analysed for homology. Each of the promoters 
was divergent suggesting that regulation for each may differ. In addition, each 
promoter was analysed using TFSearch, and like the SF2/ASF promoter, each 
lacks a TATA box. Furthermore, no particular TF binding site was found in 
abundance within any of the promoter, suggesting that SR protein expression may 
be regulated by a number of different TFs, potentially indicating that the promoters 
are found in open chromatin conformation. However, as no particular promoter 
elements have been identified to control E2-medlated transactivation of the 
SF2/ASF promoter, it was not possible to determine if similar elements were 
present in promoters for genes upregulated in response to E2, but absent in those 
that are not. The Sp1 binding site found at -575 within the SF2/ASF promoter was 
not found at similar position in any of the other SR protein promoters. This may 
suggest that either this Spl binding site is not necessary for E2-mediated 
regulation of SF2/ASF expression, or that it might act in a position independent 
manner to regulate E2-mediated expression of SR proteins. At least one Spl 
binding site is observed within each of the other SR protein promoters; however, 
this is a common TF, binding sites for which may be expected to be observed in a 
high proportion of promoters. In contrast, lack of Spl binding sites at ~-600 in 
each of the SR protein promoter might indicate that E2 regulates each promoter 
via different mechanisms. Therefore, to establish a role for E2 in transactivation of 
SR proteins, other than SF2/ASF, would require analysis of each promoter in turn, 
using similar methods as described in chapter 3.
To determine whether HPV-16 regulates localisation of SR proteins, 
immunofluoresence experiments using undifferentiated and differentiated W12E 
cells were performed. SF2/ASF, SRp20 and 9G8 are known to shuttle between 
the nucleus and the cytoplasm of HeLa cells (Caceres et al. 1998), and it was 
possible that potential redistribution of these proteins during differentiation of 
W12E cells may result in differential regulation of c/s-acting elements within the 
HPV-16 late region. Results showed that SF2/ASF and SRp20, may redistribute 
from nuclear speckles to a diffuse cytoplasmic location upon differentiation. 
However, the results were inconsistent and may depend on the method used to 
differentiate cells. When cells were differentiated using methylcellulose, SF2/ASF 
and SRp20 redistribution was observed. In contrast, cells differentiated in 
monolayer culture show nuclear speckling of SR proteins in both undifferentiated 
and differentiated W12E cells. Methylcellulose differentiation is thought to result in
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a more differentiated population of cells. Therefore, it is possible that SF2/ASF 
and SRp20 redistribute at a very late stage of differentiation, which is not achieved 
by differentiation in monolayer culture. In contrast, as the status of the viral 
genome was not assayed in cells used in these experiments, it is possible that the 
genome had integrated in some of the cells used. It Is not known whether genome 
integration would inhibit or promote redistribution of SR proteins. Therefore, 
experiments would need to be repeated to determine which, if any of these 
possibilities, were true. Alternatively, staining patterns in raft cultured W12E tissue 
may give a better indication of SR protein localisation upon differentiation. The 
final shuttling SR, protein, 9G8, does not redistribute in any case. Shuttling of 9G8 
is not dependent on continued transcription, as the protein does not get trapped in 
the cytoplasm when transcription is inhibited (Caceres et al. 1998). Therefore it is 
possible that a block to transcription is observed In differentiated W12E cells 
where SF2/ASF and SRp20 are redistributed to the cytoplasm. Alternatively, 9G8 
is not upregulated in response to HPV-16 infection, and therefore, may simply not 
be a target of the virus.
An additional protein assayed for regulation by HPV-16 was SR protein kinase 1 
(SRPK1). SRPK1 is shown to be upregulated in differentiated W12E cells and 
redistributes to the cytoplasm. In addition, SF2/ASF, SRp20, and SRPK1 were 
assayed for co-localisation with viral proteins E2 and 5:1*54. As discussed, 52 
and 51*54 are the prime viral protein candidates for regulation of SR proteins and 
SRPK1, during differentiation of HPV-16 infected cells. Little apparent co­
localisation was observed between 52 or 51*54 and either SR protein or SRPK1, 
in transfected or W12E cells. However, SRPK1 showed distribution reminiscent of 
that found in differentiated W125 cells, in U20S B1 cells, which stably express 
high levels of 52. This may indicate that 52 has a role in controlling SRPK1 
localisation in differentiation W125 cells. For 51*54, whilst co-localisation with 
both SR proteins and SRPK1 in the cytoplasm of differentiated W125 cells cannot 
be discounted, no redistribution of any of the three proteins was observed in 
transiently transfected epithelial cells. Furthermore, no redistribution of SR 
proteins was observed in differentiated W12E cells in co-staining experiments. 
Therefore, it is possible that should redistribution have been observed, so too 
might have greater co-localisation. However, similar experiments were not 
performed for 52, due to the lack of antibodies able to detect the lower expression 
of 52 in W12E cells, when compared with transfected cells. Therefore, whilst 
these experiments showed little co-localisation between SR proteins and SRPK1
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and viral proteins E2 and E1*E4, it is possible that they do interact. For example, 
it is feasible that a low level of co-localisation exists, which is difficult to detect by 
immunofluorescence. Therefore, it may be useful to determine potential 
association of the proteins in co-immunoprecipitation experiments. This could be 
done using differentiated W12E cells for E1*E4, since antibodies are available 
which can detect the protein in these cells. Conversely, SF2/ASF, SRp20 and 
SRPK1 antibodies could be used in these cells, to determine association with both 
E2 and E1*E4. Although antibodies detecting E2 by immunofluorescence in 
W12E cells were not available, E2 can be detected by western blotting in W12E 
cells. In addition, co-immunoprecipitation between E2 or E1*E4 and SF2/ASF, 
SRp20 or SRPK1 in transiently transfected epithelial cells, such as differentiated 
HaCaTs could be determined. These experiments may indicate whether E2 
and/or E1*E4 are involved in SF2/ASF, SRp20 and SRPK1 regulation during the 
HPV-16 life-cycle.
In summary, whilst a sub-set of levels of phosphophorylated SR protein are shown 
to be upregulated in response to HPV-16 E2 expression, potential redistribution of 
shuttling SR proteins upon differentiation of W12E cells remain inconclusive. 
Therefore, a number of experiments are required to determine how SR proteins 
are regulated during the HPV-16 life cycle, and what viral proteins, if any, are 
involved.
141
5 The role of SF2/ASF In LRE-mediated control of late gene 
expression
5.1 Introduction
SF2/ASF is upregulated and hyperphosphorylated In HPV-16 infected 
differentiated epithelial cells where capsid proteins (e.g. LI and L2) are also 
produced (McPhillips et al. 2004). LI and L2 transcripts can be detected In less 
differentiated cells (Milligan et al., 2006), however, c/s-acting RNA elements within 
the late region of the HPV-16 genome may act to prevent their expression 
(Kennedy et al. 1990; Kennedy et al. 1991; Gumming et al. 2003; Oberg et al. 
2003; Zhao et al. 2004; Rush et al. 2005; Zhao et al. 2005). One such element, 
the LRE, which resides at the 3' end of the LI coding region and spans into the 
late 3’ UTR, has been shown to confer negative regulatory activity upon reporter 
gene constructs In undifferentiated epithelial cells (Kennedy et al. 1991; Dletrich- 
Goetz et al. 1997; Gumming et al. 2003). As SF2/ASF Is shown to associate with 
the LRE, in both undifferentiated and differentiated W12E cells (Veerapraditsin 
2004), It is hypothesized that its upregulation and hyperphosphorylation may act to 
activate the LRE in differentiated cells and hence aid production of late transcripts.
The LRE is known to confer -20 fold negative regulatory activity upon reporter 
gene expression in undifferentiated epithelial HeLa cells (Gumming et al. 2003). It 
has been proposed that this is attributable to a number of mechanisms during 
post-transcriptional regulation of gene expression. In HPV-16 Infected 
undifferentiated epithelial cells (W12E), polyadenylation of late transcripts is 
inhibited (Milligan et ai., 2006). Whilst unprocessed RNA encoding late genes LI 
and E1*E4 were detected in total RNA from undifferentiated and differentiated 
W12E cells, polyadenylated mRNAs for LI and E1*E4 were detected only in 
differentiated W12E cells. In contrast to the in vivo situation, no such inhibition of 
polyadenylation was observed in vitro, when comparing constructs containing and 
lacking the LRE (Kennedy et al. 1990). However, these experiments used HeLa 
extracts, and therefore do not reflect the real situation observed in W12E cells. 
HeLa cells are undifferentiated epithelial cells; however, they are highly 
transformed and express high levels of cellular RNA processing factors, which 
may be Involved In regulation HPV-16 late polyadenylation via the LRE. 
Therefore, It is possible that high levels of expression of polyadenylation factors In
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HeLa cell extracts allow polyadenylation mediated by the LRE, whilst lower 
expression levels in W12E cells may not. It is also possible that c/s-acting RNA 
elements other than the LRE, which are not present in the RNA substrates used in 
in vitro experiments, conributed to inhibition of polyadenylation. However, to date 
no repressive sequences within the 3’ region of late RNAs, other than the LRE, 
have been discovered. In addition to its effects on polyadenylation, the LRE has 
also been implicated in RNA stability. Whereas constructs lacking the LRE were 
stable for more than 90 minutes in in vitro mRNA decay assays, the half life of 
LRE containing transcripts was -30 minutes (Kennedy et al. 1991). This has 
recently been confirmed in vivo (Veerapraditsin et al., manuscript in preparation). 
This suggests that the LRE acts as an instability element in undifferentiated 
epithelial cells. In addition, whilst there is no evidence to date implicating the LRE 
in translational regulation of late transcripts, it Is possible that the LRE may 
enhance translation in differentiated W12E cells. The element is found within the 
3'UTR, which has previously been shown to be involved in regulation of translation 
via a number of elements, such as the 15-lipoxygenase (LOX) DICE element 
(Ostareck-Lederer et al. 1994). Repeats of this element were shown to repress 
translation of the LOX mRNA via interactions with hnRNP K and hnRNP El 
(Ostareck et al. 1997). Furthermore, proteins associated with the LRE, such as 
SF2/ASF, have been shown to regulate translation (Sanford et al. 2004). 
Therefore, whilst there is some indication of how the LRE functions to repress late 
gene expression in undifferentiated W12E cells, how the element is then activated 
in differentiated cells is as yet unknown.
As mentioned the LRE associates with a number of cellular RNA regulatory factors 
and these are thought to mediate the functions described above. Most of the work 
in this area focused on in vitro assays using nuclear and cytoplasmic extracts from 
HeLa cells, and undifferentiated and differentiated W12E cells. Electrophorectic 
mobility shift assays (EMSAs) were used to determine what complexes are formed 
upon the LRE (Koffa et al. 2000; Gumming et al. 2003; Veerapraditsin 2004). In 
these experiments 3 complexes formed with nuclear extracts from HeLa, and 
undifferentiated and differentiated W12E cells. There was little change in the 
abundance of each complex upon differentiation, suggesting nuclear LRE 
complexes remain constant throughout differentiation. In contrast, whilst only one 
complex formed with HeLa cytoplasmic extracts, two formed in the presence of 
W12E cytoplasmic extracts (Veerapraditsin 2004). Furthermore, a shift was 
observed in complex abundance, where undifferentiated extracts formed mainly
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the lower complex and differentiated extracts formed mainly the upper complex 
(Veerapraditsin 2004). In addition, proteins binding the LRE by UV cross-linking 
were shown to change upon W12E differentiation, particularly in the cytoplasm 
(Veerapraditsin 2004). Many more proteins from W12E differentiated cytoplasmic 
extracts bind the LRE than from undifferentiated cytoplasmic extracts. This 
suggests that complexes formed on the LRE in the cytoplasm of W12E cells 
change during differentiation, which likely affects the function of the element. In 
addition, if there are few late RNAs in the cytoplasm of undifferentiated W12E 
cells, complexes formed in vitro with W12E undifferentiated cytoplasmic extract 
may be of little consequence to LRE function.
The first protein found associating with the LRE was U2AF® ,^ using HeLa nuclear 
extracts in UV cross-linking experiments (Dietrich-Goetz et al. 1997). This was 
found to associate with the 3’GU rich region of the LRE, which shows similarity to 
the natural U2AF®® binding site, B2P2. B2P2 could compete for LRE binding of a 
65KDa protein, suggesting this protein was indeed U2AF®®. Furthermore, U2AF®  ^
did not cross-link with the 5’ region of the LRE, suggesting it interacts specifically 
with the 3’GU rich region (Gumming et al. 2003). As discussed previously, U2AF®  ^
is a component of the spliceosome which associates with the polypyrimidine tract 
upstream of a 3’ splice site. Other factors involved in the spliceosome include 
components of the U1 snRNP complex, which associates with the 5’ splice site 
and SR proteins, which bridge 5’ and 3’ splice site complexes by protein-protein 
interactions. Using affinity chromatography, components of U1 snRNP were found 
associating, predominantly with the 5’ LRE, which contains 4 weak 5’ splice sites 
(Gumming et al. 2003). These include U1A and Sm proteins, which associated via 
the 5’ splice sites. Anti-Sm antibody was also shown to supershift complexes 
formed with HeLa nuclear extracts in EMSA experiments. In addition, U1 snRNA 
bound the LRE; however, U1-70K, which has previously been shown to interact 
with an inhibitory element in the BPV-1 late 3'UTR and inhibit polyadenylation 
(Gunderson et al. 1998), could not be detected in association with the LRE 
(Gumming et al. 2003). This suggests that the HPV-16 LRE does not inhibit 
polyadenylation via the same mechanism as the BPV-1 late 3’UTR element. 
However, a U1 snRNP like complex, containing, U1A and Sm proteins, and U1 
snRNA, associates with the 5’ LRE.
In addition to U1 snRNP and U2AF® ,^ SR protein, SF2/ASF was also shown to 
associate with the LRE in HeLa nuclear extracts using affinity chromatography
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(McPhillips et ai. 2004). Experiments showed association between the 3’ LRE and 
SF2/ASF, via U2AF®®. Supershifting was observed when nuclear and cytoplasmic 
HeLa extracts were pre-incubated with anti-SC35 antibody, which cross-reacts 
with SF2/ASF (Veerapraditsin 2004). Whilst the antibody probably supershifted 
SF2/ASF in the cytoplasmic extracts, as SC35 is confined to the nucleus, nuclear 
supershifting could have been a result of SF2/ASF or SC35 recognition. Transient 
transfection of HeLa cells with LRE containing constructs resulted In increased co- 
immunoprecipitation between SF2/ASF and U2AF®® (McPhillips et al. 2004). This 
suggests that U2AF®® and SF2/ASF bind the 3’ LRE in complex with each other. 
Anti-U2AF®® also co-immunoprecipitated SF2/ASF more efficiently in differentiated 
W12E nuclear extract, when compared with undifferentiated nuclear extracts 
(Veerapraditsin 2004). Therefore, as a U1 snRNP like complex associates with 
the 5’ region and U2AF^^ interacts with the 3' LRE, this provides the potential for 
formation of a splicing-like complex over the LRE in the nucleus of infected cells. 
Furthermore, as complexes which form on the LRE are unchanged during 
differentiation of W12E cells (Veerapraditsin 2004), it is suggested that this 
splicing-like complex forms in both undifferentiated and differentiated cells. In 
contrast, no interaction between SF2/ASF and U2AF®® is observed in cytoplasmic 
extracts from undifferentiated or differentiated W12E cells (Veerapraditsin 2004). 
This suggests the splicing-like complex is formed only in the nucleus and that 
SF2/ASF may interact with the LRE via a different mechanism in the cytoplasm.
In addition to components of the splicing machinery, the LRE also interacts with 
cellular factors involved in other aspects of RNA regulation. CstF-64, a sub-unit of 
the cleavage stimulating factor CstF, which is known to stabilise the formation of 
polyadenylation and cleavage complexes, associates with the LRE (Koffa et al.
2000). Pre-incubation of HeLa nuclear extracts with anti-CstF-64 antibody 
resulted in disruption of only the largest complex forming on the LRE. Interaction 
is mediated by the CstF-64 RNA binding domain, as shown in EMSAs using GST 
tagged truncated CstF-64, containing only the RNA binding domain. In addition, 
the full CstF complex was shown to bind to sense but not antisense LRE in UV 
cross-linking experiments, suggesting CstF-64 is involved in binding CstF to the 
LRE (Koffa et al. 2000). HuR, which is involved in stabilisation and transport of 
mRNA from the nucleus to the cytoplasm, also interacts the LRE (Veerapreditsin 
et al., manuscript in preparation). Affinity chromatography and EMSAs, using 
HeLa extracts showed this interaction required the 3' LRE, but HuR was also able 
to bind the 5’LRE, although with lower affinity. Furthermore, immunofluoresence
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of HuR in raft cultured W12E tissue suggested the protein localised to both the 
nucleus and the cytoplasm of undifferentiated and differentiated W12E cells. 
Overexpression of HuR in differentiated epithelial cells also resulted in production 
of more LI protein (Veerapraditsin et al., manuscript in preparation). Therefore, it 
is possible that HuR may act to stabilise LRE containing transcripts in the 
cytoplasm of differentiated W12E cells,
A further protein associating with the LRE in the cytoplasm and possibly the 
nucleus is hnRNP A1 (Veerapraditsin 2004). hnRNP A1 is known to antagonise 
the function of SF2/ASF via interaction with c/s-acting exonic splicing silencers 
(ESSs) (Eperon et al. 2000). ESS-hnRNP A l interactions are involved in inhibiting 
binding of U1 snRNP to proximal 5' splice sites. The protein can also shuttle 
between the nucleus and the cytoplasm and is known to affect mRNA export and 
stability in the cytoplasm (Hamilton et al. 1997; Izaurralde et al. 1997; Mill et at.
2001). Furthermore, a binding site for hnRNP A1 is found in the middle of the 
LRE, spanning the 5’ and 3’ regions and GST-tagged hnRNP A1 interacts directly 
with the LRE in EMSAs (Veerapraditsin 2004). Anti-hnRNP A1 antibody was able 
to shift complexes formed with undifferentiated and differentiated W12E 
cytoplasmic extract. However, it has not yet been determined whether a similar 
shift is obtained using nuclear extracts due to ribonuclease contamination of the 
anti-hnRNP A1 antibody solution. In addition, expression of hnRNP A1 increased 
upon differentiation of W12E cells (Veerapraditsin 2004). This suggests hnRNP 
A1 may be an important cellular factor involved in LRE activation in differentiated 
W12E cells.
As levels of SF2/ASF were shown to increase upon W12E differentiation 
(McPhillips et al. 2004), this protein is suggested to be vital in the switch from 
repression to activation of late gene expression by the LRE. In addition, more 
hyperphosphorylated SF2/ASF was detected in differentiated W12E cells, when 
compared with undifferentiated extracts (McPhillips et al. 2004). SF2/ASF may 
also redistribute from nuclear speckles, where it is predominantly found in 
undifferentiated W12E cells, to a more diffuse cytoplasmic distribution in 
differentiated W12E cells. Therefore, this change in abundance, phosphorylation 
status and/or localisation is hypothesised to contribute to LRE de-repression in 
differentiated W12E cells. SF2/ASF has roles not only during splicing but is also 
able to shuttle between the nucleus and the cytoplasm (Caceres et al. 1998), can 
regulate shuttling (Cazalla et al. 2002) and is also able to regulate translation
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(Sanford et al. 2004). In undifferentiated W12E cells, where SF2/ASF is 
predominantly nuclear, and is found in lower abundance and in 
hypophosphorylated form, it is suggested that formation of the splicing-like 
complex over the LRE in the nucleus is involved in repression of polyadenylation 
(Figure 5.1 A). Presence of a 5' splice site within the 3’ most exon has previously 
been shown to repress polyadenylation in vitro and in vivo (Niwa et al. 1992) and a 
number of components of the splicing machinery are also known to associate with 
polyadenylation and cleavage factors (Lutz et al. 1996; Gunderson et al. 1997; 
Gunderson et al. 1998; Vagner et ai. 2000). For BPV-1, binding of U1 snRNP to a 
5' splice site within the late 3'UTR resulted in inhibition of polyadenylation in 
undifferentiated cells (Furth et al. 1994; Gunderson et al. 1998). Whilst SF2/ASF 
may also contribute to repression of export of LRE containing RNAs from the 
nucleus to the cytoplasm, it is also possible that this is a result of inhibition of 
polyadenylation, as non-polyadenylated mRNAs are usually not exported. 
However, SF2/ASF is a shuttling protein, which is thought to be transported to the 
nucleus in hyperphosphorylated form (Caceres et al. 1998). Hypophosphorylated 
SF2/ASF is thought to reside predominantly in nuclear speckles. Therefore, late 
transcripts may be retained in the nucleus via interaction with SF2/ASF, due to the 
lower abundance of the hyperphosphorylated form, and the predominant nuclear 
localisation of the protein, within undifferentiated W12E cells.
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Figure 5.1: Potential roles of SF2/ASF during repression of the LRE in 
undifferentiated W12E cells
A) In undifferentiated cells SF2/ASF, in association with the splicing-like 
complex may cause repression of cleavage and polyadenylation by the LRE.
B) Other cellular LRE binding proteins may compete with the splicing-like 
complex for LRE binding and this may inhibit polyadenylation.
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Upregulation and hyperphosphorylation of SF2/ASF, as well as potential 
relocalisation, may contribute to late gene expression via the LRE in differentiated 
W12E cells by several mechanisms. Firstly, it is possible that the change In 
phosphorylation status and protein levels causes alleviation of inhibition of 
polyadenylation. In this instance, binding of SF2/ASF to the LRE via the splicing­
like complex in the nucleus may be required. In addition, this complex may 
increase the efficiency of splicing of the terminal late exon (Figure 5.2A). The final 
HPV-16 LI exon is long and contains a number of potential exonic splicing 
enhancers and silencers (ESEs and ESSs) (Figure 4.1). In the absence of 
additional c/s-acting RNA signals, splicing of this exon, via terminal exon definition, 
may be difficult. Presence of a splicing-like complex on the LRE, may provide an 
additional signal required to enhance terminal exon definition, via protein-protein 
interactions between factors binding the LRE and those associated with final 3’ 
splice site. Phosphorylation of SF2/ASF is known to affect protein-protein 
interactions (Xiao and Manley 1997; Xiao and Manley 1998). Therefore, increased 
hyperphosphorylation in differentiated W12E cells may enhance interactions 
between proteins binding the terminal 3' splice site and the splicing-like complex 
binding the LRE, hence increasing the efficiency of terminal exon definition. In 
addition, potential relocalisation of SF2/ASF in differentiated W12E cells may 
indicate a role for the protein in export of late transcripts. Furthermore, as 
discussed, SF2/ASF does not bind the LRE in association with U2AF®® in the 
cytoplasm of W12E cells. Therefore, formation of an as yet identified complex 
over the LRE may be involved in regulating translation of late transcripts in the 
cytoplasm of differentiated W12E cells (Figure 5.2C).
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Figure 5.2: Potential roles of SF2/ASF during de-repression of the LRE in 
differentiated W12E cells
A) In differentiated cells the splicing-like complex may relieve repression of 
polyadenylation and positively affect terminal exon definition of the final long 
LI exon. B) In addition to enhancing terminal exon definition, the LRE-bound 
splicing-like complex may also promote polyadenylation. C) SF2/ASF may 
act via a different complex in the cytoplasm to enhance translation of LRE 
containing transcripts
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An alternative hypothesis is that the LRE-bound splicing-like complex acts only to 
enhance expression from LRE containing transcripts. It is possible that formation 
of the complex may be infrequent in undifferentiated W12E cells, and therefore 
may have little effect on LRE function. In these cells, other cellular proteins, which 
may have inhibitory effects, may out compete the splicing-like complex for LRE 
binding (Figure 5.1 B). In contrast, elevated SF2/ASF in differentiated W12E cells 
may increase formation of the splicing-like complex over the LRE. In agreement 
with this, co-immunoprecipitation of SF2/ASF with U2AF® ,^ via which SF2/ASF 
associates with the LRE, is increased in differentiated W12E cells (Veerapraditsin 
2004). In this case, it is suggested that the LRE-bound splicing-like complex 
would act not only to enhance terminal exon definition, as discussed above, but 
may also promote polyadenylation, export and translation (Figure 5.2B). 
Conversely, SF2/ASF may be elevated in differentiated W12E cells to bind c/s- 
acting RNA elements, other than the LRE, within the HPV-16 late region. In this 
instance, the primary function of the splicing-like complex on the LRE may be to 
inhibit polyadenylation in undifferentiated cells.
From the data outlined above, the LRE is suggested to be one of the major c/s- 
acting RNA elements regulating HPV-16 late gene expression. Furthermore, as it 
is regulated during HPV-16 infection, SF2/ASF is hypothesised to play an 
important role in LRE control. Therefore, experiments were preformed in which 
SF2/ASF was overexpressed in undifferentiated epithelial cells to determine if this 
had any affect on LRE function. Whilst the most appropriate system in which to 
carry out experiments would be W12E cells, this was problematic. Culturing of 
W12E cells is complex, they are difficult to transfect and they remain 
undifferentiated only at low density. However, these experiments are being 
optimised and can be attempted in the future. Therefore, as model systems, HeLa 
cells and undifferentiated HaCaT cells were used. To investigate a role for 
SF2/ASF in LRE control, reporter constructs fused to the HPV-16 late 3’UTR were 
transiently transfected into these cells, along with SF2/ASF expression vectors. 
Reporter protein activity, as well as total and polyadenylated RNA levels were 
measured and compared between cells overexpressing SF2/ASF and those 
expressing endogenous levels. It was hypothesised that elevated levels of 
SF2/ASF would enhance polyadenylation of LRE containing transcripts, which 
would potentially result in increased protein expression.
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5.2 Expression from reporter constructs containing 
the LRE is not affected by SF2/ASF 
overexpression in undifferentiated epithelial cells
To investigate the possibility that upregulation of SF2/ASF expression is involved 
in LRE activation in differentiated W12E cells, SF2/ASF was overexpressed in 
undifferentiated epithelial cells. Although this does not recreate the W12E 
differentiated cell environment, it does allow us to assess whether SF2/ASF alone 
can regulate the LRE, simply via expression levels. However, it should be noted 
that SF2/ASF is already expressed in HeLa to levels similar to those found in 
differentiated W12E cells (McPhillips et al. 2004), suggesting that SF2/ASF 
regulated activation of the LRE may already occur within these cells to some 
extent. Reporter constructs containing the HPV-16 late 3'UTR, either including or 
lacking the LRE, were used to establish if overexpression of SF2/ASF could affect 
regulation by the LRE. These constructs are derived from pLW2, a CAT 
expression vector driven by the Herpes simplex virus immediate early (HSVIE) 5 
promoter and containing and SV40 polyadenylation signal. The SV40 poly (A) 
signal was removed and replaced with the 3'UTR from HPV-16, either including 
(pLW2+LRE) or lacking the LRE (pLW2-LRE) (Figure 5.3). The pLW2-LRE 
construct lacks the 5’ region of the late 3'UTR, up to the SspI restriction site, which 
contains the LRE. These constructs were then co-transfected into HeLa cells with 
pCG, pGG-SF2 or pCG-T7-SF2. The latter two constructs express SF2/ASF and 
T7 tagged SF2/ASF, respectively, whilst pCG is an empty vector. Both SF2/ASF 
and T7 tagged SF2/ASF were used as they express different levels of phospho- 
forms of SF2/ASF (Figure 5.4B). Protein expression from pCG-SF2 resulted in 
both hypo and hyperphosphorylated forms in roughly equal quantities, whereas 
the T7 tagged form of SF2/ASF seemed to result in expression of predominantly 
hypophosphorylated forms. As SF2/ASF is hyperphosphorylated upon 
differentiation of W12E cells, it was thought the use of these two expression 
vectors might result in differences with respect to LRE activation. Furthermore, 
CAT activity from cells transfected with pBluescript and pLW2 were used as 
negative and positive controls respectively (data not shown). As shown in figure 
5.4A, loss of the LRE resulted in -40 fold upregulation of reporter gene activity, as 
expected. However, CAT activity did not differ significantly upon SF2/ASF 
overexpression, either from constructs containing or lacking the LRE.
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Figure 5.3; pLW2+/-LRE
Schematic diagrams of the CAT reporter constructs containing and 
lacking the LRE. A) 3’UTR from HPV-16 from nt 7005-7456, between PstI 
and EcoRI restriction sites, cloned into pLW2. This region contains the 
LRE (orange rectangle) and the two late polyadenylation signals (LP1 and 
LP2). B) 3’UTR from HPV-16 from nt 7226-7456, between SspI and 
EcoRI restriction sites, cloned into pLW2. This region contains the two 
late polyadenylation signals but lacks the LRE.
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Figure 5.4: Reporter gene activity from constructs fused to the HPV- 
16 3’UTR, containing the LRE, is not affected by overexpression of 
SF2/ASF
A) Protein lysates were produced from HeLa cells co-transfected with 
400ng pLW2+/-LRE and 250ng pCG, pCG-SF2 or pCG-T7-SF2 and CAT 
assays were performed. Transfections were performed in triplicate and 
the graph represents mean and standard deviation about the mean from 
three separate experiments. B) Western blots using equal quantities of 
protein lysate from HeLa cells transfected with pCG, pCG-SF2 or pCG- 
T7-SF2 and either pLW2+/-LRE probed using anti-SF2/ASF and anti- 
GAPDH antibodies. GAPDH acts as a loading control.
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Although there was slight downregulation of CAT activity upon overexpression of 
SF2/ASF from both constructs, this was found to be statistically insignificant with 
SF2/ASF (t=1.45) and between p=0.01 and p=0.05 for T7 tagged SF2/ASF 
(t=2.34). This suggests SF2/ASF overexpression has little effect on protein 
expression from constructs containing the HPV-16 late 3’UTR in HeLa cells as 
model undifferentiated epithelial cells.
Although LRE-containing constructs used in the above experiments contain the 
late 3’UTR from HPV-16, they lack other processing signals such as introns, which 
is uncommon for eukaryotic genes. Furthermore, as discussed In the introduction 
to this chapter it is hypothesised that LRE complexes are involved in terminal exon 
definition of the final long L1 exon. Therefore, a chimaeric p-globin intron (taken 
from pCI-neo -  Promega) was inserted within the 5’UTR of CAT expression 
constructs containing the HPV-16 late 3’UTR (pLW2(intron)+LRE and 
pLW2(intron)-LRE) (Figure 5.5). This time, the LRE was precisely deleted from 
the pLW2(intron)-LRE construct. Addition of the intron caused increased CAT 
expression and smaller amounts of each plasmid were used in transfections due 
to saturation of CAT activity. This was not unexpected, as transcripts containing 
introns are expressed more efficiency due to their association with cellular RNA 
regulatory factors. However, expression from LRE containing constructs, was still 
reduced -10-15 fold in comparison with constructs lacking the LRE (Figure 5.6A). 
The extent of repression by the LRE was alleviated slightly by addition of the 
intron. CAT expression from pLW2-LRE is already very high, and addition of the 
intron had little effect. This suggests that transcripts expressed from constructs 
lacking the LRE may be translated at close to maximal rate, and production and/or 
export of more transcripts may make little difference. Expression of SF2/ASF from 
constructs pCG-SF2 and pCG-T7-SF2 gave different patterns of phosphorylation 
compared with previous experiments (compare figure 5.4B with figure 5.6B). 
Although this may reflect differing phosphorylation patterns, it could also reflect 
degradation of SF2/ASF in these samples. Furthermore, overexpression of 
SF2/ASF resulted in increased CAT activity from both constructs. This was not 
unexpected, as SF2/ASF will associate with intron complexes, allowing more 
efficient RNA processing and possibly translation of the reporter constructs. 
Greater CAT activity was observed from both LRE containing and lacking 
constructs when T7 tagged SF2/ASF was expressed and the increase from 
pLW2(intron)-LRE was found to be significant between p=0.01 and p=0.001
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(t=3.07). However, results show a general increase was observed with constructs 
containing or lacking the LRE, suggesting SF2/ASF is not acting via the LRE to 
increase CAT activity.
To ensure the LRE could not be activated by SF2/ASF overexpression, similar 
experiments were performed in undifferentiated HaCaT cells. HaCaT cells are not 
transformed and therefore, are more akin to undifferentiated W12E cells, in terms 
of SF2/ASF expression, in which the natural pattern of HPV-16 infection is 
observed, than HeLa cells. As discussed in the introduction to this chapter, 
undifferentiated W12E cells were not used due to difficulties in transfecting them. 
Furthermore, HeLa cells express large quantities of SF2/ASF, similar to those 
observed in differentiated W12E cells (McPhillips et al. 2004). Therefore, it was 
possible that no affect was observed during overexpression of SF2/ASF in HeLa 
cells as endogenous levels were already above the critical threshold, and the LRE 
was already being activated to some extent. In contrast, HaCaT ceils express 
lower levels of SF2/ASF compared with HeLa and differentiated W12E cells, and 
expression closely resembles that observed in undifferentiated W12E cells 
(McPhillips et al. 2004). Figure 5.7 shows co-transfection experiments of HaCaT 
cells with pLW2(intron)+/-LRE and SF2/ASF expression constructs. Whilst CAT 
activity was inhibited -20 fold from the construct containing the LRE, CAT activity 
from constructs containing and lacking the LRE is elevated upon overexpression 
of T7 tagged SF2/ASF. It is possible non-tagged overexpressed SF2/ASF did not 
have the same affect due to the abundance of the hyperphosphorylated form, 
compared with expression from the T7 tagged version. Expression of T7-SF2/ASF 
seemed to shift to a more hyperphosphorylated form when co-transfected with 
pLW2-LRE (Figure 5.7B). However, this is more likely due to the way the gel has 
run, as this sample was loaded at the edge. When this sample was run within the 
centre of the gel, T7-SF2/ASF expression did not differ between pLW2+/-LRE co­
transfected samples (data not shown). Upregulation of CAT activity was 
statistically significant between p=0.01 and p=0.001 for pLW2+LRE (t=9.18) and 
above p=0.01 for pLW2-LRE (t=16.70) using ANOVA. However, using student's t 
tests, significance was below p=0.001 In both cases (pLW2+LRE, t=0.15; pLW2- 
LRE, t=3.08). This again suggests that T7-SF2/ASF is acting on regions of the 
construct other than the LRE. Therefore, we conclude from the above 
experiments that overexpression of SF2/ASF in undifferentiated epithelial cells has 
no LRE dependent effect on protein production from constructs containing the 
HPV-16 late 3’UTR, using uninfected undifferentiated epithelial cells as a model.
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Figure 5.5: pLW2(lntron)+/-LRE
Schematic diagrams of the CAT reporter constructs containing and 
lacking the LRE, with the addition of an intron in the 5’UTR. A) 3’UTR 
from HPV-16 from nt 7005-7456, between PstI and EcoRI restriction sites, 
cloned into pLW2. This region contains the LRE (orange rectangle) and 
the two late polyadenylation signals (LP1 and LP2). B) 3’UTR from HPV- 
16 from nt 7005-7456, between PstI and EcoRI restriction sites, with nt 
7127-7206, encompassing the LRE precisely deleted, cloned into pLW2. 
This region contains the two late polyadenylation signals but lacks the 
LRE.
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Figure 5.6: Insertion of an intron into the 5’UTR of reporter constructs 
containing the LRE does not alter the affect of SF2/ASF in HeLa cells
A) Protein lysates were produced from HeLa cells co-transfected with 
150ng pLW2(intron)+/-LRE and 250ng pCG, pCG-SF2 or pCG-T7-SF2 and 
CAT assays were performed. Transfections were performed in triplicate 
and the graph represents mean and standard deviation about the mean 
from three separate experiments. B) Western blots using equal quantities 
of protein lysate from HeLa cells transfected with pCG, pCG-SF2 or pCG- 
T7-SF2 and either pLW2(intron)+/-LRE probed using anti-SF2/ASF and 
anti-GAPDH antibodies. GAPDH acts as a loading control.
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Figure 5.7: SF2/ASF overexpression affects expression from both 
constructs containing and lacking the LRE in undifferentiated 
epithelial cells
A) Protein lysates were produced from undifferentiated HaCaT cells co­
transfected with 150ng pLW2+/-LRE and 250ng pCG, pCG-SF2 or pCG- 
T7-SF2 and CAT assays were performed. Transfections were performed 
in triplicate and the graph represents mean and standard deviation about 
the mean from three separate experiments. B) Western blots using equal 
quantities of protein lysate from undifferentiated HaCaT cells transfected 
with pCG, pCG-SF2 or pCG-T7-SF2 and either pLW2+/-LRE probed using 
anti-SF2/ASF and anti-GAPDH antibodies. GAPDH acts as a loading 
control.
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5.3 The LRE may affect RNA stability and 
polyadenylation, as well as export and/or 
translation
Although no response was observed during SF2/ASF overexpression from LRE 
containing transcripts at the level of reporter protein activity, it is possible that 
SF2/ASF may affect RNA processing without affecting protein production. As 
discussed there are a number of RNA regulatory proteins associated with the LRE, 
each of which may have roles during differentiation at different post-transcriptional 
stages. For instance, it is possible that LRE containing transcripts are unstable in 
SF2/ASF overexpressing undifferentiated epithelial cells, in addition, upregulation 
of SF2/ASF may allow more efficient polyadenylation of late transcripts; however, 
protein expression may not be elevated due to inhibition of other post- 
transcriptional processes, such as export and/or translation. Therefore, to look at 
post-transcriptional regulation of LRE containing transcripts in a bit more detail, 
levels of polyadenylated and total CAT RNA were determined in HaCaT cells co­
transfected with SF2/ASF expression constructs and pLW2(intron)+/-LRE. To do 
this, total RNA was extracted from cells and RT-PCR was carried out using either 
random primers for total RNA, or oligo(dT) for polyadenylated (polyA+) RNA. The 
primers used in PCRs amplify an-200bp fragment within the 3' region of the CAT 
gene (CAT3’ F & R). In reactions, GAPDH was used as an internal control, to 
ensure equal levels of RNA were added from each sample. Following standard 
RT-PCR, quantitative RT-PCR (q-RT-PCR) was performed to accurately compare 
RNA levels between treatments. Figures 5.8 and 5.9 show the results, with -RT 
reactions being performed to control for the effects of DNA contamination.
Firstly, looking at total RNA levels in cells expressing only endogenous SF2/ASF, 
figure 5.8 shows little difference between constructs including or lacking the LRE, 
This suggests transcription and potentially RNA stability are unaffected by the 
LRE. However, upon overexpression of SF2/ASF, total CAT RNA produced from 
pLW2(intron)-LRE is highly elevated (-15 fold), whereas, total CAT RNA produced 
from pLW2(intron)+LRE is elevated only modestly (-5 fold). This suggests that 
SF2/ASF affects either transcription rate and/or stability of these transcripts and 
that the LRE may act to counteract this. In contrast to total RNA levels, polyA+ 
RNA increased -3.2 fold in cells transfected with pLW2(lntron)-LRE, when 
compared with pLW2(intron)+LRE (Figure 5.9). This suggests the LRE may inhibit
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polyadenylation from the late HPV-16 polyadenylation signal. However, the 
modest increase in polyA+ RNA levels from constructs lacking the LRE does not 
account for the -20 fold increase in protein production shown above (Figure 5.7). 
Therefore, it is likely the LRE also acts at other processing stages, such as during 
export or translation. Interestingly when SF2/ASF is overexpressed, polyA+ RNA 
is elevated from both constructs (-5-7 fold), although to a greater extent from 
pLW2(intron)+LRE when T7-tagged SF2/ASF is expressed (-14 fold) (Figure 5.9). 
However, looking at pLW2(intron)+LRE only, the difference between the two 
SF2/ASF expression vectors may simply reflect the amount of total RNA, as the 
percentage of total RNA to be polyadenylated is roughly the same from each 
(Table 5.1). Furthermore, the percentage of total RNA produced from 
pLW2(intron)+LRE which is polyadenylated is increased -3-4 fold upon SF2/ASF 
overexpression. This suggests that elevated levels of SF2/ASF may enhance 
polyadenylation at the HPV-16 late polyadenylation signal via the LRE. In 
addition, whilst polyA+ RNA levels are seen to increase upon SF2/ASF 
overexpression from pLW2(intron)-LRE, the percentage of total RNA which is 
polyadenylated decreases by -60% (Table 5.1). This may suggest that the level 
of polyA+ RNA produced from pLW2(intron)-LRE is almost at saturation and the 
majority of total RNA is not polyadenylated or used for protein production. The 
increase in poIyA+ RNA produced from pLW2(intron)-LRE is reflected in results at 
the protein level, where there is an increase in CAT activity upon SF2/ASF 
overexpression.
Transfection pCG PCG-SF2 PCG-T7-SF2
pLW2(intron)+LRE 5.4 20.3 18.1
pLW2(intron)-LRE 14.6 5.7 6.2
Table 5.1: Percentage of total RNA that is polyadeny ated for each co-
transfection.
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Figure 5.8: Levels of total reporter gene RNA upon overexpression of 
SF2/ASF
A) Total RNA was produced from undifferentiated HaCaT cells co-transfected 
with pLW2+/-LRE and pCG, pCG-SF2 or pCG-T7-SF2 and total levels of 
CAT RNA were assayed using quantitative RT-PCR. Transfections were 
performed in duplicate and the graph represents mean and standard 
deviation about the mean from three separate experiments. Results are 
normalised against GAPDH. B) Semiquantitative RT-PCR using total RNA 
samples from undifferentiated HaCaT cells transfected with pCG, pCG-SF2 
or pCG-T7-SF2 and either pLW2+/-LRE. Primers amplify within CAT (lower 
band) and GAPDH (upper band) transcripts.
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Figure 5.9: Levels of polyadenylated reporter gene RNA upon 
overexpression of SF2/ASF
A) Total RNA was produced from undifferentiated HaCaT cells co­
transfected with pLW2+/-LRE and pCG, pCG-SF2 or pCG-T7-SF2 and 
poly(A)+ levels of CAT RNA were assayed using quantitative RT-PCR. 
Transfections were performed in duplicate and the graph represents 
mean and standard deviation about the mean from three separate 
experiments. Results are normalised against GAPDH. B) 
Semiquantitative RT-PCR using total RNA samples from undifferentiated 
HaCaT cells transfected with pCG, pCG-SF2 or pCG-T7-SF2 and either 
pLW2+/-LRE. Primers amplify within CAT (lower band) and GAPDH 
(upper band) transcripts.
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5.4 Discussion
There are several proteins involved in RNA metabolism which are known to 
associate with the LRE in undifferentiated and differentiated epithelial cells. Of 
particular interest is SF2/ASF, as this protein is found to be elevated and 
hyperphosphoryiated in differentiated HPV-16 Infected cells, and it has many roles 
during RNA metabolism. Due to its upregulation, SF2/ASF is thought to be 
important to regulation of the LRE in differentiated W12E cells. It is hypothesised 
that elevated SF2/ASF acts to de-repress the LRE by several mechanisms, such 
as enhancing polyadenylation, export and/or translation. However, it is also 
possible that upregulated SF2/ASF is necessary to stimulate other cis-acting RNA 
elements within the HPV-16 late region. Therefore, it could be suggested that 
SF2/ASF association with the LRE may negatively affect late protein expression 
and that the splicing-like complex, containing SF2/ASF, may inhibit 
polyadenylation, for example. It has previously been reported that U1 snRNP, via 
U1-70K, is able to repress polyadenylation, when associated with an LRE in the 
late 3’UTR of BPV-1 in undifferentiated cells (Gunderson et al. 1998), indicating 
that the splicing-like complex associated with the HPV-16 LRE may act in a similar 
manner. To analyse this hypothesis, SF2/ASF could be depleted from 
undifferentiated HaCaT cells using SF2/ASF specific siRNAs, followed by 
transfection with reporter constructs containing the LRE. Enhanced 
polyadenylation would be observed if the LRE-bound splicing-like complex were 
involved in its inhibition. However, SF2/ASF is an essential cellular protein and 
depletion of SF2/ASF may result in death of undifferentiated HaCaT cells. 
However, more than 50% reduction in levels of splicing related protein, 
polypyrimidine tract binding protein (PTB) using siRNA can be tolerated in HeLa 
cells (Sauliere et al. 2006). This suggests that downregulation of SF2/ASF may 
also be achievable in HaCaT cells. In addition, the splicing-like complex, which 
forms on the LRE, is thought to be present in both undifferentiated and 
differentiated cells (Koffa et al. 2000; Gumming et al. 2003). Therefore, change in 
abundance of SF2/ASF may have some affect on this, possibly to increase the 
frequency of its formation. In this case, it is hypothesised that the splicing-like 
complex positively regulates expression from LRE containing transcripts in 
differentiated cells. Therefore, in this study overexpression of SF2/ASF in 
undifferentiated epithelial cells was used to determine if this has any affect on LRE 
function. Results show that protein production from reporter constructs fused to
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the HPV-16 late 3’UTR, which contains the LRE, is not affected by SF2/ASF 
overexpression. However, production of reporter total and polyadenylated RNA 
from the same constructs does show variation when SF2/ASF levels are elevated. 
This suggests that whilst steady state CAT activity produced from transcripts 
containing the LRE are not affected by SF2/ASF alone, SF2/ASF may have an 
important role during RNA metabolism of such transcripts. In addition, the data 
suggests the LRE may act as an instability element and may regulate export 
and/or translation of transcripts containing it, independently of SF2/ASF in 
undifferentiated epithelial cell model systems.
SF2/ASF Is not only an essential cellular protein, but has also been shown to 
regulate gene expression from other viruses such as HIV and Adenovirus. It is 
shown to repress tat pre-mRNA splicing from HIV-1 (Wang et al. 1998) and is also 
involved in Rev mediated splicing via interactions with the Rev response element 
(Powell et al. 1997). Furthermore, SF2/ASF plays a part in prevention of the 
switch from early to late gene expression during the adenovirus life cycle, by 
interacting with an intronic repressor element and inhibiting use of the Ilia 3 ‘ splice 
site within the LI unit (Kanopka et al. 1996; Molin and Akusjarvi 2000). No role 
during splicing was determined for LRE bound SF2/ASF in these experiments; 
however, I cannot rule out such a role. One hypothesis is that LRE-bound 
SF2/ASF acts to enhance splicing of the terminal LI exon in differentiated W12E 
cells. As discussed, the LI exon is long and its definition may be difficult due to 
the distance between the final 3’ splice site and the polyadenylation signal. 
SF2/ASF and/or components of the splicing-like complex binding the LRE may 
complex with splicing factors at the final 3' splice site, creating a spliceosome-like 
complex, and hence aid terminal exon definition. In addition a number of potential 
ESEs and ESSs are observed within the LI exon, which may act in concert with 
the LRE to enhance appropriate splicing of the final exon. To determine this it 
may be useful to employ in vitro splicing assays using probes encompassing the 
HPV-16 late region. Splice patterns would then be examined in the presence and 
absence of SF2/ASF. Furthermore, splice patterns could be assayed in vivo, 
using similar experiments as performed here. Again using undifferentiated 
epithelial cells; constructs containing the LI and L2 ORFs and late 3’UTR would 
be transiently transfected into cells, along with SF2/ASF expressing vectors and 
RNA would be purified. Primers within the late region could then be used in RT- 
PCR experiments to detect if there was an increase in use of the final 3’ splice site 
upon SF2/ASF overexpression. However, as further cis-acting elements are found
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within the HPV-16 late region, any change in splice patterns could not be 
confirmed to be solely attributable to the LRE.
Formation of a splicing-like complex over the LRE has previously been suggested 
to affect polyadenylation of late transcripts. There are two polyadenylation signals 
in the late 3’UTR, and both sites are used during the HPV-16 life cycle (Milligan et 
al. 2006). As hypothesised, it is thought that SF2/ASF may regulate LRE function 
via formation of an early splicing-like complex over the LRE. During BPV-1 
infection, an element within the late 3’UTR is shown to inhibit polyadenylation in 
undifferentiated cells, via interaction with U1 snRNP. Whiist U1-70K, the 
component of U1 snRNP which is directly involved in repression of 
polyadenylation by this element, is not found associated with the HPV-16 LRE, it is 
suggested that the splicing-like complex forming over the LRE may also inhibit 
polyadenylation In undifferentiated HPV-16 infected cells. However, results here 
suggest that overexpression of SF2/ASF enhances polyadenylation from LRE 
containing transcripts in undifferentiated epithelial cells. Therefore, elevated 
SF2/ASF in differentiated W12E cells may either alleviate the repressive activity of 
the splicing-like complex upon polyadenylation, or the splicing-like complex may 
itself enhance polyadenylation. As SR proteins are involved in bringing together 
splice components over splice junctions, it is possible that increased levels of 
SF2/ASF cause formation of the splicing-like complex with greater frequency. This 
could prevent binding of other cellular factors that may inhibit polyadenylation. 
Alternatively, formation of the splicing-like complex itself may regulate 
polyadenylation via protein-protein interactions, with cleavage and polyadenylation 
factors. Furthermore, the extent of polyadenylation from LRE containing 
transcripts (-20% of total RNA) upon SF2/ASF overexpression is high in 
comparison to normal cellular polyadenylation levels (<10%). This suggests 
enhancement of polyadenylation rather than removal of repressive activity. 
However, this may simply reflect increased productivity of reverse transcription 
reactions using oligo d(T), rather than random primers.
In vitro assays are an obvious route to further investigate the role of SF2/ASF in 
polyadenylation of LRE containing transcripts. However, Kennedy et al. showed 
that polyadenylation is not inhibited from LRE containing probes in vitro (Kennedy 
et al. 1990). Therefore, to investigate the role of SF2/ASF in LRE regulated 
polyadenylation would require further in vivo assays. For example, if siRNA 
mediated downregulation of SF2/ASF were to result in inhibition of polyadenylation
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from LRE containing constructs in transfected cells, this would suggest SF2/ASF 
to be necessary for LRE mediated regulation of polyadenylation. However, it 
would not indicate whether SF2/ASF is the vital component that directly enhances 
polyadenylation, or whether it is simply necessary to promote formation of the 
splicing-like complex, which in turn regulates polyadenylation. In the latter case, 
increased formation of the splicing-like complex may be achieved via 
overexpression of an SR protein, other than SF2/ASF. If polyadenylation were 
shown to be enhanced upon overexpression of another SR protein this would 
suggest that either the necessity for SF2/ASF in this reaction is to promote 
splicing-like complex formation, or that other SR proteins can substitute for 
SF2/ASF. In contrast, no change in polyadenylation would indicate that SF2/ASF 
is essential and directly involved in enhancing polyadenylation from LRE 
containing transcripts. One further possibility is that SF2/ASF acts to cause 
displacement of polyadenylation inhibitory proteins from the LRE. This again may 
be caused by increased formation of the spiicing-like complex. However, to 
investigate this further would probably require such inhibitory factors to be 
determined.
Aside from the function of SF2/ASF in LRE control, the element may function to 
cause instability and may also regulate export and/or translation of transcripts 
containing it. It is shown that whilst protein levels are inhibited -20 foid from 
constructs expressing LRE containing transcripts, production of polyA+ RNA is 
inhibited only -3  fold. This indicates that the LRE acts to inhibit late gene 
expression at stages after RNA processing. Furthermore, polyadenylation of LRE 
containing transcripts seems to increase upon SF2/ASF overexpression but no 
such increase is observed in protein production. It has previously been reported 
that reporter constructs containing the LRE are predominant retained in the 
nucleus (Koffa et al. 2000). This suggested that the LRE does inhibit export; 
however, non-polyadenylated RNAs, which the majority of LRE containing 
transcripts are, should not be exported from the nucleus. Therefore, previous 
results showing inhibition of export may simply be a product of inefficient 
polyadenylation. Therefore, nuclearicytoplasmic ratio of LRE containing 
transcripts in undifferentiated epithelial cells co-transfected with SF2/ASF 
expression vectors, to enhance polyadenylation, would be assayed. Nuclear and 
cytoplasmic RNA would be extracted from cells and subjected to RT-PCR, to 
compare levels of total and polyadenylated RNA in both fractions. Lack of RNA 
from LRE containing transcripts in the cytoplasm, even upon SF2/ASF
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overexpression would indicate that the LRE inhibits export. However, presence of 
transcripts in the cytoplasm would indicate that lack of export of LRE containing 
transcripts in the presence of endogenous levels of SF2/ASF might be a product of 
inefficient polyadenylation. Alternatively, this might suggest that SF2/ASF is 
involved in promoting export of LRE containing transcripts.
To examine the possible role of the LRE during translation, direct transfection of in 
vitro synthesised LRE containing transcripts into the cytoplasm of undifferentiated 
epithelial cells, followed by reporter assays would be performed. Should reporter 
activity be reduced from LRE containing transcripts, this would suggest that it is 
involved in inhibition of translation. However, lack of translational stimulation may 
simply suggest that cellular proteins Involved in this process may not be present in 
the cytoplasm. As mention previously SF2/ASF may redistribute from nuclear 
speckles to a more diffuse cytoplasmic location upon differentiation of W12E cells. 
Whilst this is not confirmed, it may be involved in cytoplasmic activities of the LRE, 
such as a possible role in translation. However, in the model epithelial system 
used in the assays performed here, SF2/ASF is predominantly nuclear. Therefore, 
it is possible that elevated SF2/ASF is necessary for functions of LRE in the 
cytoplasm of differentiated W12E ceils, but the assays described here are unable 
to detect this. To look at this in more detail, it might be useful to use mutated 
versions of SF2/ASF that localise to the cytoplasm. Transfection of cells 
expressing this with either LRE containing reporter constructs or in vitro 
synthesised RNAs might indicate whether cytoplasmic SF2/ASF can act to 
enhance protein production from LRE containing transcripts, via increased 
translation. Should protein production be observed to increase this would indicate 
that SF2/ASF plays an important cytoplasmic role during activation of the LRE. In 
contrast, no change might suggest that SF2/ASF does not have cytoplasmic roles 
with respect to LRE function. However, it must be taken into account that only 
regulation of SF2/ASF upon differentiation of W12E cells is modelled in these 
assays and that the cells used are undifferentiated. Therefore, lack of translational 
stimulation by cytoplasmic SF2/ASF may suggest that other proteins required for 
this process are not present in the cytoplasm of undifferentiated epithelial cells.
In summary, whilst SF2/ASF is known to associate with the HPV-16 LRE in both 
undifferentiated and differentiated epithelial cells, how it acts to regulate LRE 
function is largely unknown. Results here suggests that the elevated levels of 
SF2/ASF, which are observed in differentiated HPV-16 infected epithelial cells.
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may be involved in regulating polyadenylation of LRE containing transcripts. In 
addition, the LRE itself may act as an instability element, and may inhibit export 
and/or translation due to the discrepancies observed between protein production 
and poly(A)+ RNA, when comparing transcripts containing and lacking the LRE. 
Whiist no firm conclusions can be drawn from this data, it does provide further 
insight into the possible mechanisms governing LRE function.
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6 General discussion
6.1 Perspectives
Regulation of gene expression of eukaryotic genes is highly dependent on post- 
transcriptional events. For example, most eukaryotic genes are encoded on 
muitiple exons separated by introns, which are often larger. It is thought that up to 
75% of human genes are spliced, suggesting that splicing plays a vital role during 
gene expression. Furthermore, alternative splicing is often invoived in production 
of different protein isoforms, which may be required at different times throughout 
development or by different cell types. For example, sex determination in 
Drosophila is highly dependent on differential splicing of a number of genes in 
males and females (reviewed by Black 2003). One instance of this is the 
alternative splicing of drosophila doublesex (dsx) mRNA. In males, a truncated 
non-functional version of Transformer (Tra), an RS domain containing splicing 
regulatory protein, is produced due to the presence of a stop codon in exon 2 
(reviewed by Black 2003). In the absence of Tra, splicing of dsx follows the 
default pattern that results in exon 4 skipping (Figure 6.1 A). This is due to the 
weak exon 4 3’ splice site, which is not recognised by U2AF and results in 
production of the male specific dsx protein containing exons, 1,2,  3, 5 and 6. 
However, in females Transformer (Tra) protein is produced, due to removal of 
exon 2 and the premature stop codon (reviewed by Black 2003). Tra, along with 
non-sex specific proteins RBP1 (an SR protein) and Tra-2 (an SR-related protein), 
binds to an ESE within exon 4 and promotes U2AF recruitment to the weak exon 4 
3' splice site (Figure 6.1 B). In this case a splice variant containing exons 1 , 2 , 3  
and 4 is produced which encodes the female specific dsx. This provides one 
example of how alternate splicing can be used to produce different protein in 
different cells, and is therefore very important to genetic diversity and gene 
expression.
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Figure 6.1: Drosophila doublesex splicing
Schematic diagrams of splicing of the Drosophila doublesex (dsx) gene 
in males and females during sex determination (not to scale). A) In 
males, when Tra is not present, skipping of exon 4 occurs as the U2AF 
complex is not recruited to the weak exon 4 3’ splice site. This results 
in production of the male specific dsx protein which lacks exon 4. B) In 
females, where Tra is produced, a complex containing Tra, Tra-2 and 
RBP1 binds to an ESE within exon 4 and recruits the U2AF complex to 
the weak exon 4 3’ splice site. This results in production of the female 
specific protein which contains a earlier polyadenylation signal on exon 
4.
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Further highlighting the importance of splicing during gene expression, ~15% of 
disease causing mutations result in splicing defects (reviewed by Faustino and 
Cooper 2003). For example, mutations within the ATP7A gene are known to 
cause Menkes disease, a lethal disorder of copper metabolism, or less commonly, 
occipital horn syndrome (OHS), a milder form of the disease. Mutation within the 
exon 6 5’ splice donor site were found to cause skipping of this exon in the 
majority of mRNAs (Moller et al. 2000). However, Menkes disease is caused 
when no functional protein Is produced due to incorrect splicing of the remaining 
small proportion of mRNAs, which do contain exon 6. This is due to mutation of 
two highly conserved nucleotides within the splice donor site. In contrast, with 
mutations in the least conserved site within the donor site, a small amount of 
correctly spliced mRNA could be detected in samples from OHS patients (Moller et 
al. 2000). Therefore, a small amount of functional protein is produced, which 
decreases disease severity markedly. This example shows how inappropriate 
splicing can lead to different degrees of disease depending on how splicing Is 
affected. In addition to having a vital role during eukaryotic gene expression, a 
number of viruses also control protein production via post-transcriptional 
processes. These include a number of viruses, such as herpes simplex virus and 
Epstein-Barr virus. The two examples to be discussed in detail are the early to 
late shifts in the adenovirus and HIV-1 life cycles. The reason for this is they are 
well-studied systems, and the role of SR proteins during the life cycle of each has 
been the subject of much research. As regulation of SR proteins and their 
potential roles during the life cycle of HPV-16 are the focus of this thesis, the role 
of these factors In regulation of adenovirus and HIV-1 gene expression will be 
discussed. In addition, whilst adenovirus provides a good example of how 
regulation of SR proteins during the life cycle of a virus can Induce an early to late 
shift In gene expression, the HIV-1 example shows the Importance of different 
combinations of SR proteins to splice patterns, and how ESEs and ESSs 
contribute to this.
The early to late switch in the adenovirus life cycle Is, in part, controlled by 
alternative RNA processing. For example, splicing of the LI gene changes 
between the early and late phase of infection. Via the use of one 5’ and two 3’ 
splice sites, two LI mRNA species are produced: 52,55K and Ilia (Figure 6.2) 
(Kanopka et al. 1996). Ilia is the predominant form late In Infection, and splicing to 
the Ilia 3' splice site is inhibited by exogenous SR proteins, both in vitro and In 
transient transfection assays (Kanopka et al. 1996). Inhibition was found to be
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attributable to an intronic repressor element, termed 3RE, upstream of the Ilia 
branch point site, to which SR proteins were shown to bind. In addition, removal 
of 3RE from the L1 unit induces Ilia splicing in vitro (Kanopka et al. 1998). 
However, no change in abundance of SR proteins during adenovirus infection, 
which may have caused the shift from early to late 3’ splice site usage, could be 
determined (Kanopka et al. 1998). In contrast, SR proteins purified from late 
adenovirus infected cells were unable to repress Ilia splicing of the LI gene in 
vitro. SR proteins purified from these cells were also found to be 
dephosphoshorylated when compared with SR proteins from uninfected HeLa 
cells (Kanopka et al. 1998). Therefore, it was thought that virus induced 
dephosphorylation of SR proteins was involved in the switch between 52,55K and 
Ilia splicing of the LI gene during adenovirus infection. The virally encoded 
protein E4-ORF4 was previously shown to associate with serine and arginine 
specific protein phosphatase 2A (PP2A), and Kanopka et al. showed that addition 
of E4-ORF4 to in vitro assays containing SR proteins purified from uninfected 
HeLa cells, resulted in phosphate release (Kanopka et al. 1998). Furthermore, 
this could be repressed by inhibition of PP2A. In addition, transient expression of 
E4-ORF4 in HeLa cells infected with LI constructs resulted in increased Ilia splice 
site usage, a function that was dependent on the 3RE (Kanopka et al. 1998).
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Figure 6.2: The adenovirus genome
A schematic diagram of the adenovirus genome (not to scale) 
composed of 11 genes. Early genes are shown in red, and late 
genes are shown in blue, with the arrowhead indicating the direction 
in which they are transcribed. Splicing of E1A and LI genes is shown 
below, with 5’ and 3’ splice sites indicated by vertical arrows, either 5’ 
or 3’ respectively, above each transcript. mRNAs produced from 
each transcript are shown below with the name of each given to the 
right.
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To build on data gathered using in vitro and transient transfection assays, 
recombinant adenovirus genomes were produced, which were able to inducibly 
express SF2/ASF. When SF2/ASF was overexpressed in cells infected with this 
recombinant virus there was a marked reduction in L1 Ilia mRNA splicing (Molin 
and Akusjarvi 2000). In addition, splicing from genes within the early region of the 
genome was also affected. The E1A gene is spliced via the use of three alternate 
5’ splice site and one 3’ splice site to produce 13S, 12S and 9S mRNAs (Figure
6.2). 13S is abundant early in infection, whereas 9S accumulates at late times. 
SF2/ASF had previously been shown to activate 13S splicing both in vitro (Harper 
and Manley 1992) and in transient transfection assays (Wang and Manley 1995). 
During infection with wild type adenovirus, overexpression of SF2/ASF was shown 
to inhibit 9S splicing at later time, and the predominant El A mRNA was 13S (Molin 
and Akusjarvi 2000). In addition, overexpression of SF2/ASF was shown to impair 
viral DNA replication and virus particle formation, suggesting that this protein, and 
potentially other SR proteins, play a vital role in the adenovirus life cycle.
HIV-1 gene expression is also separated into early late phases depending on 
production of either regulatory proteins, or structural, enzymatic and ancillary 
proteins, respectively. Regulatory proteins are expressed from the 2kb mRNA 
species produced from the virus genome, which depends on a degree of 
alternative splicing. There are 4 5' splice sites and 8 3' splice sites, use of which 
relies on c/s-acting RNA regulatory elements within the HIV-1 genome (Figure
6.3). Different splicing patterns were thought to be partially regulated by different 
combinations of SR proteins. Ropers et al. used in vitro splicing and ex wVo 
assays to determine usage of which 3’ splice sites were enhanced by which SR 
proteins (Ropers et al. 2004). In vitro assays using truncated regions of the HIV-1 
genome containing 5' splice donor site D1 and one of 3' splice acceptors sites A1, 
A2, A3, A4a, A4b, A4c or A5, suggested that different SR proteins promote 
splicing from each site with differing efficiencies. SF2/ASF and SC35 activated 
site A1 to a similar extent, whilst SF2/ASF was a stronger activator of site A2, than 
SC35. SRp40 and SC35 both activated site A3 usage and 9G8 showed modest 
stimulatory activity from all sites assayed (Ropers et al. 2004).
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Figure 6.3: The HIV-1 genome
A schematic diagram of the HIV-1 genome (not to scale) composed 
of 9 genes encompassed by two long terminal repeat regions (LTRs), 
shown in green. Regulatory genes are shown in red, and structural, 
enzymatic and ancillary genes are shown in blue. 5’ splice donor 
sites (D1-D4) are shown as vertical arrows above, and 3’ splice 
acceptor sites (A1-A3, A4a-c, A5 and A7) are shown as vertical 
arrows below. Transcripts produced by the virus are shown by 
horizontal lines below the genome, along with the proteins they 
encode to the right and the size species they fall into.
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When further probes containing the 5’ splice donor site D4 and the 3’ acceptor 
sites A3, A4a, A4b, A4c and A5 were subjected to in vitro splicing assays, site A5 
was preferentiaily used. In contrast, addition of SF2/ASF to assays enhanced 
spiicing from sites A4a and A4b, and to a lesser extent A3, whilst SRp40 and 
SC35 promoted site A3 usage and inhibited use of site A5. These observations 
were confirmed in ex vivo experiments using HeLa cells transfected with HIV-1 
DNA and SR protein expression vectors (Ropers et al. 2004). Following RNA 
purification, splice patterns were determined using RT-PCR. As shown in vitro, 
when no SR proteins were overexpressed, site A5 was preferentially used, 
suggesting this is the default splice pattern for HIV-1. In addition, overexpression 
of SF2/ASF resulted in preferential use of 3’ splice site A2, and overexpression of 
SRp40 or SC35 gave strong D1 to A3 splicing.
Whilst the above experiments gave an indication of how splice patterns may be 
affected by expression of different SR proteins, no detail was given as to how this 
may be achieved. To this affect, two c/s-acting RNA regulatory elements within 
the HIV-1 genome will be discussed. Firstly, an ESS within tat exon 2, named 
ESS2, which had previously been shown to inhibit usage of splice site A3 via 
interactions with hnRNP A1, was more recently been found to interact with SC35 
in vitro (Zahler et al. 2004). Furthermore, SC35 binding was inhibited by hnRNP 
A1. This region was found to contain an SC35 dependent ESE, using a 
Drosophila dsx probe, which is not spliced in vitro, in the absence of an enhancer 
due to a weak 3’ spilce site. As discussed, dsx is alternately spliced in males and 
females, due to presence of Tra protein in females (reviewed by Black 2003). Tra 
enhances splicing from the exon 4 weak 3’ splice site via an ESE in exon 4, 
causing inclusion of the exon In females. The probe used in these experiments 
has the ESE removed so that spiicing to the weak 3’ splice site is inefficient. 
However, fusion of a region containing an ESE, 3’ of the 3' splice site will induce 
splicing from this site. Addition of the ESS2 region to this probe induced splicing 
in the presence of SC35, suggesting this region contains an SC35 responsive ESE 
(Zahler et al. 2004). SC35 and hnRNP A1 binding sites were found to overlap, 
suggesting that hnRNP A1 bound to ESS2 inhibits splicing from site A3, by 
inhibiting SC35 binding to an overlapping ESE (Zahler et al. 2004). In support of 
this, SC35 overexpression was found to enhance usage of site A3 in HeLa cells 
(Ropers et at. 2004). A further ESE, named GAR, was found within exon 5, which 
acted in a bi-directional fashion, potentially upon upstream splice acceptor sites 
A4a, A4b, A4c and A5 and downstream splice donor 04 (Caputi et al. 2004). This
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element was shown to enhance splicing when placed upstream of the dsx probe 
described above in the presence of SF2/ASF or SRp40, but not SC35, SRp50 or 
SRp70. Furthermore, mutation of SF2/ASF and SRp40 binding sites within the 
GAR element, decreased splicing activation in this assay (Caputi et al. 2004). In 
agreement with a role for this element in regulation of upstream splice acceptor 
sites, SF2/ASF was shown by Ropers et al. to enhance use of acceptor sites A4a 
and A4b (Ropers et al. 2004). However, SRp40 was shown to inhibit A5 site 
usage in vitro, suggesting that this protein may regulate use of other acceptor site 
within the region, or may be involved in inhibition of site A5 via interactions with 
GAR. In addition, transient transfection using the env region of the HIV-1 genome, 
indicated that GAR mediates use of splice donor site D4 (Caputi et al. 2004). 
Production of env is dependent upon D4 usage, and env levels fell when GAR was 
mutated within the SF2/ASF and SRp40 binding sites. Furthermore, tethering of 
SF2/ASF or SRp40 to the GAR region using the bacteriophage MS2 coat protein 
and binding site resulted in increased env expression when MS2 was fused to 
either SF2/ASF or SRp40 compared to MS2 protein alone (Caputi et al. 2004). 
This suggests that the GAR elements functions to regulate HIV-1 splicing in a bi­
directional manner.
In addition to roles of SR proteins during regulation of HIV-1 splicing, the virus is 
also thought to regulate activity of SR proteins. For example, SF2/ASF interacts 
with a major c/s-acting RNA regulatory element of the virus, the Rev response 
element (RRE) (Powell et al. 1997). Rev interaction with the RRE inhibits viral 
RNA splicing and activates nuclear export of incompletely spliced virai mRNAs. 
Furthermore, once in the cytoplasm, Rev is involved in enhancing translation of 
these mRNAs to ensure production of structural, enzymatic and ancillary proteins, 
which are expressed from the 4kb single spliced and 9kb unspliced RNAs, at later 
stages of infection. SF2/ASF was shown to interact with the RRE in a Rev 
dependent manner (Powell et al. 1997). It was suggested that association of 
SF2/ASF with the RRE interferes with spliceosome formation and hence inhibits 
viral splicing. Therefore, it was hypothesised that this would be overcome by 
overexpression of SF2/ASF. A CAT construct which is spliced so that the CAT 
gene is removed was used to investigate this. Whiist CAT activity was minimal 
from constructs lacking the RRE, addition of the RRE resulted in a -25 fold 
increase in CAT activity due to inhibition of splicing. However, increasing levels of 
SF2/ASF overexpression reduced CAT activity, suggesting that inhibition of 
splicing was overcome (Powell et al. 1997). In addition, overexpression of
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SF2/ASF also inhibited HIV-1 replication in vivo, as assayed by accumulation of 
the replication protein, Gag. This suggests that interaction of SF2/ASF to the 
RRE, in a Rev dependent manner, is important to inhibit HIV-1 splicing, and hence 
allow progression of the virus life cyde.
Having discussed the Importance of SR proteins to gene expression from two 
other viruses, I wiii now focus on the potential role of SR proteins in the HPV-16 
life cycle, and how the virus may regulate these factors. Although preliminary 
studies were performed to determine changes in SR protein abundance and 
localisation upon differentiation of HPV-16 infected epithelial cells, so far no more 
sophisticated experiments to look at how specific SR proteins may affect splice 
patterns, and therefore protein production have been performed. Chapter 4 shows 
that a sub-set of SR proteins are upregulated during differentiation of HPV-16 
infected epithelial cells. However, little is known about expression of SR proteins 
in normal systems, although they are thought to be constitutively expressed in 
proliferating and some terminally differentiated cells. Sanford and Bruzik showed 
that whilst SR proteins are expressed throughout nematode early embryogenesis, 
their splicing activity is developmentally regulated (Sanford and Bruzik 1999). In 
addition, splicing activity correlated with dephosphorylation of SR proteins. This 
suggests that regulation of SR protein phosphorylation is one mechanism by which 
the function of these proteins is controlled. This is exemplified during the 
adenovirus early to late switch in gene expression, where SR proteins are 
dephosphorylated to ensure a change in spiice patterns (Kanopka et al. 1998). In 
that case, dephosphorylation is used to inactivate SR proteins as alternative 
splicing regulators during the late stages of the adenovirus life cycle. However, 
results presented here suggest that HPV-16 upregulates SR proteins during the 
later stages of its life cycle. In contrast to adenovirus-infected cells, expression of 
SR proteins would be lost from HPV-16-infected cells, If the virus did not regulate 
them. This suggests that HPV-16 upregulates expression of SR proteins as they 
are vital to completion of the virus life cycle.
As discussed previously, phosphorylation status of SR proteins is important to 
their function. Therefore, it would have been useful to determine the 
phosphorylation status of SR proteins during differentiation of W12E cells. 
SF2/ASF is known to become hyperphosphoryiated in differentiated W12E cells 
(McPhillips et al. 2004); however, nothing is known about the phosphorylation 
status of other SR proteins. Mb104 antibody recognises a common phospho-
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epitope of several SR proteins (Roth et al. 1991). Therefore, as there is an 
abundance of SR proteins shown using this antibody, particularly SRp55 and 
SRp40, it is possible that the majority of each protein is phosphorylated in W12E 
cells. Indeed, McPhillips et al. found no detectable non-phosphorylated SF2/ASF 
in either undifferentiated or differentiated W12E cells (McPhillips et al, 2004). In 
contrast, little SRp20 and no SRp75 are recognised using Mb104. Whilst this is 
possibly due to low abundance in the case of SRp75, SRp20 is readily detected 
using anti-SRp20 specific antibody. Therefore, it is possible that SRp20 exists in 
predominantly non-phosphorylated form in W12E cells. Alternatively, Mb104 may 
simply not recognise this protein as well as the other SR proteins. Therefore, 
more detailed analysis of the phosphorylation status of SR proteins during W12E 
differentiation would have been beneficial. To have fully analysed this, samples 
could have been taken at more time points from the onset of differentiation. That 
way, we could determine whether there was a rapid increase in SR protein 
abundance and/or hyperphosphorylation at a specific time point during 
differentiation, or whether it was more gradual. Furthermore, use of antibodies 
specific to each SR protein would have given a better indication of changes in 
abundance of each. Should SR proteins be found in predominantly 
hyperphosphoryiated form upon differentiation, this would suggest that they might 
act to promote alternative splicing in differentiated cells. This is in contrast to both 
adenovirus and HIV-1, which deactivate SR protein mediated regulation of splicing 
at later times during infection, albeit by different mechanisms (Powell et al. 1997; 
Kanopka et al. 1998). The reason for this difference may be a result of protein 
abundance in differentiated epithelial cells. Adenovirus and HIV-1 infected cells 
have constant levels of SR proteins throughout the life cycle and expression of SR 
proteins is vital to cell viability. Therefore, these viruses must find other 
mechanisms to inhibit the default functions of SR proteins iate in infection. In 
contrast, differentiated epithelial cells do not require SR proteins, and protein 
expression is lost as the cells differentiate. Therefore, HPV-16 can regulate these 
factors for its own means, without the necessity to deal with SR protein produced 
by endogenous expression, or the effects of SR proteins on cellular gene 
expression. As SR proteins are multifunctional, use of them rather than inhibition 
of their function makes more sense as they can affect post-transcriptional gene 
expression at many stages. Therefore, HPV-16 may simply regulate SR proteins 
to aid late gene expression because of the cells it infects, whereas adenovirus and 
HIV-1 are unable to do this.
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In addition, a further sub-set of SR proteins, SF2/ASF and SRp20, may 
redistribute from nuclear speckles to a diffuse cytoplasmic iocalisation in 
differentiated W12E cells. However, as discussed this was inconciusive and may 
have benefited from a more detailed analysis of the cells, with respect to the status 
of the genome (whether it was integrated or episomal) and the extent of 
differentiation. To repeat these experiments would be important as nuclear and 
cytoplasmic roles for SR proteins during HPV-16 late gene expression are likely to 
differ. In the nucleus, SR proteins likely act to regulate appropriate splicing, and 
potentially polyadenylation of late transcripts in both undifferentiated and 
differentiated W12E cells. However, if SF2/ASF and SRp20 were found to 
relocate to the cytoplasm in differentiated W12E cells, this may suggest that they 
predominantly have roles during export and/or translation of late transcripts in 
these cells. As suggested for analysing protein abundance and phosphorylation 
status in more detail, it may be useful to look at more time points following the 
onset of differentiation. If redistribution were observed only at very late stages of 
differentiation it Is possible that SR proteins are involved in appropriate processing 
of late transcripts in the nucleus of less differentiated cells. SF2/ASF and SRp20 
may also be involved in regulating export and/or translation at later stages of 
differentiation. These two proteins may associate with the RNA within the nucleus 
and mediate it’s export to the cytoplasm. In the cytoplasm, it is possible that 
SF2/ASF enhances translation of late transcripts; however, the protein is found 
predominantly in hyperphosphoryiated form, whilst hypophosphorylation is 
associated with translational regulation by SF2/ASF (Sanford et al. 2005). 
Therefore, it is likely that if SF2/ASF were Involved in regulating translation of late 
transcripts, this would only encompass a small proportion of the protein within 
differentiated ceils.
Whilst the exact nature of SR protein regulation during W12E cell differentiation is 
yet to be determined, it is clear that phosphorylated SF2/ASF, SRp20, SC35 and 
SRp75 are upregulated in cells expressing HPV-16 E2. As this was shown using 
mb104 antibody, it is not certain that this represents total SR protein abundance; 
therefore, it would be important to use anti-SR protein specific antibodies to 
determine this. However, from the data present here, it is hypothesised that E2 
regulates expression of these SR proteins during W12E differentiation. In addition 
to general regulation of SR proteins, the role of HPV-16 E2 in transactivation of 
SF2/ASF was investigated. Whilst E2 was shown to transactivate and associate 
with the SF2/ASF promoter in vivo, no mode of interaction was determined. In
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addition, whilst transactivation of the SF2/ASF promoter in CAT assays was 
highest in U20S clone A4, endogenous SF2/ASF expression is greater in done 
B1 (comparing figure 3.4 with figure 4.4). The reasons for this are unclear, but 
may reflect differences in E2-mediated transactivation of the promoter contained 
on the plasmid and the endogenous promoter. E2 expression is also higher in B1 
clonal cells, so perhaps this has some repressive effect on the plasmid promoter, 
which is not contained within the cellular chromatin environment, and therefore 
may be more accessible to E2 binding. In addition, lower expression of E2 in A4 
clonal cells may access the endogenous SF2/ASF promoter with lower frequency 
than in B1 cells, resulting in lower transactivation of endogenous SF2/ASF. In 
contrast, during clonal selection of clone A4, endogenous expression of SF2/ASF 
may have been compromised, resulting in the lower levels observed within this cell 
clone. Conversely endogenous SF2/ASF expression may have been elevated 
during selection of clone B1.
E2 potentially interacts with the SF2/ASF promoter directly via a weak association, 
or may be tethered to it using cellular proteins. Sp1, a known cellular binding 
partner of E2, may interact with the promoter via the same region to which E2 may 
bind weakly. HPV-18 E2 is known to regulate the hTERT promoter via interactions 
with Sp1, which tethers it to the promoter (Lee et al. 2002). However, although E2 
association with this region is stronger in the presence of nuclear extract in vitro, 
the shift obtained in EMSAs does not change in size. Therefore, it is possible that 
presence of Sp1 within transcription complexes in this region may not tether E2 to 
the promoter but may strengthen its binding, perhaps by changing DNA structure, 
making transactivation more likely (Figure 6.4A). However, association of Sp1 
with the promoter in vivo has not been determined. In contrast, TBP was shown In 
many ChIP assays to associate with the SF2/ASF promoter. As discussed, HPV- 
16 E2 interacts with TFIIB (Benson et al. 1997), a component of the pre-initiation 
complex (PIC), which interacts with a recognition sequence (BRE) upstream of the 
TATA-box. TFIIB interaction with the promoter has not been tested, but would be 
expected, as it is necessary for the recruitment of RNA polymerase II. The 
SF2/ASF promoter does not contain a consensus TATA-box, but does contain a 
potential BRE, ~35nt downstream from the initiation site. Binding of TFIIB to this 
element may recruit TBP to the promoter, and hence cause assembly of the PIG 
(Figure 6.4B).
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Figure 6.4: Potential models of E2-mediated transactivation of the 
SF2/ASF promoter
HPV-16 E2 associates with the SF2/ASF promoter in vivo\ however, no 
mode of interaction has been determined in vitro. Protein and protein 
complexes are depicted as filled circles, whilst the transcription start site is 
shown with an arrow. A) E2 may associate with the promoter using Spl, 
via protein-protein interactions, or Spl, or another cellular TF may alter 
the DNA structure so that E2 can bind more readily, and promote 
transactivation. B) E2 may interact directly with TFIIB, a component of 
the PIC. C) E2 may associate via an unknown cellular factor.
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If E2 were to be recruited to the SF2/ASF promoter by TFIIB, it would be expected 
that E2 could still mediate transactivation, even with only a short region of the 
promoter covering the initiation site and the potential BRE present. In contrast, 
should Sp1 be involved In E2-mediated transactivation, this would require the 
region spanning nt -684 to -482, to which Sp1 and E2 may bind. In addition, E2 
may associate with the SF2/ASF promoter via an as yet unknown mechanism 
(Figure 6.4C). Therefore, fragmentation of the promoter and use of these reporter 
constructs in CAT assays would have been useful to determine which region was 
important for E2-mediated transactivation. This along with experiments described 
in section 3.8, would have given considerable more information as to the nature of 
E2 transactivation of the SF2/ASF promoter.
From results shown in chapter 5, upreguiation of SF2/ASF during W12E cell 
differentiation is not the sole reason for de-repression of the LRE in these cells. 
However, it is hypothesised that high levels of expression of SF2/ASF, potentially 
via formation of a spiicing-like complex over the LRE, enhances polyadenylation of 
late transcripts, as discussed in detaii in section 5.4. This is in contrast to previous 
in vitro data, which suggests that polyadenylation is not inhibited from probes 
containing the LRE (Kennedy et al. 1990). More recently, Milligan et al. showed 
that polyadenylated HPV-16 late RNAs can be detected only in differentiated 
W12E cells, suggesting that polyadenylation is inhibited in undifferentiated cells 
(Milligan et al., 2006). Whilst this could be achieved via the mechanism of other 
c/s-acting regulatory RNA elements within the HPV-16 late region, data presented 
here suggests that polyadenylation is likely to be regulated, at least partly by the 
LRE. However, polyadenylated RNA from LRE containing constructs is repressed 
only -3  fold, compared with constructs lacking the LRE, when expressed in 
undifferentiated HaCaT celis. As protein levels are repressed -20 fold from LRE 
containing transcripts, this suggests that inhibition of polyadenylation is not the 
main mechanism by which the LRE represses gene expression in undifferentiated 
epithelial cells. It is possible that the LRE works in concert with other HPV-16 c/s- 
acting RNA regulatory elements, perhaps within the LI ORF, to inhibit 
poiyadenylation, and is inefficient at doing so when isolated from these.
The LRE has also been shown to cause RNA instability. The half-life of transcripts 
containing it is -30 minutes in vitro, compared with over 90 minutes for those 
lacking it (Kennedy et al. 1991). However, no such instability was observed here, 
with the amount of total RNA produced from constructs containing and lacking the
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LRE being roughly equal. It is possible that proteins involved in stabilising late 
transcripts via the LRE in differentiated W12E cells, such as potentially HuR, are 
expressed at critical levels In undifferentiated HaCaT cells, to allow stabilisation. 
In contrast upon overexpression of SF2/ASF, total RNA from constructs lacking 
the LRE increased -15 fold, whilst expression from LRE containing constructs 
increased oniy -5  fold. This suggests that SF2/ASF somehow increases RNA 
production from these constructs, a process that may be inhibited by the LRE. In 
this case, due to the increased amount of LRE containing transcripts, the levei of 
stabilising protein(s) may not be sufficient to stabilise all the RNA. In addition, 
SF2/ASF seems unlikely to be involved in LRE-mediated stability of transcripts.
6.2 Future aims
This thesis provides evidence that SR proteins are regulated during the life cycle 
of HPV-16. However, whilst there is preliminary data to suggest that SF2/ASF 
may enhance polyadenylation of late transcripts when complexed with the LRE, 
nothing is known about the potential functions of other SR proteins, which are 
regulated by the virus. Therefore, the future alms of this investigation would be to 
not only to investigate specifically how HPV-16 regulates each SR protein, but also 
to determine why they are regulated and how they affect late gene expression 
from HPV-16 during differentiation. Firstly, as discussed, more work is necessary 
to confirm how E2 transactivates expression of SF2/ASF. Furthermore, it would 
be interesting to determine if the sub-set of SR proteins, which are upregulated in 
HPV-16 infected differentiated epithelial cells, are transactivated in the same way. 
It would be expected that HPV-16 would use a common mechanism to upregulate 
expression of all SR proteins; however, this would need confirmation as 
differences in endogenous controi of expression of different SR proteins may 
prevent the virus from doing this. As discussed this would involve following a 
similar procedure as used in chapter 3 for each promoter to be studied.
To study the roles of specific SR proteins during the HPV-16 life cycle would 
require considerabiy more work. This may involve a more intensive study of 
potential ESEs and ESSs within the HPV-16 late region, particularly within the LI 
ORF. As discussed there are a number of potential ESEs within the LI ORF 
(Figure 4.1), many of which are likeiy to contribute to late gene expression. 
Specific predicted elements could be cloned upstream of the dsx weak 3' splice
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site, followed by in vitro splicing assays. In this way, it could be determined 
whether the predicted ESE was able to enhance use of the weak dsx 3’ spilce site, 
and in response to which SR proteins. Some work has already been performed in 
this area by the Schwartz lab (Zhao et al. 2004; Rush et al. 2005). Although they 
provide evidence that elements within the late region prevent late gene specific 
splicing in undifferentiated epithelial cell, there is nothing known about elements 
that might enhance late gene expression upon differentiation. Furthermore, these 
studies use a synthetic system in which a CMV promoter drives expression of the 
HPV-16 late region with LRE deleted. Although this provides a more ammenable 
system in which to assay splice patterns and c/s-acting RNA regulatory elements, 
it may not reflect the natural system for a number of reasons. Expression from 
constructs produced by the Schwatrz lab results in production of much higher 
leveis of transcripts than would be expected using the natural HPV-16 promoters, 
which may force aberrant splicing not found in real infections. Furthermore, we 
hypothesise that the LRE itself is involved in regulation of splicing of late 
transcripts. Therefore, deletion of this eiement may also result in the production of 
transcripts not observed during natural infection. Alternatively, loss of the LRE 
may cause ESE or ESSs within the late region to behave differently, as they may 
act in concert with the LRE. Therefore, confirmation that a given predicted ESE or 
ESS is bona fide, would require that this element be mutated in the context of the 
virus, followed by transfection into epithelial cells. However, these experiments 
would be very challenging, due to the nature of the HPV-16 life cycle and the 
difficulty in producing HPV-16 stably transfected cells lines. An alternative 
approach would be to determine global changes in splicing from HPV-16 in 
response to specific SR proteins. This could follow a similar procedure to that 
used by Ropers et al. when determining the effects of SR protein on HIV-1 splicing 
(Ropers et al. 2004). In particular, transfection of undifferentiated W12E cells with 
exogenous expression vectors for a specific SR protein, followed by RT-PCR 
analysis of the resulting transcripts, may indicate how this protein alters splice 
patterns. Whilst these experiments wouid provide an indication of the role of 
specific SR proteins during splicing of HPV-16 transcripts, they would not 
determine if and when this was important during the viral life cycle.
In conclusion, it is hypothesised that SF2/ASF may regulate late gene expression 
via the LRE by enhancing polyadenylation of late transcripts. Although to date 
there is no evidence to suggest that SF2/ASF may regulate stability, export and/or 
translation of LRE containing transcripts, the possibility cannot be discounted. As
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discussed in section 5.1, SF2/ASF may be multifunctional in LRE regulation, and 
assays performed during the course of this PhD, were not sufficient to investigate 
this fully. However, it is clear that HPV-16 regulates expression of SF2/ASF, and 
potentially other SR proteins, a process which may be involved in control of late 
gene expression, possible throughout infection.
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